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To determine whether new pacing lead technology can be used to overcome problems 
with left ventricular (LV) lead placement during cardiac resynchronisation therapy 
(CRT). To establish whether cardiac magnetic resonance (CMR) data can be used to 
guide LV lead placement in real-time at CRT implant. To establish the best method of 
multi-site pacing. 
Methods 
We investigated the incidence of problems with phrenic nerve stimulation (PNS) and 
high capture thresholds at implant and at 4 and 6 month follow-up periods in 40 patients 
who underwent CRT with a new quadripolar lead. In 20 patients we used a pressure 
wire to assess the acute haemodynamic response (AHR) to pacing within different 
regions of the coronary sinus (CS) to determine whether problems with poor AHR can 
be overcome with electronic repositioning. In 23 patients we used CMR acquisition, 
processing, overlay and registration tools to guide LV lead placement in real-time 
during CRT. In 12 patients we turned on the multi-site function of a quadripolar lead, 
implanted temporary endocardial and epicardial pacing leads and measured the AHR 
whilst pacing in multiple different ways. 
Results 
Quadripolar lead technology successfully overcame problems with PNS and high 
capture thresholds at implant and at follow-up but not poor AHR. A CMR 
dyssynchrony-guided approach to LV lead placement gave an AHR comparable to the 
best that can be achieved anywhere and was associated with improved reverse 
15 
 
remodelling at 6 months.  Endocardial pacing gave the best overall AHR but in different 
patients different methods of multi-site pacing were best.  
Conclusions 
New lead technology can be used to overcome some LV lead problems but not poor 
AHR. Real-time CMR dyssynchrony guided CRT may be better than conventional 
empirical LV lead placement. Endocardial pacing gives excellent overall AHR but 
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In this thesis I aim to look at methods of improving implant success rates using novel 
quadripolar lead and cardiac magnetic resonance (CMR) imaging technology. I will 
investigate whether there is a difference in acute haemodynamic response (AHR) to 
pacing in different regions of a patient’s coronary venous system and thus elucidate 
whether quadripolar lead technology can be used to overcome problems with poor AHR 
by simple ‘electronic repositioning’. I aim to see if CRT acute and chronic outcome can 
be improved using advanced CMR acquisition, processing, overlay and registration 
techniques. I will show that biophysical computer modelling can be used to predict 
AHR changes in silico when a heart is multi-site paced. Finally I will compare, in vivo, 
multiple different methods of pacing the heart from multiple sites simultaneously to see 

















Chapter 2 gives an overview of the size of the heart failure problem, its current medical 
and device management and guidelines for treatment. This chapter also looks at how 
improvements to device therapy may be made and the methods of assessing this. 
Chapter 3 describes patient selection and the general echo, CMR and AHR assessment 
methods used for the experimental work in this thesis. 
Chapter 4 describes the use of a novel quadripolar left ventricular lead, our initial 
experience with it and its potential advantages in overcoming common CRT problems. 
Chapter 5 describes a study of the acute haemodynamic response (AHR) when pacing 
within different areas of the same CS vein and comparing this to the AHR achieved 
when pacing in different veins. 
Chapter 6 describes a study involving the use of CMR anatomical, dyssynchrony and 
scar data at time of implant to guide LV lead placement. 
Chapter 7 describes the use of biophysical computer modelling to predict the effect of 
multi-site pacing the heart using the multi-site pacing function of a quadripolar lead. 
Chapter 8 describes an acute haemodynamic and electro-anatomic mapping study of 
the benefits of different ways of multi-site pacing and determining the best method. 
Chapter 9 discusses the main findings of my studies. 
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Chapter 2. Introduction 
 
Heart Failure - the Size of the Problem 
 
Cardiovascular disease (CVD) is the main cause of death in the UK accounting for 
nearly 198,000 deaths or around a third of all mortality(1). 900 000 people live with 
definite or probable heart failure (HF) in the UK and the incidence of new HF is 
estimated at around 60 000 cases per year (2) or 1 in 100 in those over the age of 65 in 
the USA (figure 1). Survival after a HF diagnosis has improved over recent years but 
the death rate remains high with 50% of people diagnosed with HF dying within 5 
years. As life expectancy increases and heart failure treatments improve, the prevalence 
of heart failure is expected to increase by 25% by 2030 (3).  
 
Figure 1. Incidence of Heart Failure  
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Incidence of heart failure (diagnosis of heart failure based on physician review of 
medical records and strict diagnostic criteria) by age and sex (Framingham Heart 




Heart failure is a clinical syndrome that describes a constellation of symptoms that 
result from impaired cardiac pump function. The causes are multiple (table 1) (4) but 
generally patients are divided into ischaemic (HF secondary to coronary artery disease) 
and non-ischaemic groups depending on the results of clinical history and examination, 
12 lead ECG, echocardiography, coronary angiography and, more recently, cardiac 
magnetic resonance (CMR) imaging.  
 
LV systolic dysfunction because of adverse remodelling of the ventricles occurs as a 
result of the loss of myocytes and maladaptive changes in the surviving myocytes and 
extracellular matrix. The mechanism is twofold. One is because of intercurrent cardiac 
events such as myocardial infarction and the other is because of local processes (e.g. the 
autocrine pathway and molecular adaptations) and systemic processes (e.g. 
neurohumoral pathways) that are activated as a result of reduced systolic function. 
These systemic processes have detrimental effects on the functioning of the lungs, blood 
vessels, kidneys, bone marrow and muscles and contribute to a pathophysiological 
vicious cycle (figure 2). The molecular, structural, and functional changes in the heart 
and these systemic processes, coupled with electrolyte imbalances, result in electrical as 






♦ coronary artery disease 
♦ hypertension 
♦ immune/inflammatory 
 viral myocarditis 
 Chagas’ disease 
♦ metabolic/infiltrative 










 cytotoxics (e.g. trastuzumab) 
 negatively inotropic drugs (e.g. calcium-channel blockers) 
♦ idiopathic 
 cardiomyopathy (dilated, hypertrophic, restrictive, peri-partum) 
Valvular disease 
♦ mitral stenosis/regurgitation 
♦ aortic stenosis/regurgitation 
♦ pulmonary stenosis/regurgitation 





♦ Löffler endocarditis 
♦ endomyocardial fibrosis 
Congenital heart disease 
♦ e.g. atrial or ventricular septal defect 
Genetic 
♦ e.g. familial dilated cardiomyopathy 




♦ sinus node dysfunction 
♦ second-degree atrioventricular block 
♦ third-degree atrioventricular block 




♦ Paget’s disease 
♦ arteriovenous fistula 
Volume overload 
♦ renal failure 
♦ iatrogenic 




Figure 2. Pathophysiology of Heart Failure as a Result of Left-Ventricular Systolic 
Dysfunction  
Damage to the myocytes and extracellular matrix leads to changes in the size, shape, 
and function of the left ventricle and heart more generally (‘remodelling’). These 
changes, in turn, lead to electrical instability, systemic processes resulting in many 
effects on other organs and tissues, and further damage to the heart. These vicious 
cycles, along with intercurrent events, such as myocardial infarction may cause 








Medical therapy for CHF targets the pathophysiological mechanisms above. Good 
evidence for pharmacotherapy has accumulated over the past 20 years. Prognostic 
benefits in HF have been demonstrated for beta-blockers (6-8) , ACE inhibitors (9-11),  
angiotensin receptor antagonists (12, 13), aldosterone antagonists (14, 15) and, more 
recently, ivabradine (16). With increased prescribing of such medication over the past 
15-20 years, hospitalisation and fatality rates of HF patients has improved but the 






Heart failure patients often have abnormal ventricular electrical conduction that may be 
manifest on the surface ECG as a prolonged QRS duration. Typically the QRS 
prolongation has a left bundle branch block (LBBB) morphology and results in the LV 
free wall being activated and contracting later than the inter-ventricular septum (18). 
Such asynchronous contraction may then disrupt mechanical efficiency causing a 
further reduction in cardiac output. Indeed, LBBB is an unfavourable prognostic marker 
in HF with a negative effect independent of age, HF severity and medication (19). 
The aim of cardiac resynchronisation therapy (CRT) is to make the LV and right 
ventricle (RV) contract simultaneously using cardiac pacing to change the timing of 
electrical activity in asynchronous hearts. In patients who are in sinus rhythm this is 




CRT Evidence Base 
 
CRT has been shown to improve exercise capacity, quality of life, NYHA class and 
reverse remodelling (20-23). The hypothesis that prophylactic cardiac resynchronization 
therapy with (CRT-D) or without (CRT-P) a defibrillator would reduce the risk of death 
or hospitalization in patients with heart failure (HF) and intraventricular conduction 
delay was tested in the Comparison of Medical Therapy, Pacing, and Defibrillation in 
Heart Failure (COMPANION) Trial (24). 1520 HF patients (NYHA class III/IV), with 
both ischaemic and non-ischaemic cardiomyopathy (CM) and a QRS duration greater 
than 120 ms, were randomly assigned to optimal medical therapy alone or with either 
CRT-P or CRT-D. The study found that at 12 months the risk of death or hospitalization 
was reduced by 34% in the CRT-P group (P<0.002) and 40% in the CRT-D group 
(P<0.001). Although the 24% reduction in risk of death from any cause seen in the 
CRT-P arm did not quite reach statistical significance (p=0.06), the 36% reduction in 
the CRT-D arm was significant (p=0.003). 
 
The positive effect on mortality of a biventricular pacemaker without defibrillator 
(CRT-P) did reach statistical significance in the Cardiac Resynchronisation-Heart 
Failure (CARE-HF) study (25). This study of 813 patients followed for a mean of 29.4 
months showed a 36% decrease in mortality (p<0.002) in NYHA class III/IV patients 
with evidence of ventricular dyssynchrony who received CRT-P compared to medical 
therapy alone. Thus it was established that cardiac resynchronisation therapy reduces 





More recent studies have shown that the benefit from CRT seen in NYHA class III-IV 
patients in earlier studies can be extended to less symptomatic HF patients in NYHA 
class I and II. In MADIT-CRT (26), 1820 patients with ischaemic or non-ischaemic 
CM, LVEF ≤ 30%, a QRSd ≥ 130 ms and NYHA class I or II symptoms were randomly 
assigned to receive a CRT-D or an ICD alone. The primary end point was death from 
any cause or a non-fatal HF event. During an average follow-up of 2.4 years, the 
primary end point occurred in 187 of 1089 patients in the CRT-ICD group (17.2%) and 
185 of 731 patients in the ICD-only group (25.3%) (p=0.001). It should be noted, 
however, that the significant reduction in the combined primary endpoint for CRT-D 
versus an ICD alone was driven by a 41% reduction in the risk of heart-failure events 
and there was no significant difference between the two groups in the overall risk of 
death (3% annual mortality in both groups). 
 
In the RAFT study (27), patients with NYHA class II or III HF, LVEF≤ 30% and an 
intrinsic QRSd ≥ 120 ms or a paced QRSd  ≥ 200 were randomly assigned to receive 
either an ICD alone or a CRT-D. The primary outcome was death from any cause or 
hospitalization for HF. 1798 patients were followed for a mean of 40 months. The 
primary outcome occurred in 297 of 894 patients (33.2%) in the CRT-D group and 364 
of 904 patients (40.3%) in the ICD group. In the CRT-D group, 186 patients died, 
compared with 236 in the ICD group (hazard ratio, 0.75; 95% CI, 0.62 to 0.91; P = 
0.003), and 174 patients were hospitalized for HF, as compared with 236 in the ICD 
group (hazard ratio, 0.68 95% CI, 0.56 to 0.83; P<0.001). As in MADIT-CRT, RAFT 
therefore showed a reduction in HF hospitalisation in patients with mild heart failure 
but, unlike MADIT-CRT, RAFT showed a significant reduction in mortality in the 
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CRT-D group albeit with an increased risk of adverse events (haemo/pneumothorax, CS 




As a result of the above studies, numerous guidelines are available to help determine 
whom we should implant with a CRT device. One of the most recently published 
guidelines comes from the European Society of Cardiology (ESC) (28) and a summary 
of this guidance is given in table 2. 
 
The British NICE guidelines (29) from 2007 do not specifically address the issue of 
patients with a concomitant class 1 pacing indication or those in atrial fibrillation and 
excludes those in NYHA class I or II heart failure from receiving a CRT. Another key 
difference between the ESC and NICE guidelines is that NICE specifies that patients 
should not only be NYHA class III-IV and have an EF ≤ 35% but the QRSd should be ≥ 
150ms. If the QRSd is between 120 and 149ms a CRT should only be implanted if the 
patient has evidence of mechanical dyssynchrony on echocardiography. Although it is 
clear that patients with a very broad QRS (>150ms) are more likely to improve with 
CRT (26, 30), as we shall see, the NICE recommendation that mechanical dyssynchrony 







Recommendation Patient Population Class Level 
CRT-P/CRT-D 
recommended to reduce 
morbidity and mortality* 
 
-NYHA  III/IV 
-LVEF ≤35% 
-QRS ≥120 ms 
-Sinus rhythm 
-Optimal medical therapy 









CRT preferentially by CRT-D 
 recommended to reduce 





-QRS ≥150 ms 
-Sinus rhythm 








CRT-P/CRT-D should be 





-Permanent atrial fibrillation 
-Pacemaker dependency induced 
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-Slow ventricular rate and frequent 


















-QRS ≥120 ms 
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-QRS <120 ms 









Table 2. 2010 Update of ESC Guidelines on Device Therapy in Heart Failure 
Class=class of evidence. Recommendation=Level of Evidence (28) 
*Reasonable expectation of survival with good functional status for 1 year for CRT-




‡No admissions for HF during the last month and a reasonable expectation of 
survival 6 months 
 
CRT Implant Failure and ‘Non-response’ 
 
In 5-15% of patients undergoing CRT, it is not possible to implant an LV lead (31-33). 
This may because of an inability to cannulate the coronary sinus (CS) ostium, an 
inability to pass the LV lead into a CS branch, unsatisfactory pacing parameters, or 
phrenic nerve stimulation (PNS). In a study of 197 consecutive patients undergoing 
CRT, Biffi et al (34) showed that clinically relevant PNS occurred in 22% of patients at 
CRT implant or follow-up and that its occurrence was highest in those patients for 
whom the LV lead was placed at pacing sites most associated with reverse remodelling. 
In the aforementioned study, 7% of patients required an LV lead revision or CRT to be 
turned off. 
 
We have seen that when a CRT device is successfully implanted, it can improve heart 
failure symptoms, exercise capacity and quality of life as well as causing reverse 
remodelling and reducing hospitalizations and risk of death in patient populations with 
LV dysfunction and a broad QRS.  Around 30% of patients do not respond to CRT, 
however, in terms of improvement in symptoms, reverse LV remodelling, freedom from 
hospitalisation or indeed death (25, 35). This may be because the LV is not paced 
optimally (36) or because the patient will not respond to CRT no matter where the LV 





Thus strategies to improve CRT outcome include:  
 Developing better methods of identifying patients who will respond to 
CRT 
 Reducing CRT implant failure 
 Selecting and pacing the regions of the LV most likely to improve 
electrical and mechanical dyssynchrony 
  Optimisation of device settings 




Although there is good evidence that the patients most likely to respond to CRT have a 
QRSd ≥ 150ms, a recent meta-analysis(37) of 5 CRT RCTs reporting clinical events 
according to different QRS ranges suggests that, regardless of NYHA class, only those 
patients with a QRS duration greater than 150ms have a significant reduction in clinical 
events (death/ hospitalizations). The NICE guideline requirement that patients should 
have mechanical dyssynchrony on echo (see Chapter 2 General Methods) if they have 
a QRSd  of 120-149ms  reflects the fact that this patient cohort is less likely to respond 
to CRT than those with a QRSd ≥ 150ms. Nonetheless, this requirement appears 
outdated since the 2008 PROSPECT multi-centre study (38) was published. In this 
study of 498 patients undergoing CRT, 12 conventional and tissue doppler echo 
parameters were assessed as to their usefulness in predicting response to CRT. Despite 
site training in acquisition methods and central analysis, there was large variability in 
the analysis of the dyssynchrony parameters and no single echocardiographic measure 
of dyssynchrony could be recommended to improve patient selection. 
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Given the poor predictive value of standard and tissue doppler echo parameters in 
determining who will benefit from CRT, attention has turned to other methods of 
identifying likely responders. These include strain imaging (39) and scar burden as 
assessed by myocardial perfusion imaging (40) and CMR(41).  
 
Reducing Implant Failure 
 
Failure to cannulate the CS ostium or an inability to pass the LV lead into a CS branch 
can sometimes be predicted by pre-procedure imaging with cardiac magnetic resonance 
(CMR) imaging or CT. If the requisite sequences have been performed, the implanter 
may simply view the CMR or CT images prior to the implant to gain an idea of what to 
expect during the procedure. It is also possible for the CS anatomy to be overlaid on to 
fluoroscopic images in real-time during the implant itself to guide the operator (Figure 
3) (42). 
 
Figure 3. Overlay of CS Anatomy on to Fluoroscopy 
(A) An occlusive venogram. (B) The overlay of 3D coronary sinus (CS) segmentation 
from CMR imaging with a centre line for both the venogram and the overlaid 
coronary veins. This is used to determine the registration error. (C) How the overlaid 
coronary veins appear to the operator during an implant. This image was taken 
during the occlusive venogram to show the close correspondence with anatomy (42) 
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Imaging may be particularly helpful for inexperienced operators who have difficulty in 
locating the CS os using radiological landmarks alone. Perhaps more importantly, 
however, imaging may identify a thebesian valve or small CS os that may make CS 
intubation difficult for implanters of all ability. Such imaging can also identify unusual 
CS anatomy such as a persistent left sided vena cava (43). Even if these imaging 
modalities are not available at implant, in cases where there has been failure to gain CS 
access at first attempt, imaging can be used to guide any reattempt. 
 
 
Figure 4. CMR Image Overlay to Guide Implant in a Patient with Persistent Left-
Sided Vena Cava 
Image showing how CMR data can be used to create an anatomical model of the 
cardiac chambers and CS (connected to persistent left sided vena cava) which is then 
overlaid at implant. The hand injection venogram shows that the CS and great 
cardiac vein are massively dilated with no obvious target vessels for LV lead 
placement seen. The overlay depicted in blue shows the position of the branches and 
selective occlusive venogram of the posterior vein of the LV (PVLV) corresponds with 
the overlaid anatomy. The LV lead seen in its final position in the distal PVLV. 
LSVC= left subclavian vein; LMV=left marginal vein (43) 
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Other reasons for CRT implant failure are high lead capture thresholds or PNS at 
implant or follow-up. PNS and high capture thresholds are a particular problem with the 
LV lead because of the anatomy of the phrenic nerve and the relative technical difficulty 
in manipulating the LV lead into different positions if an initial site is unsatisfactory. 
One potential solution to this problem is ‘electronic repositioning’. This involves 
changing the pacing vector used to stimulate the LV and at least 4 different pacing 
configurations are usually possible with current LV leads. Quadripolar left ventricular 
leads currently allow the greatest number (10) of possible pacing configurations because 
of the two extra ring electrodes located on the LV lead compared to conventional 
bipolar leads (44). Chapter 3 will look in detail at quadripolar lead technology as a 
method of overcoming CRT implant failure and describes our experience of using this 
lead. 
 
Targeted LV Lead Placement 
 
The LV lead is often placed in a postero-lateral or lateral position in the CS as early 
studies suggested that this position generally produced the best haemodynamic response 
(45, 46).  Patients may not respond to such empirical lead placement if they have 
postero-lateral scar (36, 47), however, and more recent large scale studies have shown 
no overall difference in CRT response when an LV lead is placed in an anterior, 
posterior or lateral position (though a mid or basal location appears superior to an apical 
position) (48-50). 
 
Thus, although LV lead positioning appears to be critical to the likelihood of CRT 
response, the ideal target region for an individual patient is not clear. Derval et al (51) 
systematically assessed the haemodynamic response to LV pacing from 10 endocardial 
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and 1 epicardial (CS) predetermined LV sites in a random order: basal and mid-cavity 
(septal, anterior, lateral, inferior), apex, coronary sinus (CS), and the endocardial site 
facing the CS pacing site. They found major inter-individual and intra-individual 
variations in haemodynamic response depending on the LV pacing site but concluded 
that an optimal LV pacing site cannot be defined a priori and is specific to each 
individual (Figure 4). Thus although there do not appear to be large group differences 
in general anatomical site of LV lead placement, there are large differences within 
patients and we need to develop methods of identifying and targeting the region of the 
LV that will give the best response to LV pacing within an individual patient. 
 
 
Figure 5. Best and Worst Pacing Sites. 
Distribution of best (A) and worst (B) left ventricular pacing site among the 11 tested 
sites demonstrates that no one site is consistently best (or worst) (51). 
 
Recently Khan et al (52) have used strain imaging to identify the most delayed segment 
of contraction and absence of scar. The authors conducted an RCT in which they 
targeted LV lead placement in the most delayed viable segment defined by speckle-
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tracking echocardiography compared with usual care. They found that compared with 
standard CRT treatment, the use of speckle-tracking echocardiography to target LV lead 
placement significantly improved clinical status and reduced the combined endpoint of 
death and heart failure-related hospitalization. 
 
CMR dyssynchrony data can be used as an alternative to echo indices and Chapter 5 
describes its use in conjunction with CMR-derived anatomical information to guide LV 
lead placement during CRT implant. Although the temporal resolution of CMR is lower 
than echo it has the advantage of better spatial resolution and the availability of scar 
data if delayed enhancement (DE) imaging is used.  Chapter 5 details how CMR 
dyssynchrony can be used not only to identify patients likely to respond to CRT but, in 
conjunction with overlay technology, how  CMR scar and dyssynchrony data can be 
used in real-time to guide LV lead placement at implant to the region most likely to 




The optimal outcome from CRT may be dependent on optimal programming of the 
pacemaker device. The atrio-ventricular (AV) timing of the device can be programmed 
such that it allows adequate time for passive filling of the ventricles but not so much 
time that the ventricles have a chance to beat on their own. The LV-RV (VV) delay can 
be programmed such that both ventricles contract in the most synchronised way. The 
AV and VV delay settings are usually optimised using echocardiography derived 
indices although other methods (e.g. using a pressure wire, impedance cardiography, 
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pulse pressure) can be used to choose the timings that appear to give the best cardiac 
output.  
 
Echo assessment of AV dyssynchrony can be measured using a pulsed wave doppler 
recording of trans-mitral inflow (Figure 6), which requires the sample volume to be 
placed at the tips of the mitral leaflets (53).  
 
Figure 6. Optimisation of AV Delay after CRT 
The pulsed doppler mitral inflow pattern is seen. At a programmed AV delay of 180 
ms (left panel) the closure of mitral valve occurs before the onset of ECG QRS. 
Optimizing AV delay at 120 ms (right panel), the diastolic filling time is much longer 




VV interval optimisation probably has less of an effect on overall cardiac output but 
may have a small additive benefit (53). The ideal VV interval is usually determined by 
the delay that gives the best aortic or LVOT VTI measurement (a surrogate for cardiac 
output) (figure 7). 
 
Figure 7. VV Interval Optimisation. 
Interventricular interval delay using left ventricular outflow tract (LVOT) 
measurements of blood flow velocities for estimation of stroke volume (SV). Stroke 
volume is exponentially related to the left ventricular outflow tract diameter and 
directly to the velocity–time integral (VTI) of the left ventricular outflow tract. 
Variation of the interventricular interval (VV) interval affects the stroke volume as 
evidenced by varying volume–time integral measurements that can serve as surrogate 
markers for resynchronization. The optimal interventricular interval in this example 





Although some centres expend considerable time and resources optimising CRT timings 
at implant and/or follow-up device checks, the evidence that this makes a difference to 
outcome is equivocal. The RHYTHM II ICD study (55) single-blind randomized trial of 
121 CRT patients found no difference in outcome (freedom from CRT-D system–
related complications/NYHA class/6 minute walk distance (6MWD)/quality of life) at 6 
months between those patients randomised to an echo optimised VV delay versus those 
whose devices were programmed to pace both ventricles simultaneously. Similarly, the 
DECREASE-HF multicentre randomized trial (56) evaluated 306 CRT patients after 6 
months and found no significant difference in reduction in LV end-systolic and end-
diastolic dimensions in those patients randomised to sequential BiV (optimised VV 
delay) pacing versus simultaneous BiV or LV only pacing. Indeed there was a trend 
toward greater echocardographic improvement in the BiV simultaneous group.  
 
More recently Ellenbogen et al’s SMART-AV study (57) randomised 980 patients who  
received a CRT-D  in a 1:1:1 ratio to a fixed empirical AV delay (120 ms), 
echocardiographically optimized AV delay or AV delay optimized with SmartDelay ( a 
proprietary electrogram-based algorithm). At six months, no significant difference in the 
primary endpoint of reduction in ESV or the secondary endpoints of change in LVEDV, 
LVEF, 6MWD, quality of life, and NYHA class were seen between arms. The authors 
thus concluded that the routine use of the AV optimization techniques assessed in that 
trial were not warranted. It was conceded, however, that in certain patients who do not 






Acute Haemodynamic Response 
 
The maximum rate of rise of intra-ventricular pressure (dP/dt max) has been used as a 
marker of global myocardial contractility for many years (58). dP/dt max correlates with 
event-free survival (59, 60) and can be derived in a reproducible manner by invasive 
measurement. This can be performed using a pressure wire passed to the LV cavity, 
giving haemodynamic data in real-time which can be used to assess baseline LV 
contractility and the acute haemodynamic response (AHR) to pacing in different ways 
(61, 62). More recently data from our own centre has shown that AHR is a useful 
predictor of reverse remodelling at 6 months in patients with both ischaemic and non-
ischaemic aetiologies (63). 
 
For our studies we used a fine calibre (0.014 inch) high fidelity Certus pressure wire 
(RADI Medical Systems, Uppsala, Sweden) with a torque similar to an angioplasty 
wire. There is a pressure sensor located 30mm from its tip (Figure 8) that records 
intraventricular pressure with a frequency of 600Hz. 
 
Figure 8. RADI Pressure Wire Structure. 
 
When making measurements with the pressure wire is important to maintain a constant 
heart rate as dP/dt max is influenced by heart rate through the force-frequency response. 
dP/dt max is also to some degree dependent upon the loading conditions of the heart 
being increased by factors causing an increase in pre-load or afterload. The changes in 
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loading conditions during the time-frame of an acute haemodynamic assessment, 
however, are likely to be small, with changes in afterload predominating due to changes 
in vascular tone. The maximum rise in pressure probably occurs during the 
isovolumetric phase of ventricular contraction and this is less influenced by afterload 
than parameters derived from the ejection phase of ventricular systole. Nonetheless it is 
important during studies to try to keep intra-vascular volumes stable and minimise 
changes in sympathetic drive (avoiding over and under-sedation). 
 
Multi-site and Endocardial Pacing 
 
Although many studies are underway investigating the possible advantages of pacing 
from two or more left ventricular sites rather than the conventional one for cardiac 
resynchronisation therapy (CRT), no large studies have yet been published. What 
follows is a summary of the small studies performed thus far. 
 
In 2000, Pappone et al (64) hypothesized that pacing two left ventricular sites 
simultaneously would produce faster activation and better systolic function than single-
site pacing. 14 heart failure patients (NYHA III or IV) in normal sinus rhythm with left 
bundle branch block and a QRS duration greater than 150 ms were studied. Pacing leads 
were positioned via the coronary veins at the posterior base and lateral wall. Patients 
were acutely paced VDD at the posterior base, lateral wall, and both sites (dual-site) 
with 5 atrio-ventricular delays (from 8 ms to PR -30 ms) in a random order. Dual-site 
pacing increased peak dP/dt max significantly more than posterior base and lateral wall 
pacing (figure 9). Dual-site and posterior base pacing raised aortic pulse pressure 
significantly more than lateral wall pacing. Dual-site pacing shortened QRS duration by 
22 %, whereas posterior base and lateral wall pacing increased it by 2 and 12%, 
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respectively (p = 0.006). The authors therefore concluded that in heart failure patients 
with left bundle branch block, dual-left ventricular site pacing improves systolic 
function more than single-site stimulation. The authors suggested that improved 
ventricular activation synchrony (narrowing of the paced QRS) may have accounted for 
the additional benefit of dual vs single-site pacing in enhancing contractility. 
 
Figure 9. Pappone et al Multi-site Pacing Study 
Bar graph comparing haemodynamic changes produced by single-site pacing from 
the posterior base or lateral wall and by dual-site pacing. For each of the three pacing 
strategies, haemodynamic effects were not significantly different in patients grouped 
by aetiology of heart failure (ischaemic, n = 4; idiopathic, n =10). DCM = dilated 
cardiomyopathy LVEDP = left ventricular end-diastolic pressure; PP = pulse 
pressure(64) 
 
In 2008 Padeletti et al (65) reported a small study of acute haemodynamic response to 
simultaneous stimulation of 2 LV sites. Two LV pacing leads were successfully 
implanted in 12 CRT candidates (NYHA class III-IV, QRS duration greater than 
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120ms). Target positions were the lateral or posterolateral vein (site A) and anterior or 
anterolateral vein (site B). Tested CRT configurations were alternated by atrial 
overdrive pacing at a fixed rate and included site A and B single-site CRT and dual-site 
LV CRT (2 LV sites plus right ventricular apex) at 4 atrioventricular intervals. Overall, 
single-site LV CRT significantly enhanced stroke volume, stroke work, maximum 
pressure derivative and conductance-derived indexes of LV synchrony when delivered 
in site A whereas no significant changes were noticed with pacing in site B. 
Specifically, site-A pacing resulted in a higher stroke volume increase. Indeed, site-A 
LV pacing was associated with the best hemodynamic response in 8 patients, and site-B 
in 4 patients. At intermediate atrioventricular intervals, dual-site LV CRT resulted in 
improved stroke volume, stroke work, maximum pressure derivative, and LV synchrony 
with respect to single-site CRT delivered at the best-LV site (all p <0.05). However, 
single-site CRT at the best-LV site produced results similar to dual-site LV CRT when 
the atrioventricular interval was optimized in each patient. The authors thus concluded 
that adding a second LV lead did not result in further improvement in acute 
haemodynamic response with respect to standard CRT when the single LV pacing site 
and atrioventricular interval are optimal. 
 
The TRIP-HF (66) (TRIPle Resynchronization in Paced Heart Failure Patients) trial was 
designed to examine whether biventricular stimulation with 1 right ventricular (RV) and 
2 LV leads increases the response to CRT and produces a greater improvement in 
cardiac performance and LV reverse remodelling than standard biventricular stimulation 
in patients with permanent atrial fibrillation. This multicenter, single-blind, crossover 
study enrolled 40 patients (mean age 70+/-9 years) with moderate-to severe heart failure 
despite optimal drug treatment, a mean LVEF of 26+/-11%, and permanent atrial 
fibrillation requiring cardiac pacing for slow ventricular rate. A CRT device connected 
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to 1 RV and 2 LV leads (inserted in 2 separate coronary sinus tributaries spaced as 
widely apart as possible), was successfully implanted in 34 patients. 
 
After 3 months of biventricular stimulation, the patients were randomly assigned to 
stimulation for 3 months with either 1 RV and 2 LV leads (3-V) or to conventional 
stimulation with 1 RV and 1 LV lead (2-V), then crossed over for 3 months to the 
alternate configuration. The primary study end point was quality of ventricular 
resynchronization (Z ratio). Secondary end points included reverse LV remodelling, 
quality of life, 6MWD and procedure-related morbidity and mortality. Data from the 6 
and 9 month visits were combined to compare end points associated with 2-V versus 3-
V. Data eligible for protocol-defined analyses were available in 26 patients (table 3) . 
No significant difference in Z ratio, quality of life and 6-min hall walk was observed 
between 2-V and 3-V. However, a significantly higher LV ejection fraction (27 +/-11% 
vs 35+-11%; p=0.001) and smaller LV end-systolic volume (157+/- 69 cm3 vs 134+/-75 
cm3; p=0.02) and diameter (57+/-12 mm vs 54+/-10 mm; p=0.02) were observed with 
3-V than with 2-V. There was a single minor procedure-related complication. The 
conclusion of the study was that cardiac resynchronization therapy with 1 RV and 2 LV 
leads was safe and associated with significantly more LV reverse remodelling than 




Table 3. Leclercq et al. Multi-Site Pacing Study Reverse Remodelling Data 
Echocardiographic outcome of conventional dual-site (2-V) versus triple-site (3-V) 
pacing 
 
Lenarczyk published a further study of triple-site (dual LVsite, single RV site) pacing v 
conventional CRT. Fifty-four patients in NYHA class III–IV, EF ≤35% and QRS ≥120 
ms were included. 27 received triple-site pacemakers (TRIV group) and 27 conventional 
CRT devices (BIV group). The procedure duration was higher in the TRIV than in the 
BIV group (197.6 vs. 137.6 min, P=0.001), fluoroscopy exposure and complication-
rates were similar. After 3 months of CRT, triple-site pacing was associated with a more 
significant (P=0.05) NYHA class reduction (by 1.4 vs. 1.0 class), increase in VO2 max 
(2.9 vs. 1.1 mL/kg/min) and 6MWD (98.7 vs. 51.6 m) than conventional CRT. A higher 
EF and more improved intraventricular synchrony were observed in the TRIV than in 
the BIV group. The response rate in the TRIV group was 96.3% vs. 62.9% in the 
conventional group (P=0.002). Triple-site stimulation was an independent predictor of 
response to CRT (adjusted odds ratio 26.4, p=0.01). The conclusion of this study was 
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that triple-site resynchronization appeared to be more beneficial than conventional CRT 
and that an upgrade to triple-site CRT should be considered in non-responders to 
standard resynchronization. The authors do note, however, that this was a retrospective, 
non-randomized, single centre observational analysis whereby a triple-site technique 
was compared with an historical group of patients who had previously undergone a 
standard CRT implant (67). 
 
Our own centre published a study of dual epicardial (CS) site pacing versus 
conventional CRT in 2011 (68). This was a single centre acute haemodynamic study on 
20 patients (ischaemic and non-ischaemic aetiology). Standard RA +RV leads were 
used and a St Jude Medical Quickflex or Medtronic 4196 LV lead. One lead was placed 
in a postero-lateral vein (LV1) and a 2
nd
 lead in a lateral, anterior or middle cardiac vein 
(LV2). LV dP/dt max was recorded using a pressure wire during stimulation at LV1, LV2 
and both sites simultaneously (LV1 + LV2). Patients were deemed acute responders if 
the increase in LV dP/dt max was ≥10%. It was found that multi-site LV pacing increased 
the AHR by 16% vs. single-site pacing and was particularly beneficial in patients with 





Figure 10. Ginks et al. 2 LV Study 
Acute haemodynamic response by left ventricular pacing configuration 
 
More recently, Rogers et al (69) also published a study of dual epicardial site pacing. 
The authors describe how 43 patients were implanted with a TRIV device (RV apical 
lead + 1 lateral CS LV lead + a further CS or RV lead). In all patients an attempt was 
made to place a 2
nd
 epicardial CS lead and if this was not possible a 2
nd
 RV lead (placed 
in the high RV septum) was implanted. Devices were programmed in a randomized 
order to four pre-determined pacing configurations: conventional BiV, TriV, and dual-
site and single-site left biventricular (LV) or RV pacing for 3-month periods with 
clinical and echo assessment at the end of each period. Compared with BiV pacing, 
TriV pacing resulted in significant improvements in 6MWD, quality of life, reduction in 
LV ESV and improvement in LVEF even in the patients who received 2 RV leads rather 





Table 4. Rogers et al. Multi-Site Pacing Study 
Comparison of results for baseline, and after BiV and TriV pacing (69) 
 
Pacing the LV epicardially via the CS is limited by the distribution of the CS veins. 
Thus even if echo or CMR were to suggest that a particular region of the LV was the 
latest activated and most likely to respond to LV pacing, it may not be possible to pace 
there because no CS vein overlies the target area or the CS tributary is inaccessible. LV 
endocardial pacing is not constrained by CS vein anatomy and there is evidence to 
suggest that pacing from the LV endocardium is more physiological and thus results in 
better electrical and mechanical propagation and AHR (70, 71). Indeed there is recent 
evidence to suggest that not only is pacing the LV endocardium better than conventional 
epicardial LV pacing, but that when conventional epicardial LV pacing via the CS and 
RV  is added to LV endocardial pacing, there is an additive effect on AHR. 
 
In a recent study of 10 patients (7 ICM and 3 DCM) at our institution by Ginks et al 
(72) a temporary LV pacing lead was placed in a CS branch and an LV endocardial 
catheter placed in anterior, posterior and lateral positions in the LV cavity. Various 
combinations of LV endocardial (LVEN), RV and LVEN (BIVEN), conventional CS 
epicardial and RV (BIVCS) and conventional BIVCS pacing with LVEN (TRIV) 
pacing were assessed for AHR. TRIV pacing resulted in the greatest overall mean 
increase in AHR (figure 11) and reduction in QRSd. All forms of endocardial pacing 
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Figure 11. Ginks et al. TRIV Study 











































To summarise the findings of multi-site pacing studies thus far: 
 
 Pappone et al found an acute haemodynamic advantage to pacing two LV sites 
simultaneously compared to one. 
 
 Pedeletti found that that although there was an improvement in acute 
haemodynamic response from dual LV site pacing, there was no significant 
difference between this and single site LV pacing in the optimal site and with 
the optimal AV delay. 
 
 
 TRIP-HF looked specifically at patients with atrial fibrillation and found no 
difference between dual site LV pacing and conventional CRT in terms of its 
predefined echo-derived primary endpoint (Z ratio). It did, however, perhaps 
more importantly, find a significant improvement in ejection fraction and 
reduction in LV end systolic volume and diameter when patients were paced ‘3-
V’ (dual site LV and RV pacing) than ‘2 V’ (conventional single site RV and 
LV CRT pacing). 
 
 Lenarczyk’s study is the largest of the published multi-site pacing studies and 
appears to confirm the findings of TRIP-HF and the early work performed by 
Pappone i.e. pacing two left ventricular sites is better than one. Lenarczyk found 
significant improvements in NYHA class, VO2 Max and 6MWD in the TRIV 
group compared to the standard BIV group. Indeed the responder rate was an 




 Rogers et al found that TRIV pacing (including from 2 RV sites) was associated 
with significant improvements in clinical and echocardiographic parameters 
compared with BiV pacing. 
 
 Ginks et al found that pacing from two epicardial LV sites increased the acute 
response by 16% vs. single-site pacing and was particularly beneficial in 
patients with postero-lateral scar. In a separate study, Ginks et al found that LV 
endocardial pacing was better than conventional biventricular pacing and that 
the combination of LV endocardial, RV and LV epicardial (CS) pacing gave a 
particularly good AHR with significant reduction in QRSd. 
 
Although the data regarding multi-site LV pacing is limited to small studies, some of 
which are non-randomised, there is evidence to suggest that pacing the ventricles form 
more than the usual 2 RV and LV sites may be more beneficial than conventional CRT 




The idea of reconstructing intra‐cavity potentials mathematically without contact with 
the walls of the heart was reported by Taccardi et al. in 1987 (73). The authors 
described how ‘pseudoisochrone’ contour maps recorded from an array of semi-direct 
electrodes, regularly distributed on the surface of an intraventricular probe could 
provide information on the site of origin of ectopic paced beats in a normal dog heart. 
The derived potentials were found to be spatially averaged and of lower amplitude than 
the raw signal, however. Non‐contact mapping (NCM) has evolved since then and is 
now used clinically, for recording and mapping electrical potentials particularly in 
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cases, for example, such as right ventricular outflow tract tachycardia where activation 
mapping and pace mapping may have limited use because of  infrequent ventricular 
ectopy or non-sustained VT (NSVT) (74, 75).  
 
For the purposes of our study (Chapter 7) the EnSite 3000 non‐contact mapping system 
(St Jude Medical, Sylmar, USA) was used. This consists of a multi‐electrode array 
(MEA) with 64 laser‐etched electrodes mounted on a wire braid on a 8mm balloon  
(figure 12).This is seated on a 9F catheter, which allows introduction of the balloon in 






Figure 12. The EnSite Non-Contact Mapping Balloon 
 
The geometry of a chamber can be reconstructed using a low current locator signal 
emitted from the tip of the MEA, at 5.68Hz. This is sensed by two ring electrodes 
mounted on either side of the MEA balloon. With this system, other catheters can be 
localised in 3D. A roving electro physiological (EP) catheter is moved around the 
chamber to define the location of the chamber walls in 3D. The array then records 
intra‐cavity far‐field potentials that are sampled at 1.2kHz and digitally filtered at 
0.1‐300Hz. The resulting signals are resolved using the inverse solution to Laplace’s 
equation by the boundary element method. This allows mathematical reconstruction of 
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over 3000 virtual unipolar electrograms, which are superimposed on the chamber 
geometry. Both isopotential and isochronal maps can be generated, with colour coding 
to allow the endocardial activation pattern to be visualised. Data can be analysed 
off‐line in any orientation. Dynamic substrate mapping (DSM) is an algorithm that can 
be used to mark areas of substrate activation by observing how isopotential maps 
display the wavefront moving around lines of block, anatomic barriers, zones of slow 
conduction, or diseased tissue within a cardiac chamber. 
 
Schilling et al (76) demonstrated that the EnSite 3000 noncontact mapping system 
accurately reconstructs endocardial unipolar electrograms from the human left ventricle 
at distances from the MEA centre to endocardium (M-E) of up to 34mm. Using NCM, 
Auricchio et al showed the high prevalence of functional lines of block in patients with 
LBBB, often with the pattern of activation taking a “U‐shape” around the area of slow 
conduction (figure 13). Furthermore, the authors found that areas of slow conduction 
could be defined by low voltage or fragmented electrograms and concluded that NCM 





Figure 13. Type II LV Activation Pattern 
Figure demonstrating a U-shaped activation front that rotates around the apex and 
activates the lateral wall late.  NCM = non-contact mapping; CM=contact 
mapping(77) 
 
Lambiase et al (78) performed an NCM study to characterise the effect of CRT on left 
ventricular activation  and to examine the electrophysiological factors influencing 
optimal left ventricular lead placement. The authors demonstrated that pacing the LV in 
an area of slow conduction was associated with a significantly reduced haemodynamic 
benefit from CRT when compared with pacing outside these areas.  Biventricular pacing 
the left ventricle 32 ms before the right ventricle appeared to induce the optimal mean 
velocity time integral (VTI) and timing for fusion of depolarisation wavefronts from the 
RV and LV pacing sites. Furthermore, pacing outside regions of slow conduction was 
found to decrease left ventricular activation time (LVAT) and increase cardiac output 
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and dP/dtmax significantly thus suggesting that the mechanism of improved AHR was 
correction of the delayed LV activation.  
 
Fung et al (79)  performed a non-contact-mapping and echo study of 23 optimally 
treated patients with NYHA class III HF, QRS duration ≥120 ms and LVEF≤35%. The 
authors’ aim was to evaluate patients’ electromechanical properties by NCM and echo 
tissue Doppler imaging (TDI) and determine its relationship to CRT response. The 
authors described two distinct types of activation pattern (as previously described by 
Auricchio et al (77)) in patients with intra‐ventricular conduction delay and found that 
CRT response was higher in the patients with (type II) functional block as compared 
with a more homogeneous (type I) activation pattern in terms of improvement in 
functional status, significant LV reverse remodelling and reduction of clinical events at 
3 month follow-up. 
 
Finally, Ginks et al (71) performed a study of 15 patients (age, 63 +/- 10 years; 12 men) 
awaiting CRT in a combined x-ray and CMR laboratory. Patients underwent CMR DE 
imaging and an electrophysiological study incorporating endocardial and epicardial LV 
pacing. The AHR during different modes of pacing was determined using a pressure 
wire and NCM was used to define areas of slow conduction.  The authors found a 
significant improvement in all LV pacing modes versus baseline (p<0.001) and that LV 
endocardial CRT from the best endocardial site was superior to conventional CRT 
(P<0.05). The haemodynamic benefits of pacing were greater when LV stimulation was 
performed outside of areas of slow conduction defined by NCM (p<0.001). The authors 
also found that CMR DE imaging was able to delineate zones of slow conduction seen 




We have thus seen that since it’s development in the 1980s non-contact mapping has 
evolved and is now considered a useful tool not only for research purposes but also 
clinically in patients in whom characterisation of infrequent ectopic beats or NSVT is 
not possible with conventional activation  or pace mapping. It has been shown that 
pacing outside areas of slow conduction identified by NCM is likely to lead to a better 
AHR and that NCM can be used to characterise the LV activation pattern in patients 
with heart failure and thus determine the likelihood of response to CRT.  Those with a 
type II or ‘U shaped’ activation pattern appear to have a predominantly non-ischaemic 
aetiology and it is these patients who are most likely to respond to CRT both acute and 
chronically. NCM accuracy is reduced as the distance of the MEA from the endocardial 
surface increases but at distances up to 34mm is considered reliable. 
 
Body Surface Potential Mapping 
 
This is a non-invasive method of reconstructing electrical sources in the heart using an 
80-channel active electrode system. As part of our Multi-Site Pacing Haemodynamic 
and Electro-anatomic Mapping Study (Chapter 7) we have ethical approval to use the 
ACTIVETWO system manufactured by BIOSEMI (figure 14). BSPM has already been 
used to reconstruct the location of infarcted areas of the heart and the site of simulated 
ventricular ectopics (80). Although body surface potential mapping has been available 
for many years it has not been validated against contact or non-contact mapping 
techniques. Although I performed pilot work to confirm that it was possible to use 
BSPM prior to CMR in patients pre-CRT, the logistics of placing the electrode system 
on our Multi-Site Pacing Haemodynamic and Electro-anatomic Mapping Study patients 
meant that we have not yet been able to compare this non-invasive mapping system to 
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the NCM. This will happen in the future and if successful BSPM may negate the need 













Personalised Models of the Heart (‘Grand Challenge’) 
 
We have seen from Derval et al’s (51) work that the best pacing site for individual 
patients cannot be determined a priori and that the best and worst site is different in 
different patients. We have also seen that the best method of pacing in patients may be 
multi-site or endocardial. In this thesis I describe various invasive studies that I 
undertook to determine the AHR and electro-anatomic mechanism underlying response 
whilst pacing in different ways. Ideally, however, we would be able to determine 
whether a patient was going to respond to therapy before implanting a device and if so 
predict the best site and method of pacing a patient using simple, non-invasive means.  
We have seen in the section above that BSPM is one non-invasive method of gaining 
detailed information about electrical activity in the heart. ‘The Grand Challenge 
Modelling’ Project (see Appendix 2) seeks to address this issue by creating biophysical 
models of left ventricular mechanical, electrical and haemodynamic function from data 
acquired from echocardiography and cardiac magnetic resonance imaging that can 
predict the mechanical, electrical and haemodynamic response to CRT 
 
Using echo, CMR, CPEX, 6MWT and MLWHFQ data on patients pre-CRT and regular 
repeat measures at regular follow-up (CMR will only be performed pre-implant), the 
study aims to combine this data with invasive pressure wire and electro-anatomic 
mapping data to create computer models of patients’ hearts. By modeling the hearts of 
patients pre-CRT and the changes that occur at regular intervals after CRT, it is hoped 
that we will be able to use this data to create accurate models of the hearts of patients 
who have not yet been implanted with a device (using echo and/or CMR data as a base). 
Thus simulations will be created of what will happen in response to pacing patients’ 
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hearts in different ways pre-CRT. It may then be possible in the future to decide not to 
implant a device in a patient that computer modeling predicts will not respond to any 
form of CRT. It may also be possible to determine the exact type 
(conventional/endocardial or multi-site) and site of pacing that will give the best 
response in a particular patient. 
 
I designed the study protocol and submitted the research ethics application for this study 
(which has been approved). Prior to completing my 2 year research period I recruited 
the first patients to this multi-centre study.  The Grand Challenge Modelling Project is a 
large on-going collaboration between various UK research institutions that will take at 
least 2 more years to complete. Thus although no results from this study are yet 
available, the potential application of the technology developed is exciting. 
 
An example of the computer modelling that is currently available (based on historic 
CMR, NCM and AHR data) is described in chapter 7 (81). This chapter brings together 
the use of quadripolar lead technology, multi-site pacing and computer modelling. This 
is detailed study of 1 patient involves simulating multiple different methods of multi-
site pacing the heart and thus predicts the resulting AHR and changes in electrical 
activation that would be seen. It is this type of model we hope to be able to create using 
non-invasive data pre-CRT. We would thus be able to non-invasively assess the 
response of an individual to different types of pacing and this would enable us to decide 
whether CRT is a worthwhile option in a particular patient and if so the best place to 




Chapter 3. General Methods 
Patients 
St Thomas’ Hospital local ethics committee approved all of the studies described in this 
thesis (Appendix 2). All patients provided written informed consent. Studies were 




Patients with a CRT device generally fulfilled NICE guidelines (29): 
 Heart failure with New York Heart Association (NYHA) Class III-IV 
symptoms 
  Patients should be on optimal medical therapy 
 Have significantly impaired LV function (ejection fraction <35%) 
 QRS duration >150ms on ECG or QRS duration between120 and 149ms 
with evidence of dyssynchrony on echocardiography. 
 Age > 18 years 
Exclusion Criteria 
 Contra-indication to CMR scan 
 Significant renal impairment (eGFR<30ml/min/1.73m2) 
 Expected survival < 6 months 
 Contra-indication to anticoagulation 
 Left ventricular thrombus 





 History and clinical examination 
 Routine blood tests including FBC, U&E, CRP 
 Minnesota Living With Heart Failure Questionnaire (MLWHFQ) 
 6 Minute Hall Walk Test (6MWD) 
 12 lead electrocardiogram (ECG) 
 2D and 3D echocardiography 




Echocardiographic assessment was performed using a VIVID 7 machine (General 
Electric, Milwaukee, USA) for 2D /3D imaging and an IE33 machine (Philips Medical 
Systems, Andover, Massachusetts) for 3D imaging. Standard views (parasternal long 
and short axis, apical 2,3,4 and 5 chamber and subcostal) were used. The St Thomas’ 





Figure 15. St Thomas’ Hospital Echocardiographic Acquisition Protocol 
LAX: long axis; SAX: short axis; 2C: 2 chamber; 3C: 3 chamber; 4C: 4 chamber; 
TDI: Tissue Doppler Imaging; PW: Pulsed Wave; TR: Tricuspid Regurgitation; 
LVOT: LV outflow tract; VTI: Velocity Time Integral; CW: Continuous Wave; 






Figure 16. Echocardiographic Parameters for Analysis 
TsSD: standard deviation in the time from Q wave to peak systolic contraction in the 
12 segment model SDI: systolic dyssynchrony index; CFM: colour flow mapping; t-
IVT: total iso-volumic time; MPI: myocardial performance index; PASP: Pulmonary 




Echo Dyssynchrony  
Echocardiographic evidence of dyssynchrony was deemed present if any of the 
following criteria were fulfilled: 
 LV pre-ejection period (LVPEP) > 140ms 
 Interventricular mechanical delay (LV minus RV pre-ejection period) > 40ms 
 Septal to lateral wall motion delay (TDI) > 60ms 
 3D Systolic dyssynchrony index > 10.4%(82) 
 
Measurement of LV and RV Pre-Ejection Periods 
Pulsed wave Doppler was used with the measurement made from the LV outflow tract 
(LVOT) in an apical 5 chamber view. The RV outflow tract (RVOT) was viewed in a 
parasternal short axis view. The pre-ejection period was defined as the time from the 
QRS onset on the ECG to the onset of flow. 
 
Tissue Doppler Imaging (TDI) 
Figure 17 shows an example of colour-coded TDI to assess intra-ventricular 
dyssynchrony (septal-lateral wall delay). Once acquired this data requires post-
processing to determine the wall velocities and whether dyssynchrony is present. The 
requirement that the basal septal to lateral wall motion delay should be ≥ 60ms is based 
on work by Bax et al (83, 84) suggesting that this predicts improvements in LVEF and 




Problems with TDI include the fact that two distinct peaks of tissue velocity may be 
seen during systole, giving rise to difficulties in measuring intervals. Furthermore, peak 
velocities may occur after the end of systole, giving rise to uncertainty as to whether 
these should be included in analysis. The PROSPECT study (38) found that there was 
great inter-observer variability in taking TDI measurements and thus although it may be 
effective in predicting outcomes when preformed by centres with special expertise, 
given that only between 37% and 82% of TDI measurements were interpretable by the 
core labs, the authors concluded that current technology, degree of training standards 
and analytic methods do not allow the use of TDI in a generalized setting. 
 
Figure 17. Tissue Doppler Imaging 
Colour-coded four-chamber tissue Doppler image (upper left). Post-processing yields 
velocity tracings (right); severe left ventricular dyssynchrony is present as indicated 
by the delay in the peak systolic velocity of the septum (yellow curve) as compared to 




3D Echo Systolic Dyssynchrony Index 
A 3D volume was acquired over multiple cardiac cycles using a single breathhold. This 
was analysed to give an accurate LVEF, LVEDV and stroke volume. Using TomTec 
software (TomTec Imaging Systems, Unterschleissheim, Germany) the 3D volume was 
subdivided into 16 sub-volumes (figure 18). It was then possible to derive time-volume 
data for the entire cardiac cycle and assess the time taken to reach the minimum systolic 
volume. The standard deviation of these values across 16 segments was expressed as a 
percentage of the cardiac cycle to give the systolic dyssynchrony index (SDI), which is 




Figure 18. Real-Time 3D Echo 
Image showing a 16 segment model created from a RT3DE acquisition (87) 
Real-time 3DE (RT3DE) has been shown to predict acute response to CRT (88) and, 
more recently, Kapetenakis et al (82) have shown that patients with a RT3DE SDI of 
≥10.4% are highly likely to respond to CRT in terms of reduction in NYHA functional 
class, 20% relative increase in LVEF and 15% reduction in LV end-systolic volume. 
Interestingly, in the afore-mentioned study, RT3DE SDI appeared to be equally 
predictive of response in patients not fulfilling traditional selection criteria (atrial 
fibrillation, QRS duration <120 ms, or undergoing device upgrade). 
 
A limitation of RT3DE is the large volume of acquisition required and this gives rise to 
relatively poor temporal resolution. It may also be difficult to get adequate quality 
acquisitions in patients with atrial fibrillation as the technique relies on regular R-R 
intervals. Thus, in our experience, adequate quality 3D volume acquisitions in heart 
failure patients can only be obtained in around 75% of patients. In contrast, it is possible 
to get adequate 2D datasets (sufficient to calculate ESV/EDV and LVEF) in virtually all 
patients (using contrast if necessary). 
 
Cardiac Magnetic Resonance 
 
CMR scans were performed on a Philips 1.5T scanner ((Philips Medical Systems, Best, 
the Netherlands), using either a 32 channel or 5 channel coil (if patients were obese or 
claustrophobic with the 32 channel coil). Patients with renal failure (eGFR< 
30ml/min/1.73m
2
) did not receive contrast because of the possible increased risk of 
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Interactive imaging was performed using rapid SSFP sequences to plan the geometry to 
be used in subsequent sequences. Four viewing windows were used to show the active 
imaging plane as well as its relationship to three previously acquired images (figure 
19). The line in any of the three other images could be moved in order to change the 
angle of the active imaging plane itself. In addition the active imaging plane could be 
displaced in parallel planes to that which is shown using the “pull/push” function. 









Simultaneous Acquisition of Coronary Venous Anatomy and Myocardial Scar 
 
There is marked individual variation in the coronary venous anatomy which can make 
implanting an LV lead via the CS challenging. The CS venous anatomy can be 
visualised at implant using a CS balloon occlusion venogram involving the injection of 
an iodine‐based contrast agent during fluoroscopy. This does not, however, give any 
information about myocardial scar that may underlie possible target tributaries 
rendering them unsuitable for CRT. It may therefore be useful to have data regarding 
coronary venous anatomy and scar prior to device implant.  
 
Multi-slice CT can be used to visualize the coronary venous anatomy in three 
dimensions but involves ionizing radiation and nephrotoxic contrast agents (90). CMR 
has the advantage of not using ionizing radiation and being able to give information on 
myocardial scar as well as coronary venous anatomy. The coronary veins can be 
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assessed with (91, 92) or without (93) an intravenous contrast agent by employing an 
MTC‐prepulse.  
 
Although CMR intravenous contrast agents may allow good visualisation of the 
coronary venous anatomy, they do not give useful scar information. Conversely, 
conventional extra-vascular contrast agents used for CMR delayed enhancement (DE) 
imaging give good scar information but have only been shown to give good quality 
coronary venous anatomy visualisation in patients with normal LV function (94). Heart 
failure patients are more likely to have arrhythmias and irregular breathing patterns that 
make standard CMR image acquisition very challenging. 
 
Thus, until recently, if both coronary venous anatomy information and scar information 
were required from an MR scan, patients may have undergone two separate CMR scans 
to allow the injection of both intra and extra-vascular agents to gain coronary venous 
anatomy and scar information respectively. Duckett et al (95), however, recently 
described the use of the gadolinium-based contrast agent dimeglumine-gadobenate (Gd-
BOPTA) to acquire both coronary venous anatomy information with delayed 
enhancement imaging during the same CMR acquisition. 
 
Studies had already shown that Gd-BOPTA allowed assessment of myocardial scar and 
viability that is comparable with conventional extravascular contrast agents (96, 97). 
Using the fact that Gd-BOPTA has high relaxivity (r1=9.7(mmol/L)‐1 s‐1 at 1.5 Tesla) 
and only a weak interaction with serum albumin, Duckett et al showed in 12 heart 
failure patients that a whole heart CMR acquisition combined with an inversion 
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recovery (IR) preparation allowed excellent visualisation of the coronary venous 
anatomy (comparable with intra-procedure CS balloon occlusion venography) and 
myocardial scar in a single CMR examination (95). 
 
Using the protocol described by Duckett et al (95), we performed cardiac 
synchronization with vector electrocardiography (VECG). After localization and a coil 
sensitivity reference scan, an interactive real‐time scan was performed to determine the 
geometry of the SA, 4CH, 3CH and 2CH. A multiple slice (M2D) cine steady state free 
precession (cine‐SSFP) scan was performed in SA orientation to assess the ventricular 
function (FA=60°, TR/TE=2.9/1.5ms, resolution 2.2x2.2x10mm, 30 heart phases). The 
4CH, 3CH and 2CH views were used to assess LV function for regional wall motion 
abnormalities. Visual assessment of the 3CH (FA=60°, TR/TE=3.0/1.5ms, resolution 
2.5x2.5x10mm, 60 heart phases) view was used to determine timing of the end systole. 
For the contrast enhanced coronary vein scan 0.1 mmol/kg Gd‐BOPTA TA 
(Multihance™, Bracco Imaging SpA, Milan, Italy) was infused at a rate of 0.3ml/sec 
with subsequent saline flushing. In order to determine the optimal start point of the 
whole heart coronary vein MR‐scan, a dynamic ECG‐triggered 2D‐scan with inversion 
recovery (IR) preparation (TI=300ms) was used. For coronary vein visualization, an 
ECG‐triggered respiratory navigated 3D IR‐SSFP MR‐scan was applied to acquire the 
whole‐heart during a short interval (60‐80ms) in end systole using a centric profile order 
and the following parameters: FA=50°, TI=300ms, TR/TE=4.25/1.44ms, SENSE=3‐4 
(with SENSE =2 AP direction and SENSE=1.5‐2 in RL‐direction), resolution 1.5 x 1.5 




Patients were told to breathe normally throughout the whole heart acquisition and not 
too deep or too shallow. The overall scan time for the protocol would be 3.5 min 
assuming a 100% respiratory gating efficacy but gating efficacy was usually around 
30% and the whole heart acquisition could take over 20 minutes in patients with 
irregular breathing patterns or arrhythmias. After the coronary vein scan, a delayed 
contrast‐enhanced multi‐slice IR gradient echo sequence (FA=25°, TR/TE= 5.8/2.0ms) 
was performed at end systole to depict areas of scar. A preceding Look‐Locker 
sequence was used to determine the optimal inversion time TI (320±22ms) to null the 





Philips Viewforum™ analysis package was used to draw endocardial contours in end-
diastolic and end-systolic phases for each slice (typically 10mm thick) in the short axis 
stack (which covered the whole heart in a series of breath holds). Thus LV and RV 




Figure 20. LV Volume Analysis from CMR Short Axis Stack 
The endocardial border has been manually drawn in green and epicardial border in 
yellow 
Model Creation 
The endocardial surfaces of all four cardiac chambers and the epicardial surface of the 
LV were extracted automatically by using a model-based segmentation algorithm (98) 
from the 3D IR-SSFP whole heart image. The CS was manually segmented from the 
whole heart image using ITK-SNAP (99) to yield a highly detailed anatomical model 
which included the CS main branch and three sub-branches.  
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LV Motion Analysis 
The cine MR data were analyzed using the TomTec 4D LV Analysis tool (TomTec 
Imaging Systems, Unterschleissheim, Germany). Much like the TomTec echo analysis 
tool, the LV surface was divided into 16 segments and the regional volume computed as 
a function of the cardiac cycle. Based on regional volume, 16 mechanical delay motion 
curves are generated (figure 21). 
 
Figure 21. Regional Volume Map 
Image showing 16 segment model top left; activation front is shown top middle; 16 







In patients with myocardial scar, the position and extent was determined from the DE 
CMR. These image data were registered to the whole heart MR data. The 3D 
myocardial scar was segmented by manual segmentation using ITK-SNAP (figure 22). 
 
Figure 22. Manual Segmentation of Scar 
Upper panel shows short axis DE image. Lower panel shows same image with scar 
manually segmented in red (100) 
 
A fully automated approach to scar segmentation was also trialled. The tool (developed 
at King’s College London) (100) involves projecting scar data on to the LV epicardial 
surface using a maximum intensity projection.  A binary image was thus generated to 
give a regional distribution of scar on the LV epicardial surface. Although the automatic 
segmentation tool is quick (typically taking around 5 seconds to generate the model), 
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the quality of the model produced depends on the quality of the DE imaging and some 
manual correction is sometimes required. 
 
 
Invasive Haemodynamic Assessment 
 
Femoral or radial access was attained using a 5F sheath and an exchange length 
(210cm) 0.035 inch diameter wire was passed retrogradely across the aortic valve into 
the LV cavity using a pigtail catheter. The pigtail was then exchanged for a 5F multi-
purpose catheter and the exchange wire then removed. A 0.014 inch diameter Certus 
pressure wire (RADI Medical Systems, Uppsala, Sweden) was connected to a RADI 
analyser and then flushed and calibrated when placed level on the patient’s body. The 
pressure wire was then passed through the multi-purpose catheter into the LV cavity. 
The multi-purpose catheter was then removed.  To minimise the risk of thrombo-
embolic complications from the pressure wire in the systemic circulation, 2500 units of 
heparin was then administered. The RADI analyser was connected to a laptop equipped 




Figure 23. Real-time Haemodynamic Data Output 
The PhysioMon software display is shown. Green trace: blood pressure; Blue trace: 
LVdP/dtmax 
 
LVdP/dtmax was calculated electronically from every heartbeat for a period of at least 20 
seconds to ensure steady-state conditions. The results were averaged for the complete 
measurement period. A waiting period of at least 20 seconds was respected after any 
change in pacing settings or lead position to achieve hemodynamic stabilization. This 
method has previously been shown to reliably measure LVdP/dtmax (61, 62, 101). 
LVdP/dtmax during atrial pacing or RV pacing (atrial fibrillation [AF] patients) at 5–10 
beats above intrinsic rate (to eliminate the effect of heart rate variation) was considered 
baseline and was kept constant when testing different pacing modes (102). Data from 
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premature ventricular complexes were discarded.  Results during pacing modes were 
expressed as a percentage change from baseline. In order to minimize the effect of 
baseline drift in AHR (secondary to changes in patient intravascular volume/sedation 
levels, etc.) on the results, the baseline was reassessed prior to and after every LV lead 
reposition. Thus, the AHR during LV pacing was compared to a mean of the baseline 
taken immediately before and after each lead position change. The mean baseline drift 
in intrinsic LVdP/dtmax seen in a previous invasive hemodynamic study that we 
performed was 68 ± 17mmHg (9.4 ± 2.4% change from mean baseline) (103). Using the 
methods above to correct for baseline drift in LVdP/dtmax the mean variability in AHR 
seen when repeated measurements were taken was 4.8 ± 5.2%. 
Statistical Methods 
Statistical analysis was performed on JMP (version 9.0.1, Marlow, Buckinghamshire, 
UK) and PASW Statistics 20 (SPSS Inc, Chicago, IL, USA). Group comparisons were 
performed using a t-test or an appropriate non-parametric test (Wilcoxon rank sum, 
Kruskall-Wallis). Pearson’s correlation coefficient was used to measure the linear 
relationship between two variables and Chi squared test to compare categorical 
variables. All results are expressed as mean ± SD. P values of < 0.05 were considered 
statistically significant. Where 3 or more different pacing modalities were tested within 
individual patients, a repeated measures ANOVA was used to compare pacing 
modalities. All pacing methods were compared to each other and to avoid type 1 errors, 
p values were corrected using the Bonferroni adjustment. To perform a Bonferroni 






Chapter 4. Quadripolar Leads 
Abstract 
Background: The Quartet model 1458Q (St. Jude Medical, Sylmar, CA, USA) lead is a 
quadripolar left ventricular (LV) lead with pace/sense capability from four electrodes 
(tip and three rings). The lead is capable of pacing in 10 different configurations rather 
than the three that are available in conventional bipolar pacing leads. We describe a 
single-centre initial experience of the use of this lead in patients undergoing cardiac 
resynchronization therapy (CRT). 
Methods: Forty patients underwent attempted CRT-D implantation between October 
2009 and October 2010 with a Quartet lead. Pacing parameters, lead position, 
complications and presence of PNS were collected at implant, pre-discharge and at 15 ± 
8 weeks and 6 month follow-up. 
Results: A quadripolar LV lead was successfully implanted in 95% (38/40) of patients. 
During follow-up, one patient (3%) had a lead displacement requiring reposition. LV 
pacing parameters remained stable at 6 months (mean threshold 1.3 V at 0.6 ms and 
impedance 948 ohm). PNS at the time of implant was observed in 12 patients (32%) all 
of which were overcome by using the additional vectors available on the quadripolar 
LV lead or by repositioning the lead at the time of implant. At 6 months follow-up there 
were five (13%) cases of PNS, all of which were successfully treated by reprogramming 
to a different vector. No cases required reintervention, surgical epicardial lead 
placement, or that lead be turned off. 
Conclusion: The Quartet lead is associated with a high implant success rate, stable 
pacing parameters and a low displacement rate during the first 6 months after implant. 
The ten LV pacing vectors available with this lead allowed PNS and capture threshold 
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Failure to implant an LV lead successfully during attempted CRT occurs in 5-15% of 
cases (31-33). This may be because of failure to cannulate the CS ostium, an inability to 
pass an LV lead into a CS branch, procedural complications such as CS dissection, 
unsatisfactory pacing parameters (high capture thresholds or poor R-wave sensing) or 
phrenic nerve stimulation (PNS). 
 
The Quartet model 1458Q (St. Jude Medical, Sylmar, CA, USA), is a quadripolar LV 
pacing lead that has three ring electrodes in addition to the distal tip electrode thus 
allowing pace/sense capability from four LV electrodes. These electrodes are spaced 20, 
30 and 47 mm from the distal tip and the lead body has a maximum 4.7-French (F) 
diameter (5.1F at the level of the ring electrodes). All four electrodes may act as cathode 
and two may act as anode (M2 and P4). The right ventricular coil of the shocking lead 
may also act as an anode thus giving 10 possible bipolar and unipolar pacing 
configurations (D1-M2, D1-P4, D1-RV coil, M2-P4, M2-RV coil, M3-M2, M3-P4, M3-
RV coil, P4-M2, and P4-RV coil – figure 24). Conventional LV pacing leads usually 
have only 2 LV lead electrodes and 3 different pacing configuration options. We 
hypothesized that the 10 different LV pacing vectors available with the Quartet lead 
may allow problems with PNS and high capture thresholds to be overcome non-
invasively because if the initial configuration used is unsatisfactory there are 9 other 




Figure 24. Pacing Configurations Available with Quartet Lead 
Quartet lead in situ. 10 different pacing configurations are indicated by the turquoise 
arrows (image courtesy of St Jude Medical) 
 
Biffi et al (34) prospectively observed 197 patients undergoing CRT specifically 
looking for the prevalence of PNS. They found that it occurred in 37% of patients at 
CRT implant or 6 month follow-up and was clinically relevant in 22%.  They found that 
PNS often was not manifest at implant (whilst supine) because in some patients it only 
occurred whilst lying in the left lateral position or sitting. Overall 7% of all patients in 
that case series required an LV lead revision (5%) or for CRT to be switched off (2%) 







All patients provided informed consent and fulfilled standard National Institute for 
Clinical Excellence (NICE) guidelines for implantation of a cardiac resynchronization 
device with cardiovertor defibrillator (CRT-D) i.e. New York Heart Association 
(NYHA) class III symptoms despite optimal medical therapy, a left ventricular ejection 
fraction (LVEF) less than 35% and QRS duration greater than 120ms. The implantation 
procedure was performed with a standard technique involving cannulation of the 
coronary sinus, identification of a suitable target vein with a contrast agent and 
fluoroscopy, and placement of the quadripolar LV pacing lead using an over-the-wire 




We looked initially at the first 28 patients (table 5) who underwent implantation with a 
Quartet lead at St Thomas’ Hospital and followed them up for a mean of 15 ± 8 weeks 
(104). We then performed a further study of the first 40 patients (table 6) implanted 




Table 5. Baseline Quartet Patient Characteristics 
The baseline characteristics of the initial 28 patient cohort (104) 
 
The optimal pacing vector was chosen at the operator’s discretion based upon 
satisfactory pacing parameters and absence of PNS at the time of implant. In cases of 
PNS, the initial strategy was to reprogram to a different vector with the same lead 
position. If this did not result in an acceptable vector without PNS and a satisfactory LV 
capture threshold, then the lead was repositioned either to a different site in the same 
vein or to an alternate vein. Evidence of PNS was sought by pacing at 10 V at a pulse 
width of 0.5 ms in all patients using at least one vector. Capture thresholds were tested 
using a pulse width of 0.5 ms or 0.4 ms. At follow-up, all capture thresholds were tested 
using a pulse width of 0.5 ms. The time, contrast, and radiation doses for all patients 




Detailed assessment of the pre-implantation coronary sinus venogram and post-
implantation fluoroscopy and chest radiograph images were made to ascertain the final 
LV lead position as categorised by coronary sinus vein branch (posterolateral, lateral, 
anterolateral and anterior branches or middle cardiac vein) and basal LV, mid-LV or 
apical LV position. 
 
Table 6. Baseline Quartet Patient Characteristics (40 patient cohort) 









This was a small descriptive observational cohort study and statistical analysis was 
limited. Categorical variables were described by absolute number (n) and percentage 
(%). Continuous variables with a normal distribution were described using mean and 
standard deviation (SD). Comparisons of continuous variables with a normal 




Initial 28 Patient Cohort 
 
A Quartet lead and CRT-D device (Promote Q model CD3221-36 or Promote Quadra 
model CD 3239-40Q generator; St Jude Medical, Sylmar, CA, USA) was successfully 
implanted in 27 (96%) of all patients. The conventional D1-M2 bipolar pacing 
configuration was used as the final pacing vector in 56% of patients. PNS was found at 
implant in 41% of patients. In 8 of these 11 patients PNS was successfully overcome by 
changing the pacing configuration and in the remaining 3 patients physical repositioning 
of the LV lead was required. Two patients were found to have PNS at follow-up that 
was successfully overcome by ‘electronic’ lead repositioning. In a further 2 patients 
whose capture thresholds were found to have risen at follow-up, a change in pacing 
configuration overcame the problem in both cases. 
 
Follow-up data for this cohort of patients revealed 1 LV lead displacement (4%) at latest 
follow-up and although this is perhaps higher than the published literature (106) it 
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represents just one case. Major adverse cardiovascular events (MACE) were low at 4% 
at a mean follow-up of 15 weeks. Most cases of PNS at implant were resolved simply 
by changing the pacing vector and all cases at pre-discharge pacing check or latest 
follow-up were overcome by changing the pacing configuration or reducing the pacing 
output. No patients required their CRT to be switched off because of PNS. Rises in 
capture thresholds were also successfully overcome during follow-up simply by 
changing the pacing vector. 
 
6 month Follow-up 
 
A Quartet lead was successfully implanted in 38/40 patients (95%). In one unsuccessful 
case, we were unable to pass the quadripolar lead beyond an existing LV lead that could 
not be extracted with traction. There were no other viable coronary sinus branch options 
in this patient. The other unsuccessful case was abandoned as the patient was unable to 
tolerate the procedure because of frank haemoptysis and did not wish to undergo a 




Vascular access for implantation was left subclavian/axillary vein in 29/40 (73%), left 
subclavian/axillary and cephalic vein in 6/40 (15%) and cephalic vein only in 5/40 
(13%). The left ventricular lead was successfully placed via the coronary sinus in a 
posterolateral branch in 21/38 patients (55%), lateral branch in 12/38 (32%), 
anterolateral branch in 3/38 (8%) and middle cardiac vein in 2/38 (5%). At the time of 
implant the final LV lead position of D1 (distal tip electrode) was apical in 19/38 (50%) 
patients, mid LV in 17/38 (45%) patients and basal LV in 2/38 (5%) patients. 
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Of the 38 cases successfully implanted with a quadripolar LV pacing lead, the final LV 
lead configuration was conventional bipolar D1–M2 in 25/38 (66%) of cases. In the 
remaining 13/38 (34%) patients, the optimal final vector was M3–M2 in 5/38 (13%), 
M2–P4 in 3/38 (8%), D1–RV coil in 2/38 (5%), D1–P4 in 1/38 (3%), M3–P4 in 1/38 
(3%) and P4-RV coil in 1/38 (3%). Overall we utilised a pacing vector that did not 
incorporate D1 (and therefore used electrodes not available in current conventional 
bipolar CRT systems) in 10/38 (26%) of cases. The D1 electrode was not used as part of 
the pacing vector in 8/19 (42%) cases where the D1 pole position was apical and in 2/19 





Table 7. LV Pacing Parameters Over 6 Months 
LV pacing parameters for the Quartet LV lead over the first 6 months post implant 
 
Table 7 shows the LV lead pacing parameters at implant and follow-up. During the 
follow-up period, 2/38 (5%) patients died and 1/38 (3%) patient was lost to follow-up. 
Six month follow-up data were therefore available for 35/38 (92%) patients. During the 
first 3 months, the LV pacing parameters remained stable with satisfactory LV capture 
threshold and impedance (mean 1.25 V at a mean pulse width of 0.6 ms and 924Ω, 
respectively) (figure 25). During the first 3 months, there was one case (1/35 (3%)) of 
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loss of LV capture due to lead displacement. This required a lead reposition, which was 
carried out successfully. One patient had a significant rise in LV capture threshold from 
1 V at 0.5 ms at the time of implant, 1.75 V at 0.5 ms 24 h after the procedure and 
subsequently 4.5 V at 1 ms at 3 months. This was successfully managed by 
reconfiguring the pacing vector from M3–M2 to D1–M2 leading to an LV capture 
threshold of 1.25 Vat 0.5 ms. 
 
Figure 25. LV Capture Threshold and Impedance Trends 
LV capture threshold (V) and impedance trends (Ω) with the Quartet lead during the 
first 6 months after implant. 
Six-month follow-up data are available for 35/38 (92%) patients (table 7). The LV 
pacing parameters remained stable with satisfactory LV capture threshold and 
impedance (mean 1.30 V at a mean pulse width 0.6 ms and 948Ω, respectively) (figure 
21). Compared with implant data there was no significant change in mean LV capture 
threshold (1.30 vs. 1.25 V; p=0.3). Lead impedance measurements demonstrated a 
statistically significant rise over the first 6 months (948Ω vs. 891Ω; p=0.04) but 
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remained acceptable. There were no further lead displacements. One patient had a 
notable rise in LV capture threshold from 1.5 V at 0.5 ms at the time of implant to 1.75 
V at 0.5 ms 24 h post procedure, 2 V at 1 ms at 3 months and subsequently 3.75 V at 1.5 
ms at 6 months. Due to previous problems with PNS in all other configurations this 
patient was successfully managed with prolonging the pulse width and using the D1–P4 
vector. 
 
Phrenic Nerve Stimulation (PNS) 
 
See figure 26. 
 
PNS at Implantation 
 
PNS was seen at the time of implant in 12/38 patients (32%) with one or more pacing 
vectors. Of these 12 cases, five (42%) had ischaemic heart disease and seven (58%) 
cases had a dilated cardiomyopathy. In 9/12 (75%) cases PNS was successfully 
overcome by changing the pacing vector configuration without the need to reposition 
the lead. Of these nine cases with PNS, seven had PNS in the conventional bipolar 
configuration of D1–M2. In these seven patients, the vector was successfully changed to 
M2–P4 in 2/7 patients, to D1–RV coil in 2/7 patients, to M3–M2 in 1/7 patients, to M3–
P4 in 1/7 patients and to D1–P4 in 1/7 patients. LV lead repositioning was required in 
the remaining 3/12 (25%) patients with PNS at the time of implant in whom it was not 
possible to overcome problems of PNS by reprogramming the pacing vector in the 
initial vein of choice. In all three cases PNS was overcome by repositioning ± 
subsequent reprogramming the quadripolar lead. The final vector in these three cases 
was as follows: D1–M2 in two cases and M3–M2 in the third case. No cases required 
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referral for surgical epicardial LV lead placement. Of the cases with PNS at implant, 
9/12 (75%) had the D1 electrode positioned in an apical position and 3/12 (25%) in a 
basal-mid LV position. Of the nine PNS cases with an apically positioned D1 electrode, 
LV pacing using a more proximal vector that excluded D1 was used to successfully 
ameliorate PNS in 7/9 (78%) patients. In the basal-mid LV position, pacing using a 
more proximal pole was similarly useful in 1/3 (33%) of patients. Overall, in 8/38 
(21%) cases the quadripolar lead eliminated PNS by using a proximal pacing vector that 
did not use D1 where a conventional bipolar lead configuration may have been 
unsuccessful. 
 
PNS during Follow-up 
 
Five patients (13%) developed PNS during follow-up, of which three cases had not been 
observed at the time of implant. All cases were successfully managed by 
reprogramming using vectors on the quadripolar lead which would not have been 
available with a standard bipolar lead. No patients required repeat intervention or for the 
lead to be turned off due to PNS. Four patients experienced PNS during the first 3 
months of follow-up. Two of these cases had not been observed at the time of implant. 
At 3 months, changing the LV pacing vector from D1–M2 to M3–M2, and D1–M2 to 
M3–M4, respectively, successfully alleviated these cases of PNS. Of the remaining two 
cases observed to have PNS at the time of implant, one patient had been successfully 
managed with a lead reposition during the index implant and one patient with a change 
in pacing vector. The former case was successfully managed with changing the pacing 
vector from D1–M2 to M2–P4. The latter case was managed by reducing the pacing 
output in the same vector D1–P4. Of these four cases with PNS observed during the 
first 3 months follow-up, the final position of the D1 pole at implant was apical in 3/4 
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cases and of these 2/3 were successfully managed by pacing using a more proximal 
vector that did not use D1.The fifth case of PNS seen at the 6-month follow-up had not 
been apparent either at implant or at 3 months follow-up. The lead position was also 
apical and was successfully managed by changing the pacing vector from D1–P4 to the 
more proximal vector M2–P4. Overall, all five cases were successfully managed using a 






Figure 26. PNS and  Programming Changes 
Flow diagram showing the occurrence of PNS and subsequent pacing vector 
programming changes with the Quartet lead. 
 
Quadripolar Leads and Previous Failed Implant 
 
Four patients, two males and two females with mean age 55+21 years, underwent re-
attempt at LV lead implantation at our institution between March and May 2010 (table 
8). All four patients had New York Heart Association (NYHA) class III symptoms of 
heart failure of a non-ischaemic aetiology. The mean left ventricular ejection fraction 
(LVEF) was 28 ± 8.7% prior to reattempt at LV lead implantation. Three patients were 
in sinus rhythm and one was in atrial fibrillation. In our institution, we aim to place the 
LV lead in an optimal CS vein for resynchronization and this usually means a postero-
lateral or lateral position. In these four difficult cases, the main determinant of LV lead 
position was a pacing configuration that gave the best pacing parameters (lowest capture 
threshold with good R-wave) without PNS. 
 
In all four cases, a Pacesetter St. Jude Quartet lead model 1458Q and Promote Q Model 
CD3221-36 generator (St Jude Medical) were successfully implanted. The mean 
procedure time for the four cases was 157.5+42.1 min. The fluoroscopy time was 18.2+ 
19.8 min with a radiation dose of 1178+1417.2 cGycm2. Pacing parameters were stable 






Table 8.  Patient Characteristics pre-Quartet lead implant. 
 
We have already established that the advantage of the Quartet lead over other leads with 
cathodal programmability is the number of vectors available. Thus, if problems with 
PNS or high capture thresholds are encountered, it offers more pacing configurations 
than other CRT systems and may allow patients with previous failed attempts at LV 
lead implantation the potential to have a successful transvenously placed LV lead rather 
than the options of either an epicardial surgical approach to CRT or no CRT at all. 
 
The M3–M2 vector used as the final configuration in two of our patients is not available 
with other bipolar LV leads but, interestingly, the D1-M2 (conventional bipolar LV 
pacing) and D1-RV coil (only available when a shocking lead is in situ i.e. CRT-D) 
vectors used in the other two patients can be programmed with other CRT systems. The 
fact that we were also successful in these cases using conventional bipolar 
configurations suggests that the handling characteristics and lead geometry of the 
Quartet lead may have allowed us to attain a position in the CS that was different from 





Initial reports from our centre and others have confirmed satisfactory initial results with 
quadripolar LV lead technology. Our current implant and follow-up data demonstrates 
that the quadripolar Quartet LV lead was successfully implanted in the vast majority of 
patients and importantly in patients where previous attempts at LV lead implantation 
had been unsuccessful either due to poor LV capture threshold or PNS. During the first 
6 months after implant LV capture threshold and impedance remained satisfactory. No 
patients were referred for a surgical epicardial LV lead or had the LV lead switched off 
during the follow-up period. The optimal initial implant vector was conventional bipolar 
(D1–M2) in 66% of cases. Of the remaining patients, ten cases (29%) were optimally 
programmed (to either improve capture threshold or ameliorate PNS) to pacing vectors 
that did not use the distal pole (D1), unavailable on conventional bipolar leads, 
demonstrating the potential advantages of a multipolar lead. 
 
PNS remains a significant obstacle to the success of CRT and may only become 
apparent following implant when repositioning is not an immediate option. In a study of 
197 CRT implants, PNS was frequent and observed in 73 (37%) patients either at 
implant or during a mean 2-year follow-up period and felt to be clinically relevant in 41 
(22%) patients. Interestingly, mid to apical LV lead position in the lateral/posterolateral 
vein was the strongest predictor of PNS. Importantly, 5% of cases needed invasive 
reintervention and three leads displaced because of a proximal position to avoid PNS. 
CRT was turned off in four (2%) patients because of PNS. In comparison, we observed 
a similar overall incidence of PNS (39%) at implant and during the 6-month follow-up 
period. The majority of patients with PNS were identified at the time of implant and 
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PNS was observed more frequently where the LV lead tip was in the apical position. Of 
the patients with PNS at the time of implant, approximately two-thirds of cases were 
successfully overcome by stimulating the LV more proximally where a conventional 
LV lead may have failed or been sub-optimal. During 6-month follow-up, clinically 
important PNS occurred in 13% of patients. The capability of utilising additional pacing 
vectors, unavailable on existing bipolar LV leads was able to overcome PNS in all cases 
obviating the need for reintervention or for the lead to be turned off.  
 
There has been recent interest in the optimal position of the LV pacing lead for CRT. 
Data from the multicenter automatic defibrillator implantation trial-cardiac 
resynchronization therapy (MADIT-CRT) trial demonstrated that LV pacing in the 
apical region were associated with a significant increased risk of death or heart failure 
including structural (left ventricular end-diastolic volume and left ventricular ejection 
fraction) and functional (6MWD, quality of life and NYHA class) measures, were not 
significantly different between arms. Certainly a more apical LV stimulation site would 
appear to be associated with more PNS, supported by our data, but it is also recognised 
that a more basal LV lead position may be associated with a higher rate of displacement. 
Several bipolar LV pacing leads currently available allow the programmability of three 
or four pacing vectors; however, this quadripolar lead offers ten different pacing 
vectors. One potential advantage of this type of lead may be the ability to achieve a 
stable apical position within a CS branch and to perform perhaps clinically desirable 
basal-mid LV rather than apical stimulation by utilising the proximal electrodes. Early 
follow-up in this small series suggests good stability of pacing parameters and clinical 
utility with regard to increased programming options. Longer follow-up experience in a 
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larger series is required to fully assess the stability of pacing parameters and clinical 




This case series is a single-centre, non-randomised study of a relatively small number of 
patients. The cohort includes complex patients some of whom required lead extractions 
and others who had previous failed attempts at LV lead implant. The LV lead 
displacement rate was 3% in this patient cohort but this represents just 1 case out of 40 
and the study was not powered to detect a significant lead displacement rate. 
Satisfactory pacing parameters and encouraging PNS data in the first 6 months after 




We have seen that the Quartet lead is associated with a high implant success rate and a 
low level of complications at short-term follow-up.  Cathodal programmability (the 
capability to program either the proximal or the distal LV lead electrode as cathode) is 
available with several bipolar LV pacing leads and this ability to switch pacing 
configuration if the initial one gives rise to unacceptable pacing parameters or PNS 
appears to be a significant advantage. The Quartet lead offers more pacing vectors than 
other LV pacing leads and thus makes it more likely that common pacing obstacles can 
be overcome without the need to physically reposition the lead during implantation and 
thus risk dislodgement from the CS. It may also mean that successful CRT is achieved 
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in cases where a conventional lead would fail because of PNS or high capture 
thresholds. Equally importantly, the availability of different pacing vectors may obviate 
the need for a lead revision, surgical approach to LV lead placement, or CRT to be 
turned off in patients who encounter pacing problems after implantation.  
 
It is not clear what the optimal number of ring electrodes on an LV lead should be. 
More rings will give more programming options but at the expense of increased lead 
complexity. In different patients, different leads may be optimal and we await the 
results of further studies of the clinical effects of pacing using the additional 
























Background: It is not clear whether there is a large difference in acute haemodynamic 
response (AHR) to left ventricle (LV) pacing in different regions of the same coronary 
sinus (CS) vein. Using the four electrodes available on a Quartet LV lead, we evaluated 
the AHR to pacing within individual branches of the CS. 
Methods: An acute haemodynamic study was attempted in 20 patients. In each patient, 
we assessed AHR in a number of CS veins and along a significant proportion of each 
CS branch using three different bipolar configurations. We compared the AHR achieved 
when pacing using each different vector and also the highest AHR achieved in any 
position within the same patient with the lowest achieved in that patient. 
Results: Sixty-four different CS positions in 19 patients were successfully assessed. No 
significant difference in AHR was found overall between the three vectors tested. The 
mean percentage difference in AHR between the CS branch vectors with the lowest and 
highest dP/dtmax was +6.5 ± 5.4% (P < 0.001). A much larger difference of +16.9 ± 
6.1% (P < 0.001) was seen when comparing the highest and lowest AHR achieved using 
any vector in any position within the same patient. 
Conclusion: A small difference in AHR is seen when pacing within the same branch of 
the CS compared to pacing in different branches in the same patient. This suggests that 
although the site of LV lead placement is important, the position within a CS branch is 






Studies have shown that there is a significant difference in acute hemodynamic response 
(AHR) to pacing in different branches of the CS (45, 107). CS anatomy usually means, 
however, that it is easier to reposition a LV pacing lead within the same CS vein rather 
than between different CS tributaries. Gold et al (108) have previously evaluated the 
AHR to LV stimulation within a CS vein by placing a pacing lead in different positions 
within a tributary and found no significant group differences among stimulation sites 
within the same coronary vein but did find significant variability among sites in 
individuals. In our study, rather than repositioning the LV lead each time we wished to 
stimulate a different site in a CS tributary, we used the cathodal programmability 
available with the Quartet Model 1458Q LV pacing lead and Promote-Q Model CD 
3221-36 generator (St Jude Medical, Sylmar, CA, USA) to pace different bipolar 
configurations within each CS branch (44, 104, 109). 
 
Recent studies suggest that an apical rather than a basal or mid position is associated 
with a worse outcome (48-50). Given that the Quartet lead can be placed distally but 
allows pacing from more proximal poles other than the distal tip electrode, this may be 
advantageous in that the lead can be placed in a distal (more stable position) but pacing 
may occur via more proximal LV electrodes in the mid or basal LV that is associated 









The study was approved by the local Ethics committee and was conducted in 
compliance with the Declaration of Helsinki with all patients giving written informed 
consent to participate. Patients fulfilling standard criteria for CRT (NYHA class III-IV 
with drug-refractory heart failure, LVEF ≤35% and prolonged QRS > 120ms were 
recruited. The clinical characteristics of the patients are presented in table 9. 
 
Table 9. Patient Clinical Characteristics 
 
Implantation of a Quartet lead was attempted in 20 patients at St Thomas’ Hospital, 
London, United Kingdom. An acute haemodynamic study was successfully performed 
during CRT implant in 19 patients. Patients were lightly sedated with midazolam and 
morphine as necessary. Haemodynamic evaluation was performed using a 0.014 inch 
diameter high fidelity Certus PressureWire and PhysioMon software (RADI Medical 
Systems, Uppsala, Sweden) with a 500Hz frequency response and 50Hz filter 
bandwidth. The pressure wire was introduced into the LV through a 5-F multipurpose 
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catheter via a femoral or radial artery. The multi-purpose catheter was then withdrawn 
into the aorta, leaving the pressure wire in a stable position within the LV cavity. Once 
venous access was acquired for pacing lead implant 2,500 units of heparin was 
administered. 
 
LV-dP/dtmax was calculated electronically from every heartbeat for a period of at least 
20 s to ensure steady-state conditions. The results were averaged for the complete 
measurement period. A waiting period of at least 20 s was respected after any change in 
pacing settings or lead position to achieve hemodynamic stabilization. This method has 
previously been shown to reliably measure LV dP/dtmax. (61, 62) 
 
LV dP/dtmax during atrial pacing (AAI) or RV pacing (AF patients) at 5-10 beats above 
intrinsic rate (to eliminate the effect of heart rate variation) was considered baseline and 
was kept constant when testing different pacing modes (102).  The AHR during 
DDDLV (fixed AV delay 100ms) or VVI LV (patients in AF) pacing 5-10 beats above 
intrinsic rate was measured in as many different CS tributaries as possible in each 
patient. Data from premature ventricular complexes were discarded. We tested pacing 
parameters and AHR along a significant proportion of each CS branch by using 3 
different bipolar configurations in each position. The 3 vectors used were D1-M2 
(conventional bipolar configuration), M3-M2 and M3-P4 (figure 4.1). If pacing capture 





Figure 27. Vectors Used to Assess AHR  
A Quartet left ventricular lead with arrows showing vectors used: D1-M2, M3-M2, 
and M3-P4. D1=distal tip; M2, M3, and P4=ring electrodes 
 
Results at each pacing site were expressed as a percentage change from baseline. In 
order to minimise the effect of baseline drift in AHR (secondary to changes in patient 
intra-vascular volume/sedation levels etc) on the results, the baseline was reassessed 
prior to and after every LV lead reposition. Thus the AHR during LV pacing was 
compared to a mean of the baseline taken immediately before and after each lead 
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position change. Each CS lead position was categorized as anterior, posterior or lateral 
(this position included postero-lateral and antero-lateral positions) based on a left 




Statistical analysis was performed on JMP (version 8.0.2, Marlow, Buckinghamshire, 
UK) and PASW Statistics 18 (SPSS Inc, Chicago, IL, USA). Group comparisons were 
performed using a paired t-test or an appropriate non-parametric test (Wilcoxon rank 
sum and Kruskall-Wallis). All results are expressed as mean ± SD. P values of < 0.05 




The CS was successfully cannulated and AHR to LV pacing assessed in 19 patients. In 
1 patient it was not possible to cannulate the CS os because of its small orifice.  This 
patient later had a surgical epicardial LV lead placed. In another patient AHR was 
assessed in only 1 position as a CS dissection precluded further vein assessment and an 
LV lead was implanted at a later date (this patient was excluded from the analyses as 
inter-vein comparisons could not be made). AHR data was successfully collected from a 






Intra-vein Variability in AHR 
 
See Table 10. 
 
 
Table 10. Summary of Acute Haemodynamic Response (AHR) Data 
 
The mean percentage difference in AHR compared to baseline between an individual 
CS branch bipole with the lowest dP/dtmax and that with the highest was 6.5 ± 5.4 % 
(p<0.001) for each of the 51 CS vein positions in which the AHR for at least 2 vectors 
was successfully measured i.e. pacing capture without significant PNS using at least 2 
of the 3 pacing configurations tested. This was the intra-vein variability in AHR. 
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The overall difference in AHR between the 3 different pacing vectors was also 
compared (figure 24) and no significant difference in AHR found between the pairs D1-
M2 and M3-M2 (n=51, p=0.78) , M3-M2 and M3-P4 (n=46, p=0.80) or D1-M2 and 
M3-P4 (n=46, p=0.98).  
 
Figure 28. Comparison of AHR by Vector Pair 
The mean AHR of each pair of vectors in each CS vein position assessed is plotted on 
the x-axis against the difference in AHR between each vector pair on the y-axis. The 
horizontal solid red bar is the mean of the difference between all vector pairs and the 
horizontal dashed red bars represent the 95% confidence intervals. 
 
Inter-vein Variability in AHR 
 
The mean difference in change in dP/dtmax between the best and worst CS vectors in any 
CS vein position in an individual patient was 16.9 ± 6.1% (p<0.001). This was the 
maximum intra-patient variability in AHR. In figure 29 the maximum AHR achieved in 





Figure 29. Intervein Variation in AHR 
Individual patients are represented on the x-axis. Each black circle represents the 
highest AHR achieved for an individual CS position for a patient. The median value 
and quartiles of all CS positions tested for each individual patient are represented by 
the horizontal red bars. The black horizontal line represents the mean of the highest 
dP/dtmax overall for all CS vein positions in all patients. 
 
Although the difference in AHR seen between different bipolar configurations within 
the same vein was not large, we did find that in some veins no pacing capture was found 
with one vector but was found with another. Similarly, we found that acceptable PNS 
may be detected with one configuration (rendering it unusable) but not found with 
another bipole in the same CS position. Thus, although the difference in AHR when 
using different vectors within a CS position was not large, differences in ability to 
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achieve consistent pacing capture without PNS were seen between pacing 
configurations. 
 
LBBB v non-LBBB 
 
The difference in AHR seen in patients with LBBB and those without LBBB was 
similar. An LV lead could not be placed in one of the 4 patients who did not have 
LBBB leaving 3 non-LBBB patients (1 RBBB, 2 with non-specific intra-ventricular 
conduction delay) in whom the best overall AHR was 19.1 ±17.1 compared to 18.0 ± 
19.4 for the 15 LBBB patients (18.2 ± 10.4 for the group as a whole). The intra-patient 
variability in AHR was 14.1 ± 8.1 for the non-LBBB patients and 17.5 ± 5.8 for the 
LBBB group (16.9 ± 6.1 for the group as a whole). The intra-vein variability in AHR 
was 8.5 ± 9.7 for the non-LBBB group and 6.3 ± 4.7 for the LBBB group (6.5 ± 5.4 for 
the group as a whole). 
The overall difference in AHR between the 3 different pacing vectors was assessed with 
patients sub-divided into LBBB and non-LBBB groups. For LBBB patients the mean 
AHR seen with each configuration was 10.3 ± 12.3 (D1-M2), 10.3 ± 11.5 (M3-M2) and 
10.2 ± 11.0. For patients without LBBB the AHR seen was 7.8 ± 10.4 (D1-M2), 7.3 ± 
11.4 (M3-M2) and 12.2 ± 11.6 (M3-P4). No significant difference in AHR was found 
between the pairs D1-M2 and M3-M2 (n=45, p=0.84), M3-M2 and M3-P4 (n=42, 
p=0.8) or D1-M2 and M3-P4 (n=42, p=0.78) for the LBBB group. No significant 
difference in AHR was seen in the non-LBBB group: D1-M2 and M3-M2 (n=6, 





Sinus rhythm v AF 
 
Whether a patient was in sinus rhythm or atrial fibrillation did not appear to make much 
difference to the best overall AHR achieved or to the intra-vein and intra-patient 
variability in AHR. For the 3 patients in atrial fibrillation the best overall AHR was 17.9 
± 6.1 compared to 18.2 ± 11.2 for the 15 sinus rhythm patients (18.2 ± 10.4 for the 
group as a whole). The intra-patient variability in AHR was 17.6 ± 0.5 for the AF 
patients and 16.8 ± 6.7 for the sinus group (16.9 ± 6.1 for the group as a whole). The 
intra-vein variability in AHR was 8.5 ± 9.7 for the non-LBBB group and 6.3 ± 4.7 (6.5 
± 5.4 for the group as a whole). 
 
Ischemia and scar 
 
The difference in AHR seen in patients with an ischemic aetiology of their 
cardiomyopathy versus those with a non-ischemic aetiology was assessed. The best 
overall AHR in the ischemic group was 19.8 ±12.0 compared to 16.5 ± 8.9 for the non-
ischemic group. The intra-patient variability in AHR was 15.1 ± 7.1 for the ischemic 
patients and 18.7 ± 4.8 for the non-ischemic group. 5 of the ischemic group of patients 
had at least some full thickness postero-lateral scar on pre-procedure delayed 
enhancement MRI. The overall best AHR achieved when pacing in the postero-lateral 
regions of the LV in these patients gave rise to a very similar response to that seen 
overall in our cohort with a mean AHR of 18.4 ± 10.5. The intra-vein variability in 





There is evidence to suggest that a high scar burden has an unfavourable effect on 
clinical and functional outcomes post CRT (40). Trans-mural postero-lateral scar in 
particular has previously been associated with a poor response in terms of clinical and 
echocardiographic response at 6 months post-CRT (36). Our data, however, suggests 
that pacing close to but outside scar can give rise to an AHR comparable to the best that 
can be achieved anywhere. The larger variability in AHR seen in those patients with 
poster-lateral scar perhaps suggests that although a poor AHR may be seen with one 
vector (placed directly in scar) another configuration within the same vein may lie close 
to but not actually within scar thus allowing a good hemodynamic response. 
 
Figure 30. Change in dP/dtmax by CS Vein Anatomical Position 
Each black circle represents the highest AHR achieved using any of the three vectors 
assessed for that CS vein position in an individual patient. The median value and 
quartiles for each anatomical position are represented by the red horizontal bars. The 
black horizontal line represents the mean of the highest dP/dtmax overall for all CS 
vein positions in all patients. 
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CS Vein Position 
 
We analyzed the overall effect of CS vein anatomical position on AHR (figure 30). We 
recorded the highest AHR achieved using any of the 3 bipolar configurations in each 
position successfully tested.  The pacing configuration that gave the largest increase in 
dP/dtmax was located in a lateral vein in 67% of patients, in an anterior vein in 22% of 
patients and in a posterior vein in 11% of patients. These proportions broadly 
corresponded with the proportion of all vectors tested in each position (61%, 29% and 
10% respectively).  The mean increase in dP/dtmax was +5.7 ± 9.8 for an anterior vein, 
+11.4 ±11.9 for a lateral vein and +14.4 ±9.7 for a posterior vein. There was no 
significant difference in AHR between anterior and lateral positions (p=0.17) or 
between posterior and lateral positions p=0.23). A significant difference in favour of a 
posterior position was seen, however, between anterior and posterior positions (p=0.03).  
 
Figure 31. Response Versus Non-response 
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Individual patients are represented on the x-axis. The proportion of CS positions for 
each patient giving a >10% increase in dP/dtmax (acute hemodynamic responder) is 
represented by blue and <10% (non-responder) in red. The number of CS vein 
positions assessed for an individual patient is given at the base of each column and 
the column width is proportional to this. 
 
Responders v Non-Responders 
 
For each patient we analyzed the proportion of CS positions that gave rise to a >10% 
increase in dP/dtmax. A 10% improvement in cardiac index has previously been used to 
define responders (107) and this cut-off for improvement in dP/dtmax. was chosen as it 
has been shown to be a sensitive and specific predictor of likely reverse remodelling 
following CRT (103) (figure 31). 5 patients did not respond in any CS position and 4 
patients responded in every CS position tested. In 9 patients (50% of patients in whom 
an LV lead was successfully implanted), a response was found in at least 1 vein but not 
in at least 1 other vein. 
Discussion 
 
Gold et al assessed AHR within CS veins in a similar number of patients (19 subjects) 
to our cohort but assessed changes in dP/dtmax in only 1 vein in the vast majority of 
these (88%)  (108). In our study we managed to pace multiple sites within individual 
veins and were able to compare the AHR in multiple veins within individual patients in 
90% of our study group. Thus we were able to assess intra and inter-vein variability in 
AHR in the majority of our patients. 
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Our data suggest that a small but significant difference in AHR is seen when pacing 
using different configurations within the same branch of the CS. Consistent with Gold 
et al, no significant group differences were seen in AHR when the different pacing 
configurations were compared. A large and significant difference was seen, however, 
when pacing in different branches of the CS within the same patient. This suggests that 
although the site of LV lead placement is important, position within a CS branch is less 
important than choosing the right branch in terms of AHR.  
 
It has previously been shown that the cathodal programmability available on the Quartet 
lead can be used to overcome problems with PNS and high capture thresholds (104, 
109, 110). The multiple vectors available, however, do not appear to allow optimal 
AHR to be achieved if the lead is not placed in the most suitable CS vein. So although 
the Quartet lead may allow placement in a distal (and more stable) CS vein position, 
there does not appear to be a significant variation in the AHR that can be achieved by 
pacing using the more proximal LV lead electrodes within a CS branch and thus a poor 
response elicited using a conventional bipolar configuration is most likely to be 
overcome by physical repositioning in another CS tributary rather than a change in 
vector. 
The best CS vein is not necessarily a lateral or postero-lateral branch, as the best AHR 
seen in this study was in an anterior or posterior vein in one third of patients. Although 
a significant difference in AHR was seen between anterior and posterior positions, no 
difference was seen between lateral and anterior positions or lateral and posterior 
positions. This suggests that within individual patients large variations in AHR exist and 
the best and worst veins are different in different subjects. Indeed, when CS positions 
are divided by whether they give rise to >10% increase in dP/dtmax or not, it can be seen 
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that in half of all patients, whether they are likely to respond or not to CRT is critically 
dependent on whether the right CS vein is chosen. In the other half of patients, however, 
it would appear that no matter which vein is chosen the same outcome will be achieved 
whether that be ‘response’ or ‘non-response’. 
Conclusions 
 
Although cathodal programmability of the Quartet lead appears to be useful in 
overcoming problems with PNS and high pacing capture thresholds, changing the 
pacing vector does not appear to offer large acute hemodynamic advantages within a 
vein. Great variation in AHR is seen in different CS veins within the same patient, 
however, and the vein that gives the best hemodynamic response is not necessarily 
lateral or postero-lateral. Choosing the best CS vein for CRT remains critical to likely 
response and robust non-invasive methods of predicting which vein will give the best 
outcome need to be developed. In the mean time invasive assessment of AHR at CRT 
implant appears to be a useful aid to optimum LV lead positioning. 
Study Limitations 
 
The order of the pacing vector sequence was not altered randomly from vein to vein or 
patient to patient and thus we cannot rule out sustained effects from earlier pacing 
sequences. The patient population was relatively small and a range of AV delays could 
not be assessed because of time limitation. For the same reason, the study was limited to 
the acute hemodynamic effects of LV pacing as compared to BiV pacing. Previous 
studies have demonstrated the non-inferiority of DDDLV pacing compared to DDDBIV 
pacing (62, 111), however,  and recent work suggests that a dP/dtmax  rise of  >10% 
using DDDLV pacing at CRT implant predicts reverse remodelling at 6 months (103). 
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To guide left ventricular lead placement in real-time during CRT implant using CMR-
derived scar and dyssynchrony data. 
Background  
Optimal LV lead placement via the coronary sinus (CS) is critical to CRT response. 
Current angiographic methods for selection of lead position are largely empirical and 
operator-dependent. 
Methods  
23 patients underwent CMR and anatomical models of the cardiac chambers, coronary 
veins and scar were registered to a 16-segment time-volume dyssynchrony map. The 3 
latest activated segments with <50% scar were chosen as targets and overlaid onto live 
fluoroscopy. An intra-ventricular pressure wire was used to assess acute haemodynamic 
response (AHR) to DDDLV pacing and validate CMR guided LV lead placement. 
Chronic CRT response (end systolic volume reduction ≥15%) was assessed 6 months 
post implant. 
Results 
20/23 patients underwent successful CMR guided LV lead placement. The lead was 
placed in the CMR target segment in 75% (15) of patients. Mean change in dP/dtmax for 
the CMR target was +14.2 ± 12.5% versus +18.8 ± 11.8% for the best AHR anywhere, 
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+3.4 ± 9.0 % for the worst position and +12.0 ± 13.8% for the region identified by an 
expert implanter based on CS venography. The optimal AHR was anterior in 30% of 
patients. Using CMR guidance the acute responder rate was 60% versus 50% on the 
basis of angiography alone. At 6 months 60% of patients were echocardiographic 
responders. 92% of echocardiographic responders were successfully paced in a CMR 
target segment compared to only 50% of non responders (p=0.04). 
Conclusions  
CMR guidance compared well when validated against AHR. Lead placement was 
possible in the CMR target region in most patients with an AHR comparable to the best 
achieved in any CS branch. Chronic response was significantly better in those patients 
successfully paced in a CMR target segment. These results suggest that CMR guidance 















Cardiac resynchronization therapy (CRT) is an established treatment for heart failure 
but around 30% of patients do not respond (25, 35) which may relate to sub-optimal 
lead positioning.(36) Pacing the postero-lateral LV generally produces the best 
haemodynamic response (45, 46) which is the conventional target site for LV lead 
placement, however patients may not respond if they have postero-lateral scar.(36) 
Large scale studies have shown no difference in CRT response when the lead is placed 
in an anterior, posterior or lateral position however a mid or basal location appears 
superior to an apical position (48-50). There is however great variation in acute 
haemodynamic response (AHR) when pacing different regions of the LV with the 
optimal location varying among patients (51, 112). Pacing the latest mechanically 
activated region of the LV is associated with better CRT outcomes (113, 114) but to 
date no studies have assessed real time CMR LV lead guidance based on this parameter. 
 
We hypothesized that optimal CRT response will occur if those regions
 
of the 
myocardium most delayed by electromechanical dyssynchrony can be identified using 
CMR and targeted for pacing. Using novel data acquisition, processing, overlay and 
registration software we aimed to identify the latest mechanically activated regions of 
myocardium without scar to allow real time CMR guided LV lead implantation.  
 
We set out to validate CMR guidance by comparing the optimal lead position defined 
by CMR overlaid onto fluoroscopy to an optimal acute haemodynamic LV lead position 
anywhere within the CS measured with a high-fidelity pressure wire.(63) Comparison 
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of the optimal site was made with the site chosen by an expert CRT implanter blinded to 






Study Population (Table 11) 
Patients fulfilling standard CRT criteria (NYHA class II-IV drug refractory heart 
failure, LVEF ≤35% and QRS ≥ 120ms) were included. The study was approved by the 
local ethics committee and written informed consent was obtained from each patient. 
Baseline assessment of NYHA class, Minnesota Living with Heart Failure 
Questionnaire (MLWHFQ) score, 6 minute walk distance (6MWD), peak oxygen 
uptake (VO2 max) and echocardiographic assessment of LV systolic function and 
volumes was performed. Patients with a contraindication to CMR or significant renal 
impairment (estimated glomerular filtration rate <30 ml/min/1.73m
2
) were excluded.  
 
Patients 23 
Age 66 ± 11 
Male/female (%) 87/13 
NYHA Class (II/III/IV) 3/19/1 




Table 11. Patient Pre-CRT Clinical Characteristics 
NYHA= New York Heart Association; LVEF=left ventricular ejection fraction; 
IVCD=intraventricular conduction delay; LBBB=left bundle branch block; 
On ACE-I or ARB 100% 
On Aldosterone antagonist 35% 
On statin 83% 
LVEF (%)* 25 ± 8 
LVESV (ml)* 154 ± 53 
Ischemic/non-ischemic (%) 52/48 
MLWHFQ 51 ± 23 
6MWD (m) 207 ± 
152 
VO2 max 15.1 ± 
3.6 
Sinus rhythm/Atrial fibrillation (%) 78/12 
Heart Rate (bpm) 76 ± 16 
PR Interval (ms) 170 ± 18 






RBBB=right bundle branch block. ACE-I=angiotensin converting enzyme inhibitor; 
ARB: angiotensin receptor blocker. 
* derived from 3D echo if available pre and post CRT (otherwise 2D echo data 
used) 
 
Cardiac MR Image Acquisition and Processing 
 
Respiratory and cardiac-gated CMR images were acquired on a Philips Achieva 1.5T 
MR system (Philips Healthcare, Best, The Netherlands). Two, three, four chamber and 
multiple slice short axis cine steady state free precession (SSFP) images were acquired.  
Contrast enhanced CMR images of the coronary veins and myocardial scar were 
acquired using previously described methods (42, 43, 95). The epicardial surface of the 
LV and endocardial surfaces of the right ventricle, left atrium and right atrium were 
extracted automatically using a model-based segmentation algorithm applied to the 3D 
IR-SSFP whole heart image data (98). The CS was manually segmented from the whole 






Figure 32. Whole Heart Segmentation 
Postero-Anterior view of a whole heart segmentation showing cardiac chambers and 
coronary venous system (LV in dark blue, RV in green, LA in orange, RA in light 
blue and CS in red) 
 
A modified American Heart Association (AHA) 16 segment LV model (115) (figure 
33; CMR dyssynchrony: panels A and B) was created using TomTec 4D analysis 
software (TomTec Imaging Systems GmbH, Unterschleissheim, Germany). The same 
analysis tool was used to create a regional volume map showing the mechanical delay 














Figure 33. CMR Dyssynchrony 
Panel A shows the modified AHA 16 segment model of the LV as a bullseye plot 
(Sept=septum, Ant=anterior, Lat=lateral, Inf=inferior). Panel B shows the LV model 
created from CMR cine imaging and labelled according to the 16 segment model 
shown in the bullseye plot. Panel C shows the individual regional volume curves for 
each LV segment during a complete cardiac cycle. 
 
The position and extent of myocardial scar was determined from LGE CMR images and 
segments with >50% trans-mural LGE were considered non-viable.(116) Scar data was 
manually segmented from the CMR multi-slice short axis stack images using ITK-
SNAP software (99) and registered to the whole heart CMR data allowing scar to be 





Figure 34. CMR Scar 
Panel A shows full thickness scar in red overlaid on to the LV epicardial surface. 
Panel B shows the same patient’s full thickness scar overlaid in grey on to a 16 
segment bullseye plot of the LV. The cyan outline around the bullseye plot represents 
the CS. The white arrows indicate the same region of scar in both panels for this 
patient. 
 
MR Target Segments 
 
Segments with scar affecting >50% of their area were excluded as targets. Antero-septal 
(segments 6, 12 and 16) were excluded as pacing these segments would result in an 
activation pattern similar to RV pacing. Segments were also excluded if their regional 
volume curve was flat (overall regional volume change < 2.5ml) suggesting akinesis 
(71)(figure 35). Prior to CRT implant, two independent imaging specialists agreed on 
the target segments for LV lead implant by choosing the three latest mechanically 




Figure 35. Regional Volume Map 
Time is a percentage of the total cardiac cycle on the x-axis and volume change (ml) 
on the y-axis. In this example segment 11 is the latest mechanically activated segment 
but is excluded as a potential target because the regional volume change from peak is 
<2.5ml. The target segments in this patient are therefore 10, 9 and 4 (no scar seen on 
LGE imaging). 
 
Image Overlay and Registration 
 
An in house developed platform based on the Philips EP Navigator (Philips Healthcare) 
was used to overlay and register the CMR-derived model during CRT implant (22). 
Accurate registration of the CMR model to live x-ray images was achieved using PA, 
LAO 30 and RAO 30 views with a catheter looped in the right atrium. The EP navigator 




images throughout the procedure. Respiratory motion was compensated for as published 
previously (117). The 3D heart roadmap was translated along the head to foot vector of 
the patient. We have previously shown that the above methods allow accurate overlay 
and registration of 3D anatomical models to live fluoroscopic images (figure 36) (42). 
 
 
Figure 36. CMR model overlaid on to fluoroscopic image in real-time 
Silver spheres indicate the previous positions of the LV electrodes in an AP view. 
 
Implant and Comparison of MR Guidance with Acute Haemodynamics 
 
Haemodynamic evaluation was performed using a 0.014 inch diameter high fidelity 
Certus PressureWire and PhysioMon software (RADI Medical Systems, Uppsala, 
Sweden) with a 500Hz frequency response and 50Hz filter bandwidth. The pressure 




radial artery. The LV lead was placed in as many different CS positions as possible. 
Pacing was performed in DDDLV mode with a fixed AV delay 100ms (VVI LV in AF 
patients) 5-10 beats above intrinsic rate to eliminate the effect of heart rate variation.  
The LVdP/dtmax was recorded for at least 20 s to ensure steady-state conditions.  LV 
dP/dtmax during atrial pacing (AAI) or RV pacing  for AF patients at 5-10 beats above 
intrinsic rate was considered baseline and was kept constant when testing different 
pacing modes. A waiting period of at least 20 s was respected after any change in 
pacing settings or lead position to achieve hemodynamic stabilization. These methods 
have previously been shown to reliably measure LV dP/dtmax.(61, 62, 101, 102) 
 
Results at each pacing site were expressed as a percentage change from baseline. In 
order to minimize the effect of drift the baseline was reassessed prior to and after every 
LV lead reposition and comparisons were made to a mean of these two readings.  Data 
from premature ventricular complexes were discarded. The LV lead was finally placed 
in or as close as possible to one of the 3 target segments. AV and VV delays were 
optimized with pressure wire guidance at the end of the procedure. 
 
CMR Guidance v Anatomical Target Segments 
 
Each CS vein position in which pacing was attempted was marked on to still images of 
the CS balloon occlusion venogram for each patient. At least two views (PA, RAO 30 
or LAO 30) for each patient were assessed by an independent CRT expert implanter 
(JPS). All the positions in which it was possible to obtain hemodynamic data were 
ranked in order of preference i.e. LV lead placement based solely on the CS venograms. 
The AHR achieved when pacing in the highest ranked angiographic position in which 
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pacing could successfully be performed without PNS was compared to the CMR and 
haemodynamic guided targets. 
 
Follow-up and Response 
Patients were followed-up at 6 months with repeat assessment of NYHA class, 
MLWHFQ, 6MWD, VO2 max and echocardiographic parameters. Echocardiographic 
reduction in ESV ≥15% at 6 months was used to define reverse remodelling response 




Statistical analysis was performed on JMP (version 9.0.1, Marlow, Buckinghamshire, 
UK). Group comparisons were performed using a t-test or an appropriate non-
parametric test (Wilcoxon rank sum, Kruskall-Wallis). Pearson’s correlation coefficient 
was used to measure the linear relationship between two variables and Chi squared test 
to compare categorical variables. All results are expressed as mean ± SD. P values of < 




21/ 23 (91%) patients underwent successful CRT implantation and haemodynamic 
study. In one patient only the postero-lateral vein was suitable for use; this had a 
favourable dP/dtmax response but the patient was excluded from analysis. In one patient 
CS intubation failed due to the presence of a valve and a further patient suffered a CS 
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dissection precluding LV lead placement (both patients subsequently received 
successful CRT). The full protocol with LV lead placement in at least two separate CS 
branches was successfully completed in 20 patients. AHR was successfully assessed in 
a mean of 4.7 ± 1.6 different LV segments in these 20 patients and successful LV 
pacing in at least 1 target segment was achieved in 75% (15). In 5 patients it was 
impossible to pace a target segment either because of failure to capture or absence of an 
accessible vein to the target (4 ischaemic patients with scar adjacent to the target 
segments). The CMR targeted dP/dtmax in these patients was based on the nearest 
position to a target segment in which successful pacing could be performed. 
 
CMR Guided v Conventional LV Lead Placement   
 
The mean increase in dP/dtmax with the CMR guided approach was +14.2 ± 12.5% 
versus +18.8 ± 11.8% (p=0.69) for the best AHR achieved in any segment for those 
patients and +3.4 ± 9.0% (p<0.001) for the worst AHR in any segment (figure 37). A 
CMR guided approach compares with an increase in dP/dtmax of +12.0 ± 13.8% (p=0.23) 
for the highest ranked region based on CS venography. The mean AHR for all segments 




Figure 37. Mean Change in AHR 
Best=mean of best segment overall for each patient; Worst=mean of worst segment 
overall for each patient; Target = mean of highest ranked CMR target segment for 
each patient; Expert = mean of the highest ranked angiographic segment for each 
patient. 
 
At least one anterior and one lateral or postero-lateral LV segment was paced in all 
patients completing the protocol.  A conventional lateral or postero-lateral LV lead 
position gave the best AHR in only 70% (14/20) of cases. In the remaining 6 patients 
the best AHR was anterior and in 2 of these patients at least one of the CMR defined 
target segments was adjacent to the site of best response (figure 38 shows the overall 
AHR for each segment). Mean QRS duration and LBBB morphology did not 
differentiate these two groups (QRS 152 ± 20ms vs 152 ± 20ms and LBBB in 12/14 

















Figure 38. Mean Percentage Change in dP/dtmax 
Mean percentage change in dP/dtmax compared to baseline for each LV segment. 
Mean for all patients. 
 
A positive significant correlation between the best overall AHR achieved in each patient 
(figure 39) and the CMR derived systolic dyssynchrony index (SDI) was seen (r=0.63, 
p=0.003) supporting the hypothesis that CMR-derived dyssynchrony directly correlates 
with AHR. Consistent with recent work, a non-significant negative correlation between 




Figure 39. Correlation between dP/dtmax and CMR Dyssynchrony 
Scatter plot showing correlation between highest dP/dtmax achieved in each patient 
and MRI systolic dyssynchrony index (SDI) (r=0.63, p<0.001) 
 
Basal v Mid v Apical Pacing 
 
The mean change in dP/dtmax achieved when pacing basally  (segments 1-5) (figure 33 
panel A and figure 40) was +14.7 ± 12.6% versus +11.2 ± 11.8% for mid-LV pacing 
(segments 7-11) and +6.8 ± 10.9% for apical pacing (segments 13-15). There was a 
significant difference between basal versus apical regions (p=0.04) and mid versus 
apical regions (p=0.05) but not basal versus mid regions (p=0.71). An apical position 
gave rise to the best AHR in just 3 patients but the difference in AHR between the 
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apical segment and the best non-apical segment in these patients was not large  (+11.2 ± 
14.7% versus  +9.9 ± 14.3% respectively). Of these 3 patients one had extensive inferior 
scar but the other 2 patients had no scar.  
 
Figure 40. AHR by LV Region  




An AHR of ≥10% has been shown to be a sensitive and specific predictor of long term 
response to CRT (63) and was seen in 70% of our patients. Of the 6 patients in whom 
the highest ranked target segment did not result in an AHR ≥ 10%, only one had an 
AHR>10% in a non-target segment, suggesting that if a patient is an acute non-
responder despite pacing in a target segment, it is very unlikely pacing in another 
segment will improve outcome. The likelihood of acute non-response was greatly 
increased by the presence of scar with 5 of 6 acute non-responders having scar on CMR. 
(postero-lateral in 3 and anterior or inferior in 2 patients). Conversely, of the 10 patients 
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without scar only 1 was not an acute responder. Interestingly, however, the mean overall 
AHR seen in ischemic and non-ischemic patients was similar, (+18.3 ± 12.2% v +19.1 ± 
11.8% respectively). 
 
Of the 15/20 patients in whom a CMR target segment was paced, the acute AHR rate 
was 73% (11/15) according to the best dP/dt in any CS position, 67% (10/15) were 





At 6 months 12/20 (60%) patients were echocardiographic responders (reduction in 
ESV of ≥15%). The 8 echocardiographic non-responders all had an ischaemic aetiology 
to their heart failure. Consistent with previous clinical trials (38), a greater proportion of 
patients were clinical rather than echocardiographic responders with 75% having an 
improvement in CCS at 6 months. 11/12 (92%) echocardiographic responders were 
successfully paced in a CMR target segment compared to only 4/8 (50%) 
echocardiographic non-responders (p=0.04).  Thus only 1 of the 5 patients who was not 
paced in a target segment reverse remodelled. 10/14 (71%) patients with an acute AHR 









We have used CMR to guide LV lead placement and compared the results acutely to an 
optimal haemodynamic standard and angiographic approach and chronically with 
reverse remodelling. We were able to accurately acquire and process CMR derived CS 
anatomy, scar and dyssynchrony data (derived from a single CMR scan) and fuse this 
with live fluoroscopy during CRT implant.  We were able to pace in at least one CMR 
target segment in the majority of patients which gave rise to an AHR comparable to the 
best possible in any segment. In keeping with previous studies (51, 63, 112) we showed 
a marked difference in AHR dependent on LV pacing site which may explain sub-
optimal CRT response if a purely anatomical approach is used. Our results suggest that 
if a target segment is successfully paced, it is unlikely that any other segment will give 
rise to a significantly better acute response.  
 
Our chronic results show an improved reverse remodelling rate of 92% in patients that 
successfully had the lead positioned in a CMR target segment compared to 20% in those 
in which the CMR target could not be paced.  Our technique of using CMR guidance 
may allow an implanter to individualize their approach to the patient and guide them to 
the optimal target segment. Whether this will lead to an improved chronic outcome 
against a standard approach is as yet unproven and would require a randomized study of 






Comparison with Previous Studies 
 
2D echo speckle tracking radial strain analysis has been used to identify the latest 
mechanically activated LV segments and targeting these regions is associated with an 
improved echocardiographic response and prognosis post CRT(52, 113). Non-contrast 
CMR has also been used to identify the site of latest mechanical activation by radial 
strain analysis (121). These previous studies, however, either used dyssynchrony 
imaging data to retrospectively analyze whether the LV lead was placed in a concordant 
or discordant region of the LV or used multiple fluoroscopic views at the time of 
implant to approximate the actual target region suggested by radial strain analysis. We 
have previously shown that CMR derived data of CS anatomy and scar can be 
registered onto fluoroscopy during CRT implant with a good validation between CMR 
derived and fluoroscopic parameters and the potential to facilitate CRT in patients with 
previously failed implants and unusual anatomy (42, 95). These previous studies did not 
use CMR derived dyssynchrony data to target LV lead placement and this is the first 
study to use CMR derived dyssynchrony and scar analysis fused with fluoroscopy to 
guide LV lead placement and compare it with a haemodynamic standard. 
 
Comparison with Angiographic Approach 
 
The acute CMR guided response rate was greater (60%) than with an angiographic 
approach (50%). One might argue that using an angiographic approach gives a similar 
outcome to a complex CMR guided approach and may be unnecessary. It should 
however be stated that the choice of lead position using angiography was made by an 
international expert implanter and an alternative argument would be that using such a 
CMR guidance system may allow even a relatively inexperienced implanter to achieve 
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the same result as an experienced operator.  The large difference in AHR between the 
best and worse positions in each patient highlights the fact that if the wrong target vein 
is chosen this may result in a sub-optimal outcome. The benefit of a CMR guided 
approach over a standard approach may be that CMR derived dyssynchrony and scar 
may predict the likelihood of a favourable response. In our patients, the greater the 
degree of dyssynchrony, the greater the acute response. Similarly the presence of scar 
was associated with a poor response. Thus a preoperative CMR may guide lead 
placement and also be useful in predicting which patients are likely to respond on the 
basis of baseline dyssynchrony and scar. This may allow physicians to target potential 
non-responders and consider non-standard CRT approaches such as endocardial or 
multi-site pacing.  
 
In this study 92% of the patients that reverse remodelled were paced in a CMR target 
whereas in the chronic non responders a high proportion of patients were unable to be 
paced in a CMR target (only 50% were paced in a target CMR segment). All of the non-
responders had an ischaemic aetiology and this may reflect the generally poor response 
to CRT in patients with scar.  In several patients the venous anatomy precluded reaching 
the CMR target segment and this raises the possibility of an endocardial approach 




This study is limited by its small size and lack of control group but is a proof of concept 
for CMR CRT guidance. A range of AV delays could not be assessed because of time 
limitations and, for the same reason, the study was limited to measuring the AHR to LV 
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rather than biventricular (BiV) pacing. It is possible that DDD-BiV pacing would be 
superior and more comparable to a normal CRT strategy. DDD-LV pacing was the only 
option, however to ensure a steady state for accurate hemodynamic measurements and 
previous studies have demonstrated the non-inferiority of DDD-LV compared to DDD-
BiV pacing (62, 111).  Data from our group has suggested a good correlation between 
AHR and chronic response in terms of LV reverse remodelling (≥15% reduction in ESV 
at 6 months) predominantly in non ischemic patients (63). Other studies, however, have 
shown that baseline LVdP/dtmax rather than acute change at implant are predictive of 
outcome in terms of symptoms and mortality (122). Improvement in dyssynchrony 
rather than AHR may be a more reliable predictor of CRT response and accordingly our 
data show a good correlation of AHR and the degree of CMR derived LV dyssynchrony 




It is feasible to acquire, overlay and accurately register CMR derived anatomical, scar 
and dyssynchrony data to guide CRT implantation. LV lead placement was possible in 
at least 1 target region in most patients and gave an AHR comparable to the best that 
could be achieved in any branch of the CS. Patients successfully paced in a CMR target 
had a better chronic response to CRT than those that were not. A CMR guided approach 
to LV lead placement may therefore increase the proportion of patients that respond to 
CRT and increase the level of response in ‘responders’. Whether CMR image guidance 
produces a reduction in procedure time, fluoroscopy time, radiation dose and improves 
long-term outcomes needs to be evaluated in a randomized controlled study. 
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Response to cardiac resynchronization therapy (CRT) is reduced in patients with 
posterolateral scar. Multipolar pacing leads offer the ability to select desirable pacing 
sites and/or stimulate from multiple pacing sites concurrently using a single lead 
position. Despite this potential, the clinical evaluation and identification of metrics for 
optimization of multisite CRT (MCRT) has not been performed. 
Methods 
The efficacy of MCRT via a quadripolar lead with two left ventricular (LV) pacing sites 
in conjunction with right ventricular pacing was compared with single-site LV pacing 
using a coupled electromechanical biophysical model of the human heart with no, mild, 
or severe scar in the LV posterolateral wall. 
Results 
The maximum dP/dtmax improvement from baseline was 21%, 23%, and 21% for 
standard CRT versus 22%, 24%, and 25% for MCRT for no, mild, and severe scar, 
respectively. In the presence of severe scar, there was an incremental benefit of 
multisite versus standard CRT (25% vs 21%, 19% relative improvement in response). 
Minimizing total activation time (analogous to QRS duration) or minimizing the 
activation time of short-axis slices of the heart did not correlate with CRT response. The 
peak electrical activation wave area in the LV corresponded with CRT response with an 
R
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Biophysical modeling predicts that in the presence of posterolateral scar MCRT offers 
an improved response over conventional CRT. Maximizing the activation wave area in 
the LV had the most consistent correlation with CRT response, independent of pacing 





















The Quartet quadripolar LV lead (St Jude Medical, Sylmar, CA, USA) has the ability to 
perform true multisite pacing (MSP) of the LV using two different vectors with a 
minimum 5-ms delay between them. With the addition of RV pacing, this allows up to 
three ventricular sites to be paced simultaneously. Given the relative close proximity of 
the electrodes, increasing the number of pacing sites may not necessarily produce a 
significant improvement in electrical activation, however. Furthermore, the increased 
number of pacing sites and the corresponding increase in the temporal and spatial 
pacing combinations means that optimizing such a device for a specific patient is a 
challenge in itself. The number of potential pacing permutations greatly limits the 
capacity to comprehensively evaluate all combinations or optimize the lead through trial 
and error in a single patient, thus necessitating improved optimization algorithms. The 
difficulty in both testing and validating such algorithms is that while safety studies of 
MSP are currently being performed, there are currently no clinical data on the 
haemodynamic effect of multisite stimulation using the quadripolar lead. In silico 
biophysical models allow the possibility of testing multiple pacing parameters (123). 
 
To provide an initial prediction of the efficacy of MSP with a quadripolar lead and to 
facilitate the proposal of optimization algorithms, we applied this approach to evaluate 
the effects of MSP in a computational coupled electromechanical human heart model 
(Figure 41) (81). The model simulates single or multisite LV pacing in conjunction 
with right ventricular (RV) pacing and can be tested in the presence of no, moderate, or 
severe LV transmural posterolateral scar. These simulations predict the contractile 
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ability of the heart for each pacing combination, measured using dP/dtmax and provide a 
quantitative evaluation of the effects of MSP compared with conventional CRT.  
 
Figure 41. Heart Geometry and Coronary Venous Anatomy  
(A) Electrode position and (B) the region of LV posterolateral scar in blue. 
 
Using a complete set of pacing combinations, we evaluated three potential optimisation 
algorithms based on total activation time, cumulative fraction of activated volume, and 
activation time of short axis slices, parallel to the base of the heart (figure 42). 
 
Figure 42. Heart Model Activation Cross Sections 
143 
 
(A) The activation patterns, where white regions are activated and black regions 
inactivated for evenly spaced 10-mm slices taken from the heart model in (B). (C) The 
point of first activation at 15 ms in slice 3, the point (marked with a yellow x) and time 
where the first loop of activation is formed at 92 ms, the point when the LV is fully 




The computational model is based on a coupled electromechanical human heart model 
developed previously using invasive data from a 60-year-old female with NYHA class 
III heart failure, an LVEF of 25% and LBBB (QRSd 154 ms). The mechanics and 
electrophysiology model were validated pre and post-CRT against endocardial 
activation patterns derived from non-contact mapping, CMR derived wall motion, and 
pressure wire measures. In this study, two simplifying assumptions were made to reduce 
confounding factors. The heart was assumed to have no intrinsic activation and the 
myocardium was treated as homogenous. 
 
Simulations were performed using the bidomain approximation of myocardial electrical 
activation in the heart. Simulations were performed using CARP (124) on the UK 
National HPC resource HeCTOR (www.hector.ac.uk). The electrophysiology model 
had 35 million and 26 million extra and intracellular degrees of freedom, respectively, 
and 208 million elements, and took approximately 3 hours to solve using 512 cores. 
Mechanics simulations were performed using CMISS (www.cmiss.org) on ORAC at the 






To simulate pacing, we manually aligned the coronary venous anatomy from 3D IR-
SSFP whole heart sequences with model geometry derived from cine CMR sequences. 
The coronary venous anatomy provided the location for the quadripolar lead that was 
introduced into the model. RV septal (RVS) and apical (RVA) lead positions were 
introduced in the centre of the RV. All electrodes are shown in Figure 41A. LV pacing 
was between vector D1-M2 or M3-P4. RV pacing was between the RV tip in the 
septum or apex position and the RV coil. Stimulation was simulated by raising the 




Simulations were performed using the model with no scar or in the presence of a trans-
mural basal LV posterolateral scar with a 60-mm diameter, as shown in Figure 41B. 
Scar was simulated by reducing conduction and decreasing anisotropy. Conduction 
velocities decreased by approximately 50% between viable tissue and scar (125).  From 
the cable equation conduction velocity is proportional to the square root of conductivity 
(the inverse of resistance). Hence, scar was simulated by a 50% or a 90% decrease in 
the conductivity value corresponding to 30% or 70% decrease in conduction velocity, 
for mild and severe scar, respectively. The quadripolar lead was placed across the scar 
with the most distal pole (D1) out of the scar, M2 on the scar border, and M3 and P4 





Cardiac Function and Efficacy of CRT 
 
The efficacy of each pacing mode was evaluated using the change in dP/dtmax as a 
metric of improvement. RV apical pacing dP/dtmax was used as a baseline, as the model 
had no intrinsic activation. We normalized all CRT responses by dP/dtmax calculated for 




For standard CRT (single site LV and RV stimulation), simulations were performed 
with the LV or RV site paced first with a 5, 15, 30 or 45 ms delay. For MSP (2 LV 
pacing sites and one RV), the three stimulations were separated by two delays, one 
delay interval was always 5 ms and the other delay interval was 5, 15, 30, or 45 ms. The 
sites could be paced in any order except that the RV site had to be paced either before or 
after the 2 LV pacing sites. Activation times for combinations of pacing sites were 




QRS duration has been reported to correlate with CRT response (84, 118) and to test 
this hypothesis, we compared CRT response with QRSd, using total activation time of 
both ventricles as an analogue of QRS duration. Previous studies have shown that 
pacing the LV only increased QRS duration, potentially due to late activation of the RV 
(126). To account for this effect we provide results for activation times, both for the 
combined LV and RV and for the LV alone. If the bulk of the heart is rapidly and 
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synchronously activated, then late activation of peripheral regions that prolong QRS 
duration may confound relationships between QRS and CRT response. 
 
Maximizing the peak rate of volume activation may minimize bulk activation 
asynchrony and lead to improved cardiac function. To test this hypothesis, we 
calculated derivative of the cumulative activation curve and plotted this against CRT 
response. The length dependence of cardiac muscle combined with the circumferential 
fibre direction in the mid-LV wall means that effective LV contraction may be achieved 
when a continuous strand of activated myocardium is formed around the circumference 
of the LV. When all myocardium is activated in such a loop, the length dependence of 
the muscle will spatially regulate tension development so that during isovolumetric 
contraction muscle length is maintained, allowing it to generate higher tension and 
hence improved dP/dtmax. To test if activation loops in the LV correlate with dP /dtmax in 
seven short-axis slices, we evaluated the time that the first loop of myocardium around 
the LV is activated, when the whole of the slice is activated in both the LV and RV, and 






dP/dtmax was calculated for a homogenous instantaneous activation of the myocardium, 
resulting in a theoretical maximum dP/dtmax of 1,295 mmHg/s. Baseline dP/dtmax (RV 
apical pacing) was 906, 885, and 825 mmHg/s for no, mild, and severe scar or 0.7, 
0.683, and 0.64 of the maximum value. 
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Single-Site and Multisite LV Stimulation 
 
Figures 43 and 44 show the fraction of the theoretical maximum dP/dtmax reached with 
standard CRT and MSP in the presence of no, mild, and severe scar, for different 
combinations of LV and RV pacing locations and delay intervals. Standard CRT caused 
a 21%, 23%, and 21% change in dP/dtmax from pacing combination D1-M2 5ms RVS, 
M3-P4 15ms RVA, and M3-P4 45ms RVA for no scar, mild scar, and severe scar, 
respectively. These changes correspond to an absolute increase of 0.150, 0.154, and 
0.133 in the fraction of maximum dP/dtmax reached for no scar, mild scar, and severe 
scar cases, respectively. 
 
MSP (two LV and one RV stimulation site) caused a 22%, 24%, and 25% change in 
dP/dtmax from pacing combination D1-M2 5ms M3-P4 5ms RVS, M3-P4 5ms D1-M2 
5ms RVS and M3-P4 5ms D1-M2 45ms RVS for no scar, mild scar and severe scar 
respectively. These changes correspond to an absolute increase of 0.153, 0.164, and 
0.162 in the fraction of maximum dP/dtmax reached for no scar, mild scar and severe 
scar cases respectively. Thus, in the presence of severe scar, there was a benefit with 
MSP versus conventional CRT (25% vs 21% representing a 19% relative improvement 





Figure 43. Simulated Standard CRT Pacing Response 
Top panel corresponds to pacing the RV first, and bottom panel pacing the LV first 
with increasing intervals between the two. Red lines correspond to septal and blue 
lines apical RV pacing. Triangle and square symbols correspond to LV pacing from 




Figure 44. Simulated Multisite CRT Pacing Using  the Quartet Lead 
Red lines correspond to septal and blue apical RV pacing, and triangle and squares 










Figure 45. Simulated Conventional CRT v Multi-Site Pacing 
(A) Hemodynamic effect of standard versus MSP dependent on the presence and 
severity of posterolateral scar. With difference between standard versus Multi-Site 
CRT (MCRT) labelled. (B) Comparison of optimal pacing combinations from Figures 
3 and 4, for conventional CRT (CCRT, gray lines) and multi-polar CRT (MCRT), 
black lines) for no (solid line), 50% (dashed line), and 90% (dash dot line) scar. 
 
CRT Efficacy and QRS Duration 
 
To test if minimizing either biventricular or LV activation time is a potential method for 
optimizing lead timings or positions, we plotted total and LV activation time against 





Figure 46. Normalized Pressure Against LV or Biventricular Activation Time 
Plot of normalized pressure against LV or biventricular activation time for 
conventional and MCRT in the presence of no scar, 50%, and 90% scar. Point 
symbols correspond to pacing from RVA (square), RVS (circle), D1-M2 (triangle), or 





Figure 47 plots the peak rate of volume activation (the rate of change of the fraction of 
the myocardial volume that is activated) for each pacing and scar combination, in the 







Figure 47. CRT Response v Peak Rate of Cumulative Activation 
Correlation between CRT response and peak rate of cumulative activation for 
conventional CRT and MCRT in the presence of no scar, 50%, and 90% scar. 
MCRT=Multi-polar CRT 
 
LV Activation Time 
 
To evaluate the formation of continuous strands of activated tissue, we calculated the 
time taken for short-axis slices of the heart or the LV to become fully activated or the 
time taken for the first loop of continuous activation around the LV to form. Figure 48 





Figure 48. Correlation between LVTAT and dP/dtmax 
Correlation as defined by the R
2
 value of a linear fit between the time taken for the 
whole slice or the first loop to form and the normalized rate of pressure development 




This is the first human biophysical model that has tested the efficacy of MSP using a 
quadripolar lead. The model predicts that: (1) pre-excitation of the LV in regions of 
slow conduction improves haemodynamic response to CRT, (2) multisite CRT offers 
moderate improvements in acute haemodynamic response over conventional CRT but 
that this is the case only in the presence of scar, (3) minimizing QRS duration or 
activation times of short-axis slices provide a poor indicator of CRT response, and (4) 
154 
 
cumulative volume activation maps provide a potential metric of CRT response that is 
robust to cases with scar. 
 
Standard and MSP 
 
As shown in Figure 43, in the absence of scar, approximately 0.85 of the maximum 
dP/dtmax could be achieved with either standard or MSP. It was only in the presence of 
posterolateral scar that MSP showed a benefit. As the level of scar increased, the 
optimal response between multisite and standard CRT diverged (25% vs 21%, 
representing a relative increase of 19%). As the level of scar increased, the optimal 
combination of poles locations in both the LV and RV changed for both standard and 
MSP demonstrating the impact of scar on optimal lead placement. 
 
Figure 43 shows that if the RV (apical or septal) is the first site to be activated then 
regardless of the severity of posterolateral scar, increasing the delay interval decreases 
CRT efficacy. In the presence of scar, pre-exciting the LV with standard CRT improves 
response, regardless of LV or RV pacing location, consistent with earlier studies (127) 
that showed an improved benefit of LV pre-excitation over simultaneous LV and RV 
pacing. Similarly for MSP in the absence of posterolateral scar, the model predicts no 
significant benefit from LV pre-excitation and limited benefit in the presence of mild 
scar for any pacing lead combination (figure 44). Only in the presence of severe scar 




The effect of RV septal or apical pacing remains controversial. In standard CRT, RV 
septal pacing has been shown to provide no benefit over RV apical pacing (114) 
Consistent with these results, the model predicted no clear benefit from RV septal or 
apical pacing for standard CRT. Interestingly, there was a consistently better response 
to CRT with RV septal pacing as opposed to apical pacing in the MSP simulations.  
 
Figures 43 and 44 predict that in a clinical context, when temporal optimization may be 
unavailable or limited, MSP provides an optimal or near optimal outcome in 85% of 
pacing combinations for near simultaneous activation compared to 71% of pacing 
combinations for conventional CRT. Meaning MSP may provide a more robust 
outcome in the absence of temporal optimization. 
 
Pacing in Scar 
 
Consistent with canine (128)  and human (129) studies, the model results predict that 
with optimal pacing timing and location, CRT in the presence of scar can still 
significantly improve pump function. Specifically, the model predicts that, with lead 
capture, pacing in scarred regions and thus pre-exciting the scarred myocardium often 
results in an optimal site. Controversy remains regarding the detrimental effects of 
pacing in or near scar, however, and these conflicting results could be due to differences 
in capture of the scarred region, as if electrical activation fails to propagate from the 
pacing site then patients will receive no benefit. Notably lead position optimization 
strategies have resulted in apparently conflicting conclusions. Previous reports have 
suggested that pacing in or near regions of scar compromises response (36, 130) 
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conversely an alternate strategy proposes pacing at the point of latest mechanical 
contraction maximizes response. 
 
Although not explicitly inconsistent, in many cases, slow conduction in scar will result 
in the last region to contract being one that is scarred or compromised; this location is 
then either an optimal or a poor pacing location depending on the doctrine adopted. The 
model predicts that if the scarred region has viable but slow conduction then pre-
exciting the scarred region can result in an optimal response; thus, the optimal increase 
in dP/dtmax for standard and MSP was achieved by first pacing from D1-M2 in the 
absence of scar but in the presence of scar, it was optimal to pace first from M3-P4, 
which was located in the middle of the scar region. This is in keeping with non-contact 
mapping data where LV pre-excitation in areas of slow conduction improved 
haemodynamic response (78).  
 
Apical versus Basal Pacing 
 
There has been much interest recently in the position of the LV pacing lead for CRT in 
terms of an apical or basal pacing site. Recent data from the MADIT-CRT trial showed 
that leads placed in the apical region were associated with an unfavourable outcome 
(48).  For standard CRT simulations, with a single LV stimulation site, the optimal site 
was basal in models with mild or severe scar. In models without scar, there was 
marginal difference between apical and basal pacing. For MSP, pacing at both apical 






Previous studies have reported that minimizing QRSd correlates with CRT response 
(84, 131) while other studies found no change in QRSd despite seeing a response to 
CRT (119, 132). To directly address this issue, we evaluated the correlation between 
QRSd, maximum rate of volume activation, and short-axis slice activation times in both 
the RV and LV and the LV alone. 
 
We found that QRSd did not consistently correlate with CRT response. Single-site LV 
pacing has been reported to prolong QRS while improving CRT response (126). This 
could be attributable to late activation of the RV prolonging the QRS while having 
limited impact on LV function, yet even when the confounding effects of the RV on 
total activation time were removed (figure 46), the correlation between CRT response 
and LV activation time in the model was still poor. This relationship was similar for 
both standard and MSP with the relationship deteriorating further in the presence of 
scar. 
 
We hypothesized that minimizing the activation time of the LV, RV and LV, or a loop 
in a short axis slice would correlate with CRT response by corresponding to the 
formation of a continuous contracting region of myocardium that would cause an 
effective contraction of the LV. Despite showing a strong correlation of basal activation 
with CRT response in the absence of scar, this relationship deteriorated rapidly in the 




It is possible that calculating the time of formation of other continuous loops of 
activating myocardium would correspond to CRT response. These loops could 
potentially lie out of the short-axis plane or in loops of myocardium following the 
direction of principle stress. The only metric to show a consistent correlation with the 
CRT response was the peak rate of cumulative activation in the LV. Given an 
approximate constant conduction velocity and the continuous smoothly varying LV 
geometry, this metric corresponds to the peak surface area of the activation wave and 
maximizing its size will synchronize the bulk activation time of the heart. This metric 
correlated with both standard and MSP and was independent of scar, RV or LV lead 
location, and timing interval. 
 
The cumulative activation of the LV is not routinely measured in CRT patients. It can 
be approximated by evaluating the rate of cumulative volume contracting, although the 
relationship between activation time and deformation is dependent on the activation 
pattern. It is possible that simple patient-specific activation models could provide a 
means to evaluate this metric and be used for the model-guided optimization of CRT 




The model was based on a single patient dataset due to the need for a single 
comprehensive and consistent dataset. However, we cannot necessarily assume that all 
patients would respond in the same fashion. The patient on whom the model was based, 
however, was a typical candidate for CRT with a broad LBBB and LVEF<35%. 
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In modelling the scar, we assumed a homogenous and discrete region that may not be 
the case for many patients with ischaemic heart disease that may have multiple and 
heterogeneous areas of scar. The presence of multiple infarct regions would affect the 
model predictions. Specifically, the presence of scarred or compromised regions in 
close proximity to the RV lead could favour pre-excitation of the RV to achieve an 
optimal response. DE CMR shows us that scar geometry is varied and often complex. In 
this study, we aimed to investigate the general impact of trans-mural posterolateral scar 
severity on conventional CRT and MSP efficacy independently from any one individual 
patient’s scar geometry. This leads to the use of a defined analytical description of scar 
geometry; however, the model results may change for different scar locations or 
geometries. 
 
MSP was delivered using a commercially available lead and it is possible that other lead 




This biophysical model, testing the efficacy of multisite LV pacing using a quadripolar 
lead, shows that MSP may offer an improvement in AHR over conventional CRT but 
that this benefit is only seen in the presence of scar. Posterolateral scar is a well-
recognized predictor of poor CRT response and therefore MSP delivered using such 
lead technologies may be a potential way to improve response in the CRT population, 
especially in patients with ischemic cardiomyopathy. These findings will clearly require 
in vivo evaluation. 
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To determine the best method of multi-site pacing for CRT and the mechanism 
underlying the response. 
Background  
Pacing the left ventricle (LV) from more than one site simultaneously improves acute 
hemodynamic response (AHR) and medium term-outcome in CRT. The best method of 
multi-site pacing is not clear, however. By using the multi-site pacing function of a 
quadripolar LV lead and additional temporary endocardial and epicardial LV leads, we 
aimed to pace from multiple sites in multiple different ways in order to establish the 
best method of multi-site pacing.  
Methods  
A haemodynamic study was performed in 12 patients with a previously implanted St 
Jude Quartet lead. The generator was temporarily reprogrammed to allow true multi-site 
pacing from the quadripolar lead. A second temporary LV lead was placed in another 
branch of the CS and a temporary decapolar LV roving catheter, a RADI pressure wire 
and an ESI non-contact mapping balloon were placed in the LV cavity. Simultaneous 
pacing from up to five ventricular sites was then performed.  
Results 
The best mean AHR overall was found using DDDLV endocardial pacing. 
Conventional biventricular pacing led to a 13% increase in AHR and this was similar to 
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various combinations of multi-site pacing (MSP). Within individuals, however, the best 
pacing modality varied greatly. MSP using 2 vectors from the Quartet lead was best in 
25%, endocardial pacing was best in 25% of patients, conventional single LV site 
pacing was best in 25%,  in 1 patient a combination of  2 different epicardial leads was 
best and in 2 patients ‘quad-site’ pacing was best. 
Conclusions  
Multi-site pacing the ventricles from 3, 4 or 5 sites simultaneously does not appear to 
confer an overall AHR group advantage compared to conventional CRT. Within 
individuals, however, different methods of multi-site pacing are best and may improve 
response in patients who do not improve with conventional CRT. CRT thus needs to be 















CRT is an established treatment for heart failure (24, 25, 35) but 30-40% of patients do 
not respond (25, 35) and this may relate to sub-optimal lead positioning (36). 
Investigators have demonstrated that the region of best acute haemodynamic response to 
CRT varies greatly between patients and the optimal site may need to be individualised 
for each patient (51, 107). There is also evidence to suggest that pacing the left ventricle 
from more than one coronary sinus (CS) site simultaneously may improve acute 
hemodynamic response (AHR) and medium-term outcome (64-66, 69, 133). 
 
Multi-site pacing (MSP) via the CS is limited by the number of vein tributaries 
available, however, whereas endocardial pacing is not and thus a greater number of LV 
sites can be accessed. Furthermore, endocardial pacing may give rise to a more 
physiological electrical and mechanical propagation which results in a better acute 
haemodynamic response (70). Recent work suggests that not only is endocardial pacing 
better than conventional epicardial pacing via the CS but the combination of epicardial 
and endocardial MSP may give the best overall AHR particularly in patients with an 
ischaemic cardiomyopathy (71). No studies to date, however, have compared MSP from 
two epicardial (CS) sites simultaneously with endocardial pacing or indeed 
simultaneous endocardial and epicardial pacing to dual epicardial site pacing.  
  
We aimed to ascertain the best method of multi-site pacing by using the multi-site 
pacing function of the Quartet 1458Q LV lead (Jude Medical, Sylmar, CA, USA) (134) 
in patients with a chronically implanted CRT system  and then adding further temporary 
CS epicardial and endocardial leads to allow multiple different combinations of MSP to 
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be performed. Using a Certus pressure wire (RADI Medical Systems, Uppsala, Sweden) 
and EnSite EC1000 non-contact mapping (NCM) balloon array (St Jude Medical, 
Sylmar, CA, USA) we aimed to ascertain the LVdP/dtmax and electrical properties 




The study was approved by the local ethics committee and informed consent was 
obtained from each patient. Patients fulfilling standard criteria for CRT (NYHA class II-
IV drug refractory heart failure, LVEF ≤35% and QRS ≥ 120ms) who had previously 
been implanted with a Quartet Model 1458Q LV lead and Promote Q Model CD3221-
36 or Promote Quadra CD3239-40 generator (St Jude Medical, Sylmar, CA, USA) at 
least 3 months prior to the invasive study were recruited. Patients with a mechanical 
aortic valve or significant peripheral vascular disease were excluded. 
 
Baseline assessment included NYHA functional class, ECG and 2D echocardiography 
prior to original CRT implant. Each patient’s heart failure aetiology was confirmed on 









Parameter       Mean (SD) or Numbers 
Patients                                                                      12 
Age (years)                                                                        63 (7) 
Male (%)                                                       100 
LVEF (%)                                                           27 (8) 
NYHA Class (II/III)      2/12 
Ischaemic/non-ischaemic (%)                                    75/25 
Sinus rhythm/Atrial fibrillation                        11/1 
QRS duration pre-CRT (ms)                                                   136(25) 
QRS morphology (LBBB/non-specific       10/2 
IVCD)                                          
Table 12. Multi-Site Pacing Patient Characteristics 
IVCD =intraventricular conduction delay; LBBB=left bundle branch block; 




The implanted CRT-D system was uploaded with investigational software enabling 
multi-site LV pacing for the duration of the study. Patients were lightly sedated using 
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diazemuls (5-10mg). Bilateral femoral venous access was used to place a 5F Supreme 
quadripolar electrophysiological catheter (St Jude Medical, Sylmar, CA, USA) to the 
high right atrium and an SL3 Fast-Cath Introducer (St Jude Medical, Sylmar, CA, USA) 
was used to cannulate the coronary sinus. A QuickFlex Micro 1258T/92 LV pacing lead 
(St Jude Medical, Sylmar, CA, USA) was then placed in a CS vein tributary as far 
separated from the chronically implanted Quartet lead as possible. 
 
An NCM array was passed via 10F femoral arterial access retrogradely across the aortic 
valve to the LV cavity. A 0.014 inch diameter high fidelity Certus PressureWire and 
PhysioMon software (RADI Medical Systems, Uppsala, Sweden) with a 500Hz 
frequency response and 50Hz filter bandwidth were used to assess real-time mean peak 
LVdP/dtmax as a marker of LV contractility. The pressure wire was placed retrogradely 
to the LV cavity via the NCM array. Via the other femoral artery, a steerable 6F 
Livewire decapolar catheter (St Jude Medical, Sylmar, CA, USA) was passed 
retrogradely to the LV cavity to perform endocardial pacing from different sites within 
the LV (figure 49). The NCM array uses the inverse solution method to reconstruct 
endocardial potentials within the LV cavity (76) and the chamber geometry was 
reconstructed using a locator signal from the LV decapolar catheter. Intravenous heparin 
(70u/kg) was administered to achieve systemic anticoagulation (target activated clotting 




Figure 49. Fluoroscopic Image of Multi-Site Pacing Study Catheter Set-up 
Fluoroscopic image showing the Quartet LV lead in a postero-lateral branch of the 
coronary sinus (CS), a second temporary epicardial lead in an anterior branch of the 
CS, an LV endocardial roving catheter, an ESI array balloon in the LV cavity and an 
RV lead at the RV apex. 
 
LVdP/dtmax whilst pacing 5-10 beats above intrinsic rate (to eliminate the effect of heart 
rate variation) was recorded for a period of at least 20 s to ensure steady-state conditions 
during any pacing modality.  LV dP/dtmax during atrial pacing (AAI) or RV pacing (AF 
patient) at 5-10 beats above intrinsic rate was considered baseline and was kept constant 
when testing different pacing modes. A waiting period of at least 20 s was respected 
after any change in pacing settings or lead position to achieve haemodynamic 
stabilisation. These methods have previously been shown to reliably measure LV 
dP/dtmax (61, 62, 101, 102, 135). Results at each pacing site were expressed as a 
percentage change from baseline. In order to minimize the effect of baseline drift in 
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AHR (secondary to changes in patient intra-vascular volume/sedation levels etc) the 
baseline was reassessed prior to and after every change in pacing modality and 
comparisons were made to a mean of these two readings.  Data from premature 
ventricular complexes were discarded.  
 
Two 3-channel Merlin Pacing Systems Analysers (PSA’s) (St Jude Medical, Sylmar, 
CA, USA) were used in order to synchronize the AV and VV delays from the implanted 
CRT device with the additional LV CS epicardial and endocardial leads. The temporary 
RA quadripolar lead was required in order to ensure reliable sensing and thus allow 
simultaneous multi-site pacing when LV endocardial pacing or LV epicardial pacing 
using the 2
nd
 CS lead in addition to pacing from the chronically implanted CRT device. 
An iterative approach to optimising the AV delays  led us to conclude that a paced AV 
delay of 80ms was required to achieve near simultaneous LV capture using the 
endocardial LV lead or 2
nd
 CS LV lead when the Quartet CRT system AV paced delay 
was set at 100ms. 
 
In order to achieve the greatest vector separation distance when multi-site pacing using 
the Quartet lead, vectors D1-RV Coil and P4-RV Coil were the first choice pacing 
vector pair for multi-site pacing using the Quartet lead. M2-RV coil was used if D1-RV 
Coil was unusable as vector 1 (V1) and M3-RV coil was used if P4-RV coil was not 
usable as vector 2 (V2) because of a high capture thresholds or PNS (in 1 patient M2-
RV Coil was used as V2 as neither M3-RV Coil or P4 to RV coil were usable). The 
minimum programmable VV delay of 5ms was used between the 2 vectors used and 
also between V2 and RV stimulation: V1 – (5 ms delay) – V2 – (5 ms delay) – RV. A 
pacing protocol was performed in the following order: (Rate 5-10bpm above intrinsic 
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rate, paced and sensed AV delay 100ms): RV only, 1 Quartet vector only (V1), RV + 
V1 (RV + V1), RV + 2 Quartet Vectors i.e. V1 + V2 (RV +V1 +V2), 2
nd
 CS lead only 
(EPI), RV + 2
nd
 CS lead (RV + EPI), LV endocardial pacing only (LVEN), RV + 
LVEN, RV + LVEN + V1, RV + LVEN + V1 + V2, RV + LVEN + V1 + EPI, RV + V1 
+ V2 + EPI, RV + LVEN + V1 + V2 + EPI, RV + D1-M2 (conventional biventricular 
CRT pacing). LVEN and RV + LVEN were repeated with the LV rove catheter in 
different positions. MSP from the Quartet was also repeated using a reversal of the 
vector sequence to V2-V1-RV and also with the VV delays from V1-V2-RV increased 
to 40ms. 
 
Capture was verified with each pacing modality by looking for a change in QRS 
morphology at a paper speed of 200mm/s. This was also validated with reference to LV 
pacing by analysis of the activation wavefront on non-contact mapping. In all modes 
involving LV endocardial pacing the LV rove catheter was placed in a random order in 
as many different endocardial positions as possible. 
 
Derivation of LV and Trans-Septal Activation Times 
 
Virtual unipolar electrograms recorded at 1200Hz (temporal resolution of 0.83ms) from 
the endocardial surface were used to measure activation times (figure 50). The high 
pass filter was set at 8Hz. The onset of LV activation was defined as the first peak 
negative dV/dt at any point in the LV. The end of LV activation was defined as the time 
of the latest peak negative unipolar electrogram on the virtual endocardial surface. The 
trans-septal activation time was defined as the time from QRS onset to peak negative 





Figure 50. Non-Contact Mapping Unipolar Electrograms 
64 Unipolar Virtual Electrograms Recorded Whilst ‘QuinV’ Pacing (pink shading 
indicates excluded signal) 
 
Definition of Regions of Slow Conduction 
 
Dynamic substrate mapping (DSM) was performed after completion of the procedure to 
define areas of consistently low peak negative voltage, using a method validated 
previously (136). Zones of slow conduction were delineated as regions which the 
activation wavefront failed to enter, with the endocardial voltage amplitude threshold 





Figure 51. Dynamic Substrate Map 




Statistical analysis was performed on PASW Statistics 20 (SPSS Inc, Chicago, IL, 
USA). Data were analysed using generalised estimating equations using an 
exchangeable correlation structure, to explore the extent of differences between pacing 
methods. All pacing methods were compared to each other and to avoid type 1 errors, p 
values were corrected using the Bonferroni adjustment. To perform a Bonferroni 
correction for each p value, the p value was divided by the number of comparisons 
made. Pearson’s correlation coefficient was used to measure the linear relationship 










An invasive haemodynamic protocol was completed in all 12 patients. In three patients 
it was not possible to collect electro-anatomic data because of recurrent ventricular 
tachycardia when placing the EnSite array in the LV cavity in one patient (it was also 
not possible to place the LV endocardial roving catheter in this patient). In another 
patient it was not possible to get satisfactory arterial access for the EnSite balloon to 
pass (but a full multi-site pacing study was still performed without electro-anatomical 
mapping data). In the third patient it was not possible to perform an electronanatomical 
mapping study because of failure of the EnSite mapping system (again, a full multi-site 
pacing protocol was followed but without electro-anatomical mapping data). There were 




The best overall mean AHR (figure 52 and table 13) was found using LVEN pacing 
(25.6% increase in LVdP/dtmax at best endocardial site over baseline). This was 
significantly (p<0.05) better than all other non-endocardial pacing modalities. 
Conventional Biventricular pacing (D1-M2) led to a 13.1% increase in AHR and this 
was similar to the various combinations of MSP using 2 vectors of the Quartet, the 2
nd
 
epicardial CS lead, the LV endocardial lead and the RV lead. No significant differences 
were found in AHR between the various different methods of MSP although all were 




Figure 52. AHR Achieved Using Different Pacing Modalities 
AHR as % change in LVdP/dtmax over baseline (AAI pacing) on y-axis 
V1 = Quartet Vector 1; V2 = Quartet Vector 2; BiV = RV and LV Pacing; BiV (D1-
M2) = Conventional CRT using Quartet; EPI = 2
nd
 CS lead; LVEN = LV endocardial 
pacing only; BIVEN = LVEN + RV; TriV = Multi-Site Stimulation(MSP) from 3 
Ventricular Sites; QuadV = MSP from 4 Ventricular Sites; QuinV = MSP from 5 























AHR (% change 
over baseline) 
Intrinsic 120 ± 22 183 ± 35 42 ± 23 -8 ± 6 
RV 113 ± 33 227 ± 16 84 ± 15 1.2 ± 4.1 
V1 140 ± 54 216 ± 48 73 ± 49 8.9 ± 12.9 
RV + V1 139 ± 72 192 ± 29 48 ± 48 13.1 ± 13.9 
RV +V1 +V2 187 ± 30 200 ± 29 7 ± 9 14.7 ± 11 
EPI 151 ± 50 232 ± 9 63 ± 44 10.8 ± 15.9 
RV + EPI 114 ± 22 208 ± 23 87 ± 9 9.6 ± 13.5 
RV + EPI + V1 160 ± 7 183 ± 35 24 ± 43 15.9 ± 11.4 
Best LVEN 132 ± 44 165 ± 20 34 ± 32 25.6 ± 14.3 
RV + LVEN 163 ± 40 180 ± 28 15 ± 22 21.6 ± 13.1 
RV + LVEN + 
V1 
145 ± 26 168 ± 12 17 ± 18 14.2 ± 15.8 
RV + LVEN + 
V1 + EPI 
153 ± 36 176 ± 25 16 ± 16 15.8 ± 16.7 
RV + LVEN + 
V1 + V2 
150 ± 28 168 ± 15 15 ± 18 11.9 ± 17.1 
RV + EPI + V1 
+ V2 
141 ± 46 190 ± 19 47 ± 51 13.9 ± 13.4 
RV + LVEN + 
EPI + V1 + V2 
143 ± 21 167 ± 23 16 ± 14 15.7 ± 15.4 
BiV (RV + D1-
M2) 
93 ± 31 170 ± 3 73 ± 33 15.0 ± 16.0 
 
Table 13. Summary of Activation Times and AHR 
174 
 
Left ventricular activation Time (LVAT); QRS duration (QRSd). Trans-septal 
activation time and acute haemodynamic response (AHR) for each of the pacing 
modes: RV =right ventricle; V1= Vector 1 (D1-RV Coil or M2-RV Coil), V2=Vector 2 
(P4-RV Coil or M3-RV Coil); EPI=2
nd
 Epicardial LV Lead; LVEN=LV endocardial 
lead; D1-M2 = conventional bipolar biventricular pacing 
 
Within individuals, however, the best pacing modality varied greatly (table 14).  
Endocardial (LVEN or BIVEN) pacing was best in 3/12 (25%) patients, MSP using two 
vectors from the Quartet lead was best in 3/12 of patients, conventional biventricular 
pacing was best in 2/12 patients, LV epicardial pacing (using the second epicardial lead) 
was best in one patient (in this patient the chronically implanted Quartet lead was in a 
distal anterior branch and the EPI lead was placed in a proximal anterior branch as no 
other CS tributaries were possible) and in one patient a combination of two epicardial 
leads was best (TRIV – LV1 + EPI + RV). In two patients a form of ‘Quad-V’ pacing 
was best: (V1+ EPI + LVEN + RV) in one and (V1 + V2 + EPI + RV) in the other. 
Although ‘Quin-V’ pacing (V1 + V2 + EPI + LVEN + RV) gave a good overall mean 
AHR (15.8 ± 16.7), Quin-V pacing did not give the best AHR in any individual patients. 
 
All four of the patients in whom a form of endocardial pacing was best (including 
patient 8 in whom ‘Quad-V was best) had an ischaemic aetiology to their 
cardiomyopathy. Of the two patients without ischaemic heart disease, in one MSP using 
the Quartet lead was best and in the other conventional biventricular pacing using D1-



















Anterior Quad V (V1 
+V2 + EPI) 
I 
(N/A) 




Anterior BiV (D1-M2) N 
(Type II) 




Anterior TriV (V1+V2) I 
(Type II) 












Anterior TriV (V1+V2) N 
(indeterminate) 





























Anterior LVEN I 
(Type II) 




Anterior BiV (D1-M2) I 
(II) 














Table 14. Lead Positions, Vectors Used and Aeitology of Cardiomyopathy 
I = Ischaemic Aetiology; N = Non-Ischaemic Aetiology; I = Type I Activation 
Pattern; II = Type II Activation Pattern; N/A = Activation Data Unavailable 
 
Activation Patterns and Times 
 
A reduction in QRSd was seen only with forms of endocardial pacing and this was 
significant when compared to RV only and EPI only pacing (p<0.01) but not with other 
pacing modalities.  There was no significant difference in LVAT between any of the 
different pacing modes. A weak negative correlation was seen between AHR and QRSd 
(R
2
=0.22, p<0.01) and AHR and trans-septal time ((R
2
=0.22, p<0.01). There was no 
significant relationship between LVAT and AHR. 
 
The intrinsic LV activation pattern seen (71, 77) in the 9 patients in whom non-contact 
mapping was possible was Type I in two patients (both ischaemic aetiology) and Type 





Figure 53. Intrinsic Activation in a Patient with a Type II Activation Pattern. 
Red arrow on left hand side series of 4 images indicates U-shaped pattern of 
activation rotating around apex. Panel of 64 images on the right shows corresponding 
unipolar electrograms for intrinsic activation derived from NCM.  RAO: Right 
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Endocardial pacing appears to give a superior overall mean AHR compared to other 
pacing modalities. This is consistent with previously published work from our 
institution (71, 72) and others (137). This may relate to activation being more 
physiological and thus resulting in better electrical and mechanical propagation 
compared to conventional epicardial pacing via the CS (70). Indeed, only LV only 
(LVEN) and BiV Endocardial (BIVEN) pacing lead to a significant reduction in QRSd 
compared to other pacing modalities. The negative correlation between QRSd and AHR 
seen in this study, however, was weak. Again this is consistent with previous work 
suggesting that the mechanism of acute haemodynamic benefit may be more effective 
mechanical recruitment of the LV myocardium rather than shortening of the LV 
electrical activation time (71).  
 
Multi-site pacing the heart from 3, 4 or 5 sites simultaneously does not appear to confer 
a significant overall AHR advantage compared to conventional DDDBiV pacing from 
an optimal LV CS site. Within individuals, however, the best pacing modality varies 
and although a form of MSP was best in 50% of patients, the method of MSP varied 
with four different methods of MSP being best for individuals. Interestingly, MSP using 
the Quartet Lead was best in half of this sub-group (3/6 patients) and in a further 
patient, MSP using the extra CS lead (EPI) in addition to the MSP function of the 




The only patient in whom the 2
nd
 CS lead (EPI) gave the best AHR was one in whom 
the original chronically implanted Quartet lead had been placed in a distal anterior 
branch of the CS. Given that this patient had no other CS target vessels, the EPI lead 
was placed in a proximal position in the same anterior CS tributary as the Quartet. This 
raises the possibility that an improved AHR may be achieved in this patient simply by 
pacing using the chronically implanted Quartet lead from a more proximal pole (e.g. P4-
RV Coil alone). Gold et al (108) have shown, however, that there is not a large intra-
vein variability in AHR and this was confirmed by our own study of intra-vein 
variability using different pacing vectors of the Quartet (135) which suggested that if a 
poor AHR was seen with one Quartet vector, it was unlikely that large increase in AHR 
would be seen without physically repositioning the lead. 
Our data with regard to LV endocardial pacing giving an excellent overall AHR 
disguises the fact that LV endocardial pacing did not give an excellent AHR in all LV 
positions. The mean LVEN AHR was 16.5% better than baseline. Whilst this is very 
good it was not significantly better than conventional BiV CRT or the MSP 
configurations assessed in this study. This again emphasises the findings of Derval (51) 
et al who found that there is not one pacing site (or combination of pacing sites) that is 
best for all patients and the choice of pacing modality needs to be tailored to the 
individual. 
 
Implanting a permanent endocardial pacing lead is not as straight-forward as implanting 
a conventional CRT device. It will probably require a trans-septal puncture, life-long 
anti-coagulation and may interfere with the mitral valve apparatus. MSP using two CS 
leads is more straight-forward but implantation is still more technically challenging than 
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standard CRT. In any case, MSP using 2 CS leads in this study gave the best AHR in 
only one patient. It is thus promising that MSP using just one (commercially available) 
CS lead gave a good overall AHR and the best possible AHR in 25% of our cohort. If 
an improved AHR can be achieved simply by switching on the MSP function of an LV 
lead with no further invasive procedures required this is an exciting option. While it 
may not make a difference in most patients, in a significant minority of patients it may 
make a ‘non-responder’ respond. 
 
Although previous studies have compared dual site epicardial pacing to conventional 
CRT or simultaneous epicardial and endocardial pacing to single LV site pacing, this is 
the first study to allow comparison of both MSP modalities. It is also the first study to 
present invasive AHR data using the MSP function of the Quartet lead and thus allow 
comparison of this type of MSP with dual epicardial or epi/endocardial MSP. Not only 
this, we extended the MSP protocols such that we assessed the AHR from four and five 
ventricular sites simultaneously. Although ‘Quin-V’ pacing did not give the best AHR 
in any patients, two different forms of ‘Quad-V’ pacing were best in individuals and 
thus increasing the number of ventricular pacing sites from the three tested in other 




This study is limited by its small sample size. Given the highly invasive and time-
consuming nature of the study, however, this is unavoidable. The order of the pacing 
vector sequence was not altered randomly and thus we cannot rule out sustained effects 
from earlier pacing sequences. Ideally a range of AV delays and more VV delays would 
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have been assessed but this was not possible because of time constraints. Indeed the 
number of possible LV-LV-RV or RV-LV-LV vector combinations and delays mean 
that an empiric approach to MSP programming may need to be taken or a computer 






























Chapter 9. Discussion 
 
The prevalence of heart failure is high and the population rising as treatments improve 
and life expectancy increases. There are a large number of RCTs supporting the use of 
medication in heart failure and device therapy for patients on optimal therapy who fulfil 
specific criteria. Even in those patients implanted with CRT devices who fulfil guideline 
criteria, however, a significant proportion do not gain symptomatic benefit and an even 
larger proportion do not appear to undergo significant LV reverse remodelling. 
 
A proportion of patients eligible for CRT may not get the chance to ‘respond’ to therapy 
because of implant failure and the reasons for this include failure to get into the CS 
ostium, an inability to pass the LV lead into a CS branch, unsatisfactory pacing 
parameters and phrenic nerve stimulation (PNS). In my introduction I suggest that 
methods of improving CRT success might include i) Developing better methods of 
identifying patients who will respond to CRT; ii) Reducing CRT implant failure; iii) 
Selecting and pacing the regions of the LV most likely to improve electrical and 
mechanical dyssynchrony; iv) Optimising device settings; v) Pacing the heart in novel 
ways. 
 
My thesis specifically then describes the use of quadripolar lead technology (Chapters 4 
and 5) and image guidance to overcome CRT implant failure, the use of CMR 
dyssynchrony and scar data to improve electrical and mechanical dyssynchrony 
(Chapter 6) and multi-site and endocardial pacing (Chapters 7 and 8) as novel ways of 
pacing the heart to improve AHR. My introduction also explains why CRT device 
optimisation probably does not make a difference to outcome overall in the HF 
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population but may be of benefit in certain individuals. Chapters 5 and 6 suggest that 




I have shown (in Chapter 4) that the Quartet quadripolar lead is associated with a high 
implant success rate and a low level of complications at 6 month follow-up. I have 
shown that the Quartet lead offers more pacing vectors than conventional LV pacing 
leads and thus makes it more likely that common pacing obstacles can be overcome by 
‘electronic repositioning’ and thus without the risk of dislodgement from the CS 
involved with physical repositioning. Successful CRT may be therefore be achieved in 
cases where a conventional lead would fail because of PNS or high capture thresholds. 
The availability of different pacing vectors may obviate the need for a lead revision, a 
surgical approach to LV lead placement, or CRT to be turned off in patients who 
encounter pacing problems after implantation. The benefit of having four LV lead 
electrodes rather than the usual two that has been demonstrated by the work in this 
thesis and publications from other centres, means that quadripolar leads from multiple 
device manufacturers are likely to be available in the near future and may become an 
industry standard. 
 
Although I have shown that the cathodal programmability available on a quadripolar 
lead can be used to overcome problems with PNS and high capture thresholds, my study 
of acute haemodynamic response to pacing within a vein (Chapter 5) showed that the 
multiple vectors available do not appear to allow optimal AHR for and individual to be 
achieved if the lead is not placed in the most suitable CS vein. Thus although a 
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quadripolar lead may allow placement in a distal (and more stable) CS vein position, 
there does not appear to be a large variation in the AHR that can be achieved by pacing 
using the more proximal LV lead electrodes within a CS branch and thus a poor 
response elicited using a conventional bipolar configuration probably cannot be 
overcome by a change in pacing vector. 
 
My study of AHR within a CS vein also showed that the best CS vein is not necessarily 
a lateral or postero-lateral branch, as the best AHR seen in this study was in an anterior 
or posterior vein in one third of patients. Although a significant difference in AHR was 
seen between anterior and posterior positions, no difference was seen between lateral 
and anterior positions or lateral and posterior positions. This suggests that within 
individual patients large variations in AHR exist and the best and worst veins are 
different in different subjects. Indeed, when CS positions are divided by whether they 
give rise to ≥10% increase in dP/dtmax (‘acute responder’) or not, it can be seen that in 
half of all patients, whether they are likely to respond or not to CRT is critically 
dependent on whether the right CS vein is chosen. In the other half of patients, however, 
it would appear that no matter which vein is chosen the same outcome will be achieved 
whether this be ‘response’ or ‘non-response’. 
 
Chapter 7 gave a detailed analysis of computer modelling in a single patient. This 
chapter brought together three themes of my thesis: quadripolar lead technology, multi-
site pacing and computer modelling to predict response to CRT. The study managed to 
non-invasively assess what would happen if a patient was conventionally or multi-site 
paced using a quadripolar lead. Given the multiple different pacing configurations 
available and the multiple different delays allowed between pacing vectors, this study 
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would not be possible in vivo. Interestingly the predictions made are consistent with 
previous studies at our own and other centres. In patients without scar, MSP probably 
does not confer additional haemodynamic benefit. In patients with increasing amount of 
scar, however, MSP does appear to improve dP/dtmax compared to standard CRT. The 
benefit seen does not appear to result in a reduced QRS duration, however, and this is 
consistent with the in vivo study of multi-site pacing described in Chapter 8. 
 
CMR-Guided CRT (PRISM pilot study) 
 
I have shown that CMR can be used to guide LV lead placement and compared the 
results acutely to an optimal haemodynamic standard and angiographic approach and 
chronically with reverse remodelling. I have shown that we were able to accurately 
acquire and process CMR derived CS anatomy, scar and dyssynchrony data (derived 
from a single CMR scan) and fuse this with live fluoroscopy during CRT implant.  We 
were able to pace in at least one CMR target segment in the majority of patients and this 
gave rise to an AHR comparable to the best possible in any segment. I have shown that 
a marked difference in AHR is seen dependent on the LV pacing site chosen and this 
may explain sub-optimal CRT response if a purely anatomical approach is used. The 
results of my PRISM pilot study suggest that if a target segment is successfully paced, it 
is unlikely that any other segment will give rise to a significantly better acute response.  
 
More importantly, our chronic results show an improved reverse remodelling rate of 
92% in patients that successfully had the LV lead positioned in a CMR target segment 
compared to just 50% in those patients in whom a CMR target could not be paced.  Our 
technique of using CMR guidance may therefore allow an implanter to individualise 
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their approach to the patient and guide them to the optimal target segment. Whether this 
will lead to an improved chronic outcome against a standard approach is as yet 
unproven and requires a randomized study of CMR guided CRT. I have submitted the 
proposal for this RCT and the study (PRISM RCT) has been approved by our local 
research ethics committee. The power calculations suggest that 270 patients will need to 
be recruited to this study in order to show a significant difference in reverse remodelling 
rates (≥ 15% reduction in ESV) between an image-guided and conventionally implanted 
CRT group. This study will thus require multi-centre participation and will likely take a 
further 2 years to complete. 
 
Multi-Site and Endocardial Pacing 
 
My Multi-Site Pacing and Electro-Anatomic Mapping Study confirmed that endocardial 
pacing appears to give a superior overall mean AHR compared to other pacing 
modalities. This is consistent with previously published work and may relate to 
activation being more physiological and thus resulting in better electrical and 
mechanical propagation compared to conventional epicardial pacing via the CS. Also 
consistent with previous work, I have shown that only endocardial pacing leads to a 
significant reduction in QRSd compared to other pacing modalities but that the 
correlation between QRSd and LVAT reduction and improvements in AHR are not 
strong. This may be because more effective mechanical recruitment of the LV 
myocardium rather than shortening of the LV electrical activation time is the main 




I have shown that MSP from three, four or five sites simultaneously does not appear to 
confer a significant overall mean AHR advantage compared to conventional CRT but 
within individuals, the best pacing modality varies. Indeed four different forms of MSP 
were best in 50% of patients and MSP using the Quartet Lead was best in half of this 
sub-group (3/6 patients). The fact that so many different methods of pacing were best in 
different patients again emphasises the findings of Derval (51) et al who found that 
there is not one pacing site (or combination of pacing sites) that is best for all patients 
and the choice of pacing modality needs to be tailored to the individual. 
 
Out study was necessarily very invasive with significant associated risks. It is thus 
promising that MSP using a single commercially available LV lead gave a good overall 
AHR and the best possible AHR in 25% of our cohort. If an improved AHR can be 
achieved simply by switching on the MSP function of an LV lead with no further 
invasive procedures required, this is an exciting option. While it may not make a 











Chapter 10. Conclusions 
 
In this thesis I have shown that quadripolar lead technology can improve implant 
success rates and reduce the need for re-intervention at follow-up. I have also shown 
that the electronic repositioning technology available with this lead probably will not 
improve the haemodynamic response of patients who do not improve with CRT. 
 
I have shown that a CMR dyssynchrony and scar-guided approach to CRT implant is 
feasible and may lead to an improved acute and chronic outcome. This approach is 
currently very labour intensive, however, and a large randomised controlled trial is due 
to start imminently to determine whether a CMR-guided approach to CRT improves 
outcome. Developments in image processing technology mean that analysis times have 
been significantly reduced since I started my image-guided CRT project and semi-
automated tools mean that the need for manual segmentation and analysis may soon 
become redundant. 
 
My multi-site pacing study has confirmed that all patients are different and we cannot a 
priori decide the best pacing modality for a patient. The fact that so many different 
pacing modalities were best in different patients in our small cohort of patients 
emphasizes the need for an individualised approach to implanting CRT especially in 
those patients least likely to respond (e.g. ischaemic patients with large scar burden, 
Type I activation pattern, narrow QRS etc). The fact that multi-site pacing using a 
commercially available lead gave the best acute haemodynamic response in a quarter of 
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our study patients is promising as all other methods of MSP tested would require a 
further invasive procedure. 
 
The multiple different configurations and AV and VV delays possible when MSP is 
performed suggest that we need better non-invasive ways of predicting response to 
therapy. I have shown an example in Chapter 7 of biophysical modelling in a single 
patient. The results of this in silico study have yet to be validated in vivo but projects 
such as ‘Grand Challenge’ hopefully will lead to computer modelling programs that can 
reliably predict the outcome of various forms of pacing using simple, non-invasively 
acquired (CMR/echo) data. We may thus be able to save some patients from having 
CRT implants that will not improve their symptoms or outcome and in others we may 
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We would appreciate your giving consideration to our invitation to participate in 
the clinical research and evaluation of a new technology which has been 
developed with the intention of improving and streamlining the implantation of 
cardiac devices. This is a Cardiac Resynchronisation Therapy (CRT) 
pacemaker, an advanced type of pacemaker that is used to treat patients with 
your symptoms. Your clinician has already recommended that this treatment 
may be suitable for you as part of your routine care. This device can also come 
with a function to assist with the treatment of potentially dangerous heart rhythm 
disturbances, and this defibrillator function may also be suitable for you; this is 
called a CRT-D device. The type of device you have will be decided by you and 
your clinician. Either way, you are eligible to take part in this study. 
 
Before you decide, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you 
wish. Please ask us if there is anything that is not clear or if you would like more 
information. Please take time to decide whether or not you wish to take part in 




Thank you in advance for reading this and giving consideration to our invitation 
to participate in this study. 
 
 
What is the purpose of this study?  
We have known for some time that some people who have heart failure benefit 
from having a special pacemaker implanted which will make the pumping 
chambers of the heart beat more efficiently. This is called Cardiac 
Resynchronisation Therapy or CRT. This therapy restores the timely 
contractions of the upper (the right atrium) and lower chambers of the heart (the 
right ventricle and the left ventricle) by detecting the heart's natural electrical 
activity and by pacing the chambers in a coordinated way. These pacemaker 
leads are connected to an implantable device which functions as a pacemaker 
(and in many patients works as a defibrillator as well). 
 
To make the heart pump as efficiently as possible it is necessary to place the 
pacing leads in good positions. Of particular importance is the pacemaker lead 
to the left side of the heart. This is responsible for re-coordinating the heart’s 
contraction. However this is technically the most challenging part of the 
procedure to put in the CRT device. 
 
The purpose of this study is to see whether a new technology can be used to 
facilitate the placement of the lead to the left side of the heart. Usually when the 
procedure is being done to put in a pacemaker like this, it is performed using X-
Ray as the method of guiding the doctor where to place the pacemaker leads. 
We are looking at the potential to use information derived from an MRI scan of 
the heart in addition to the X-Ray information. This can tell us about the veins 
around the heart where the left-sided lead needs to be placed, as well as about 
areas of scarring (if you have had a heart attack in the past). If you choose to be 
involved in the study, we would carry out your procedure (to put in the 
pacemaker) using this information from the MRI scan. This would be in addition 
to information from X-ray (which is how the procedure is normally done). The 
information from the MRI scan is superimposed on the X-ray screen that we 
normally used during the procedure.  
 
So, taking part in the study will not affect the type of pacemaker you have. It will 
affect the way in which the procedure is performed. If you choose to take part in 
the study, we will do an additional MRI scan beforehand, and use this 
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information to guide the procedure (along with X-ray, which is the standard 
approach). 
We will also discuss with patients taking part in the study the option of using a 
pressure recording wire (discussed below) to evaluate the changes in pumping 
function of the heart as a result of the pacemaker. 
 
Why have I been chosen?  
Your doctor has determined that you are a candidate for Cardiac 
Resynchronisation Therapy (CRT) or Cardiac Resynchronisation Therapy with a 
Defibrillator (CRT-D). These therapies are designed to treat and lessen the 
symptoms related to your heart failure. Cardiac Resynchronisation is a therapy 
that stimulates both the right and left side of the heart to improve the heart's 
ability to pump. Defibrillation delivers electrical pulses or shocks (defibrillate) if 
dangerous rhythms are detected.  
 
Do I have to take part?  
Your participation in the study is completely voluntary. You will not be paid for taking 
part.  If you decide to take part, you will be given this information sheet to keep and be 
asked to sign a consent form, you will also be given a copy of the signed consent form 
to keep.  If you decide to take part, you are still free to withdraw at any time and 
without giving a reason. A decision to withdraw at any time, or a decision not to take 
part, will not affect the standard of care you receive, will involve no penalty or loss of 
benefits, will not affect your relationship to your doctor and will not be detrimental to 
your treatment. 
 
What will happen to me if I take part?  
If you choose to take part you will have many of the same baseline tests as in 
routine care, such as an ECG, blood tests and an ultrasound scan of your heart. 
In addition, we would perform one or two MRI scans of your heart on separate 
dates before your pacemaker procedure, depending on whether you have 
already had one scan done as one of the routine tests before having a CRT or 
CRT-D device. If so then you will only need one additional scan, otherwise you 
will need two scans. Each scan takes approximately one hour and is performed 
on a separate visit as an out-patient (i.e. you do not need to be admitted to 
hospital for it). 
 
The first scan is to look for any evidence of scarring in the heart which may 
arise from previous heart attacks or may be due to other causes. 
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The second scan will try to evaluate the anatomy and distribution of the veins 
on the surface of the heart, which is where the left-sided pacemaker lead is 
placed. This needs to be done on a separate scan as a different contrast agent 
is used to outline the cardiac veins. 
 
During the implantation of the pacing leads the information from the MRI scans 
will be used to superimpose the location of the veins in the heart onto the 
monitor which the cardiologist uses to position the pacemaker leads. 
If there is scarring in the heart muscle from previous heart attacks, information 
about the area affected will also be available to the cardiologist from the MRI 
scan. We generally 
need to avoid areas of scarring when positioning the pacemaker leads as this 
may make the treatment work less effectively. 
 
The technology required to superimpose this information has been developed 
over the last 5 years in King’s College London and is not available or widely 
used in clinical practice. However the equipment used to perform the procedure 
is the same as that which is used routinely and you would have the same 
device whether or not you decide to take part. Dr Rinaldi, a consultant 
cardiologist, would be performing your procedure. 
 
In some patients we also plan to record the pressure within the heart by passing 
a fine calibre pressure recording wire up to the heart via the artery at the top of 
the leg. This is done in a similar way to a coronary angiogram, but the tube in 
the artery at the top of the leg is a bit smaller. The wire is passed into the left 
ventricle (the main pumping chamber) and the information it provides tells us 
about the blood pressure response to stimulating the heart with the pacemaker. 
Putting this wire in will add about 20 minutes to the procedure. 
 
After the pacemaker / defibrillator has been implanted, you will need to have 
routine checkups, just as you would have if you had not been in the study.  
 
What are the alternatives for treatment?  
The alternative to taking part in this study is to have the procedure performed in 




What are the side effects of any treatment received when taking part?  
The main additional component if you decide to take part is the additional 1 or 2 
MRI scans. This does not involve ionising radiation (such as X-rays or CT 
scans). Each scan takes about an hour and involves the administration of a 
contrast agent. The risk of side effects with this is very low. The contrast agent 
should not be given to people with poor kidney function as this may be harmful. 
We would therefore check your kidney function is OK by doing a blood test, 
unless a recent result is already available.  
There will be no changes to the way your device works or to your treatment as a 
result of your participation in the study.  
 
What are the possible disadvantages and risks of taking part?  
The other aspects of MRI scanning are that you may not be able to tolerate this 
if you are claustrophobic (as the scanner itself is relatively narrow and 
enclosed) and if you have any metal in your body then we need to check the 
details of this, as it can be dangerous especially if the metal is in your eyes or 
brain. As the scan needs to be performed on a separate day from your 
pacemaker procedure, this may involve a separate trip to the hospital, although 
we can offer you a variety of times and days for this to be performed. 
It is possible that with the MRI scan we are not able to obtain images of 
sufficient quality to help with the pacemaker procedure. In this eventuality we 
would perform the procedure in a routine manner. 
At the time of the procedure, the pressure wire passed to the heart poses a 
small risk of bleeding or bruising at the top of the leg, and an extremely small 
risk (less than 1 in 1000) of causing a stroke. In order to stop this from 
happening, we would give a small dose of a blood thinning drug (heparin) at the 
time of the procedure. If you would like to take part in the study but do not want 
to have this part of it, then please indicate that when you come to fill in the 
consent form, and we can still do the procedure without the pressure recording 
wire. 
 
What are the possible benefits of taking part?  
You may benefit from participating in this study because we will have additional 
information about the heart and the layout of the veins for the purpose of 
positioning the left sided pacemaker lead. The intention is that this new 
technology will allow us to see better information on the screen during the 
pacemaker implant procedure, thus enabling the procedure to be done more 
quickly and more accurately. These benefits have not been proven; this is one 
of the reasons that we are carrying out the research. 
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The information we get from this study may therefore help us with the treatment 
of other patients in the future.  
 
 
What happens when the research study stops?  
After the research stops your care will continue as usual. This means that your 
pacemaker/defibrillator device will be programmed in the usual way and you will 
be asked to come regularly to the hospital to have it checked.  
 
What happens if there is a problem?  
We are very keen to ensure that all participants in this study receive treatment 
and care to our usual very high standards. However, if there are complaints or 
you do suffer some harm these will be addressed properly in the normal way. 
Detailed information on this is given in Part 2.  
 
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will 





If the information in Part 1 has interested you and you are considering 
participation please read the additional information in Part 2 before 








What if relevant new information becomes available?  
Sometimes during the course of a research project, new information becomes 
available. If this happens, your doctor will tell you about it and discuss with you 
whether you want to continue the study. If you decide to continue in the study 
you will be asked to sign an updated consent form. If you decide to withdraw, 
your doctor will make arrangements for your care to continue.  
If the study is stopped for any other reason, we will tell you and arrange your 
continuing care.  
 
  
What will happen if I don't want to carry on with the study?  
If you withdraw from the study we will need to use the data collected up to your 
withdrawal and your care will continue as usual.  
 
  
What will happen if I become pregnant during the study?  
Candidates who are pregnant or plan to become pregnant in the next six (6) 
months may not be enrolled in this study. If you become pregnant after 
enrolment but before treatment you must immediately advise us and you will be 
removed from the study. However, if you become pregnant after treatment your 
care will continue as it would have done when having the treatment with or 
without the new procedure involving MRI. 
 
  
What if there is a problem?  
If you are harmed by taking part in this study, you should contact your doctor for 
further information. If you have any complaints about the way your doctor has 
carried out the study, you may contact the Patient Advice and Liaison Service 
(PALS) at your hospital. The PALS service will also be able to advise you 
regarding the standard NHS complaints procedure should you feel that there 




Will my taking part in the study be kept confidential?  
Any personal information obtained about you during the course of this study will 
remain confidential. Information from this study will be submitted to the sponsor 
and your NHS Trust. During the course of the study the responsible authority, 
sponsor or review board may inspect and copy your records. Identifying 
information, such as your name, will be removed from copied records when not 
absolutely necessary. In recording the results of the study, you will be referred 
to by an alphanumeric code number. In participating in the study, you authorise 
the sponsoring company to use the information obtained during the study for 
scientific communications and publications. Should the data collected from this 
study be published, your identity will not be revealed and your name will not be 
disclosed outside the hospital at any time. If you agree, your GP will be 
informed of your participation in this study.  
In accordance with the laws relating to data protection, you will be able to 
exercise your rights to access and to rectify this data at any time. If you agree to 
take part in the study your GP will be informed of your participation. 
  
 
What will happen to the results of the research study?  
The results will be analysed for the purpose of publication in scientific journals. 
If you would like to find out about the results of the study please ask your study 
doctor who will be able to provide you with this information.  
 
  
Who is organizing and funding the research?  
This study is organised by the Cardiology Team at Guy’s and St Thomas’ NHS 
Foundation Trust and King’s College London, and sponsored by the Research 
& Development Department of the Hospitals’ Trust.  
 
  
Are the researchers involved in this study being paid?  
Your doctor and his research team will receive no payment for their involvement 





Will I be paid for my participation in this study?  
Participants in this study will not receive any payment for taking part, but you 
would be reimbursed for travel expenses incurred by any visits as a result of 
taking part  
 
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed by and approved by the Guy’s Hospital Ethics 
Committee.  
 
Contact for further information  
If you have any problems, concerns or other questions about this study you 
should preferably contact the investigator first : 
 
Dr Aldo Rinaldi  
Consultant Cardiologist  
St Thomas' Hospital 
 Lambeth Palace Road  
London  
SE1 7EH 
Tel: 020 7188 9257 
 
 
If you have any complaints about the way the investigator has carried out the 
study, you may contact : 
 
Complaints department  
Guy's and St Thomas' NHS Foundation Trust  
Guy's Hospital  
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St Thomas Street  
London SE1 9RT 
Tel: 020 7188 3514 
  
 
Thank you for taking the time to read parts one and two of this patient 
information sheet and to think about taking part in this study.  
 
  
If you agree to take part in this study, please complete and sign the 





































We would like to invite you to take part in a research study. 
Outline explanation 
Your heart doctor has recommended that you have a special pacemaker called a Cardiac 
Resynchronisation Therapy (CRT) device implanted. The aim of CRT is to improve the 
way the heart beats. Although CRT has been shown to work in many people, around a 
third of patients do not improve with this type of pacemaker. We aim to see whether 
other ways of pacing the heart are better. 
What is the purpose of the study?  
CRT usually involves putting 1 pacing wire in each of three chambers of the heart. The 
aim of this study is to see whether patients do better if we pace the main pumping 
chamber of the heart from 2 places at the same time. 
What does the study involve? 
Most patients will undergo an MR scan of their heart as part of their usual care before 
their pacemaker implant. A few patients in this study will be asked if they are willing to 
have extra images taken during their MR scan and also to have a special new type of 
electrical trace (ECG) of their heart. The extra images will make the scan around 20 
minutes longer. The extra ECG will take a further 20 minutes after the MR scan.  
Around a week or so after the MR scan you will have your CRT implanted in the usual 
way but the pacemaker used will have a new type of electrical wire that will let us 
stimulate the heart from more than one area at the same time using just one lead. You 
may also be eligible for this study if you have had this special type of pacemaker 
implanted recently. 
 
You will be brought back to St Thomas’ Hospital at least one week after your CRT 
implant for the extra study. 
 
This extra study is not part of routine care and you would not undergo this study if you 
were not participating in this research. 
 
During the study we will place two extra temporary pacing wires in your heart. One will 
be placed on the outer surface and one on the inner surface of your heart. The two extra 
pacing wires, heart pressure wire and balloon to measure electrical activity will be 




We will measure the changes in blood pressure that result from pacing the main 
pumping chamber of the heart from two areas rather than one. We will test this by 
measuring the pressure changes in the heart that we get from pacing using the extra 
wires and also using the pacing lead from the pacemaker you will have recently had 
implanted. We will also measure electrical activity using a special small balloon that we 
will also put into the heart. 
 
Why have I been chosen?   
You have been chosen to take part in this study because you are eligible for a CRT 
pacemaker under current guidelines.  
Do I have to take part?   
No. You are under no obligation to take part. If you do not want to take part it will not 
affect your routine care. 
What happens if I decide not to take part?  
If you do not take part in the study you will still receive a CRT pacemaker implanted in 
the usual way with standard follow-up. 
What will happen to me if I take part (see Figure 1)? 
1) If you are one of the patients asked to have a special electrical tracing of your heart 
(ECG) during your MR scan, you will spend an extra 20 minutes during the scan having 
extra images taken. You will then have a special ECG (that is much more detailed than 
usual) that should take no more than 20 minutes. 
2) Around a week or more after the heart MR scan, you will have your pacemaker 
implant (using a specific type of pacemaker that will allow us to do the study at a later 
date) in the standard way. 
3) At least one week after the pacemaker implant you will undergo the study procedure 
under local anaesthetic and sedation. During this procedure we will measure pressure 
and electrical changes in the heart in response to pacing in different ways. When all the 
measurements have been made, we will remove the extra wires from your heart and the 
tubes inserted from the groin (but will not remove the pacemaker or leads that were 
implanted the week before). 
4) You will spend a total of around 4 hours lying flat on the operating table. 
5) Following the procedure you will need to lie flat in bed for several hours until the 
tubes inserted in your groin have been removed. You will usually go home the day after 

























How does this differ from “standard practice” i.e.routine care (if you were not to 
take part in the study)? 
In addition to routine care, you would have: 
1) A longer MR scan and special ECG (a few patients only). 
2) You will be asked to come back to hospital for a two day stay during which you will 
have an extra detailed study of the pressures and electrical activity of your heart in 
response to pacing it in different ways. This will require two extra days in hospital after 
you have had your pacemaker implanted. 
What are the possible disadvantages and risks of taking part in the research 
study?  
Patient consents to be in study 
Patient undergoes usual 45 minute cardiac MR 
scan at least one week before pacemaker implant. 
Some patients will be asked to spend 20 minutes 
extra in the MR scanner and have a special ECG 
after this. 
Patient undergoes pacemaker (CRT) 
implantation as normal around one week after 
MR scan 
Patient has invasive study at least one week 
after CRT implant. This will involve 
placing tubes in the right and left side of 
the groin and passing wires into the heart. 
End of study. Patient may go 
home the following day. 
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The MR scan is safe and does not involve radiation. You will probably have this as part 
of your routine care even if you are not part of the study. 
The risks of the pacemaker implantation are the same as if you were not part of the 
research study. 
The invasive electrical study that we will perform at least one week after your 
pacemaker implant will involve lying flat on the operating table for around 4 hours and 
carries several significant risks: 
1. There is a risk of a stroke in anyone undergoing this sort of study because of clot 
forming on one of the wires that we place in your heart. We reduce this risk by giving 
you a blood thinning agent (heparin) during the procedure. 
2. The heparin does increase the risk of bruising and bleeding around the groin sites 
where the tubes for the study are inserted but this is not usually serious. 
3. There is a risk of puncturing the heart and fluid collecting around it requiring 
drainage. 
4. There is an additional x-ray dose on top of that of the CRT implant if you take part in 
this study. The extra dose is about the same as seven years of natural background 
radiation in the UK and carries a less than 1/1000 risk of cancer. 
Over the past 10 years we have performed similar studies in around 25 patients without 
any serious problems. 
What are the possible benefits of taking part? 
There is no direct benefit to you. If we find that pacing your heart from multiple sites at 
the same time using the pacemaker lead you have had implanted improves your 
response to pacing, we may programme your device to act in this way in the future. 
What happens when the research study stops? 
You will still be routinely followed up in our clinic and monitored by the cardiologists 
who undertook the study. 
What happens if there is a problem?  
We are very keen to ensure that all participants in this study receive treatment and care 
to our usual very high standards. However, if there are complaints or you do suffer 
some harm these will be addressed properly in the normal way. 
Will my taking part in this study be kept confidential? 
Yes 
What will happen if I don't want to carry on with the study? 
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If you withdraw from the study we will need to use the data collected up to your 
withdrawal and your care will continue as usual.  
 
What will happen to the results of this study?  
We plan to publish these in a research paper with the aim of advancing the knowledge 
of pacemaker treatment for heart failure. All patient identities are treated as strictly 
confidential and anonymous in any publication. 
Who is organising the research?  
This study is organised by the Cardiology Team at Guy’s and St Thomas’ NHS 
Foundation Trust and King’s College London and sponsored by the Research & 
Development Department of the Hospitals’ Trust.  
What happens if for any reason you are no longer able to take part or give ongoing 
consent to take part? 
We would then withdraw you from the study and you would receive the usual care that 
every patient would receive. If you are agreeable we will still use the research 
information obtained towards the analysis of results. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has 
been reviewed by and approved by the St Thomas’ Hospital REC.  
Contact for further information  
If you have any problems, concerns or other questions about this study you should 
preferably contact the investigator first: 
Dr Aldo Rinaldi  
Consultant Cardiologist  
St Thomas' Hospital 
 Lambeth Palace Road  
London  
SE1 7EH 
Tel: 020 7188 9257 
 
If you have any complaints about the way the investigator has carried out the 
study, you may contact: 
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Complaints department  
Guy's and St Thomas' NHS Foundation Trust  
Guy's Hospital  
St Thomas Street  
London SE1 9RT 

























PATIENT INFORMATION SHEET 
 
Project: Grand Challenge Modelling Project 
REC Ref: 10/H0802/71 
 
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully. Talk to others about the study if 
you wish.  
 
Part 1 tells you the purpose of this study and what will happen to you if you take part.   
Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  Take 







It has been recommended by your heart doctor that you have a cardiac 
resynchronisation therapy (CRT) device implanted. This is a special kind of 
pacemaker that usually consists of 3 electrical leads which are placed in the 
heart to improve the way it beats. Although this type of pacemaker makes many 
people feel better, around a third of patients do not improve with this treatment 
in terms of their ability to exercise and quality of life. 
 
What is the purpose of the study?  
At present it is not clear which patients will get better after CRT. The aim of this 
study is to see if the measurements we take during heart scans can be used to 





Why have I been chosen? 
You have been chosen to take part as you are eligible for CRT on the basis of 
our current guidelines. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time and do not need to give a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
 
What will happen to me if I take part? 
You will be given a consent form to sign. 
As part of your routine care before having CRT, you will be seen in the 
outpatient department. You will fill in a questionnaire, have a blood test, a urine 
test, a walking test, a bicycle test and an ultrasound scan of your heart called an 
echo scan. These tests are routine and take around 2 hrs in total. Some 
patients will be asked to raise their legs (supported by a cushion) for 5 minutes 
during the echo scan. 
 
On the same day you will also have a scan called a magnetic resonance 
imaging (MRI) scan. This gives us further detailed information about the heart. 
The MRI scan involves lying still in a scanner for around an hour. The MRI does 
not involve X-rays and is part of the routine work-up for the type of pacemaker 
you are having. 
 
Patients in Sheffield will also have the following tests performed: 
1) A grip strength test. This gives us further information about the strength of 
your peripheral muscles e.g. forearm, in relation to your heart muscle. This 
involves gripping a measuring device with your hand as hard as possible, 
maintained for about 5 seconds, with the best of 3 attempts recorded. There will 
be a rest of 30 seconds between each attempt. Taking around 5 minutes. 
2) A measure of the blood flow in your brachial e.g. arm artery will also be 
recorded, this is called flow mediated dilatation. This is performed using an 
ultrasound probe e.g. without X-rays, looking at the diameter of your artery 
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before and after the flow is stopped using a blood pressure cuff for a maximum 
of 5 minutes. The whole test will take around 30 minutes. 
3) An indirect measure of the force of blood ejected from the heart, using a 
device called a force plate. This involves, standing, sitting and lying on a fixed 
platform, the force is recorded by the platform and requires no invasive 
measurements. This will take around 5 minutes. 
Once your CRT is implanted we would like to follow you up at 6 and 12 months 
with a repeat of the questionnaire, walking and cycling tests and echo scan of 
your heart. Sheffield patients will also have repeat blood and urine tests at 
these follow-ups. Some St Thomas’ Hospital patients will have extra echo 
images taken at their 6 week and 3 month device checks. 
 
This information will be used to develop computer models that may be helpful in 
the future for predicting which patients will get better with CRT. 
 
How does this differ from “standard practice” i.e. routine care (if you were 
not to take part in the study)? 
The assessment with the blood test, questionnaire, walking test, cycling test 
and echo scan before the CRT implant are all routine. The MRI scan is also part 
of our routine assessment for CRT. 
In addition to routine care: 
1) The echo scan before the CRT implant may be 10 minutes longer than usual 
2) You will have a repeat questionnaire, walking test, cycling test and echo scan 
at 6 and 12 months after the CRT implant. Some St Thomas Hospital patients 
will have extra echo images taken at their 6 week and 3 month device checks. 
You would need to attend at these times even if you were not in a study to have 
your CRT device checked. Sheffield patients will also have repeat blood and 
urine tests, grip, force plate and blood flow tests at these follow-ups, 
3) The MRI scan may take slightly longer than a standard scan. 
 
What do I have to do? 
You will need to have the routine tests which include the blood test, 
questionnaire, walking test, cycle test, echo scan and MRI prior to your CRT. 
You will then have your CRT implant. We will need to see you at 6 weeks and 3 
months for a standard check of your CRT (this is not part of the research). We 
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will also see you at 6 and 12 months after your CRT has been implanted to 
repeat the initial assessments (but not the MRI scan). 
 
What is the procedure that is being tested? 
We are looking at the electrical and mechanical function of the heart using echo 
and MRI. This allows us to develop computer models of the heart that we hope 
will help us to predict which patients are likely to get better with CRT. 
 
What are the contraindications of taking part?  
If carried out properly, MRI is harmless. We have safety procedures and well-
trained staff to minimise any possible risks associated with the procedure. 
Because MRI uses a strong magnet, it is not safe for some people to be 
scanned. This includes people who have a heart pacemaker or some other 
types of metal in the body. You will be asked to fill in a screening form to make 
sure that you can have a MRI scan. 
 
What are the possible disadvantages and risks of taking part?  
The MRI scan may be uncomfortable as you need to lie flat for around an hour. 
Most people tolerate this procedure very well. 
 
The test to measure the blood flow in the arm may be uncomfortable or painful 
when the blood pressure cuff is inflated for 5 minutes (Sheffield patients only). 
 
You will be required to have more tests than usual at your follow-up 
appointments. 
 
The radiation dose (26mSv) from having the CRT implanted is the same as if 
you do not take part in this research study. It is the about the same as 12 years 
of natural background radiation. 
 
What are the possible benefits of taking part? 




What happens when the research study stops? 
You will continue to have normal follow-up in clinic. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on 
this is given in Part 2. 
 
 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept 








Sheffield patients: Dr Paul Sheridan, CVBRU, Northern General Hospital, 
Sheffield 
Tel: (0)114 2714950). 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 






What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the procedure that is being studied.  If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study. 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will need to use the data collected up to your 
withdrawal. We will ask you to keep in contact with us to let us know your 
progress. 
What if there is a problem? 
Complaints: If you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your 
questions (St Thomas’ Hospital patients: contact Prof. Reza Razavi on 
02071885440 and Sheffield patients: contact Dr Paul Sheridan on (0)114 
2714950). Should you wish to complain formally, you can do this through the 
NHS Complaints Procedure. Details can be obtained from the hospital. 
 
Harm:  In the event that you are harmed during the research study there are no 
special compensation arrangements.  If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for 
compensation against Guy’ & St. Thomas’ NHS Trust but you may have to pay 
your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you. 
Will my taking part in this study be kept confidential? 
Procedures for handling, processing, storage and destruction of your data are 
compliant with the Data Protection Act 1998. All information which is collected 
about you during the course of the research will be kept strictly confidential.  
Any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it. Your data will be 
collected from the referral letter and patient notes, as well from your oral 
information; Data will be automatically stored securely, in an encrypted format; 
Authorised persons such as researchers, regulatory authorities and Research 
and Development (for monitoring of the quality of the research) will have access 




What will happen to the results of the research study? 
We aim to publish these in a research paper so as to advance the knowledge of 
echo, MRI and CRT. All patient identities are treated as strictly confidential and 
anonymous in any publication. 
Who is organising and funding the research? 
The research is organised by Prof Reza Razavi, St Thomas’ Hospital, London 
and funded by the EPSRC Grand Challenge Project. 
 
Who has reviewed the study? 
The study has been independently reviewed by the St Thomas’ Hospital Ethics 
Committee (Project Ref: 10/H0802/71). 
 
A copy of the information sheet and a signed consent form to keep will be given to 
you. 
 
Thank you for considering taking part in this study. 
 
